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Chapter 1: General Introduction 
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1.1  Influenza in Africa 
In 2013, there were 160 million estimated cases of acute lower respiratory tract infections, 
including influenza-like illness, which occurred globally (1), resulting in 2.7 million deaths (2). It is 
estimated that a majority of these deaths, up to 90%, occur in the developing world (3-5). In Africa 
and Asia, acute lower respiratory tract infections are two to ten times more common and have 
three to seven-fold worse outcomes than in the industrialized world. Indeed they are the leading 
cause of death in children (6). 
In Sub-Saharan Africa (SSA), data and surveillance for influenza has been limited due to a 
combination of factors that include limited public health infrastructure and resources, and other 
competing health priorities such as human immunodeficiency virus (HIV), tuberculosis (TB), and 
malaria (7-9). In response to the threat of avian influenza A(H5N1) that occurred in Asia in 2003, 
and eventually reached three African countries (Djibouti, Egypt, and Nigeria) (10), several African 
countries in partnership with international institutions and governments invested in the 
development of epidemiologic and laboratory influenza surveillance (9, 11).  
As a result of the establishment of these surveillance platforms, several African countries were 
able to detect and monitor influenza A(H1N1)pdm09 (11). However, with the exception South 
Africa and Madagascar which routinely reported influenza activity to the World Health Organization 
(WHO) with data that suggested a strong seasonality as of 2009, data from most of the SSA 
countries remains inadequate to inform influenza public health policies (8). This is largely because 
data on the burden of influenza have not been documented. This notwithstanding, the limited 
published data from these countries has suggested a high burden of influenza, especially among 
young children <5 years (4, 11, 12), and persons with chronic medical conditions such as HIV/AIDS 
and TB (12-15).  
Other than influenza, data from the surveillance and research platforms has been used to 
characterize the epidemiology of respiratory syncytial virus (RSV) and other respiratory pathogens. 
RSV is an important viral cause of pneumonia and bronchiolitis, and available data from SSA shows a 
substantial morbidity and mortality burden associated with RSV among young children <5 years (5, 
12, 16), and among those who are immunocompromised (12, 13, 17). 
 
1.2 Influenza in Kenya 
 
1.2.1 Kenya 
Kenya is a country that is situated in East Africa with a territory that lies on the equator 
between 5°N and 5°S covering an area of 581,309 square kilometers (18) (Figure 1.1). As of 2014, 
Kenya had an estimated population of 45 million inhabitants with half of the population aged below 
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nineteen years [median age of 19 years; 15% of the total population comprising of young children 
aged <5 years; and 3% comprising of elderly persons aged ≥65 years] (19, 20).  
 
                      
Figure 1.1: Map of Kenya showing the location of influenza surveillance sites. These are: 1) Kakamega County Referral  Hospital    
(CRH); 2) Nakuru CRH; 3) Nyeri CRH; 4) Kenyatta NH; 5) Mombasa CRH; 6) Kakuma refugee camp; 7) Siaya CRH; 8) St. Elizabeth 
Hospital, Lwak; 9) Tabitha Clinic, Kibera; 10) Embu CRH; 11) Garissa CRH; 12) Dadaab refugee camp; 13) Ting’wang’i HC 
 
There is a considerable climate variability within Kenya. The coastal tropical region is 
characterized by hot and humid weather year round and records average monthly temperatures as 
high as 29°C with an average annual rainfall of over 1,000 mm. The northern and northeastern parts 
of Kenya have semi-arid and desert-like conditions and experience sunny and dry weather most of 
the year. The climate is cooler in the areas around the capital city (Nairobi) and the central parts of 
Kenya, which has a relatively higher altitude, and temperatures may drop as low as 7°C during the 
July-August cold season. The Western parts of the country, in the close proximity to Lake Victoria 
experience some of the highest rainfalls levels in the Country (1250 –1700 mm annually). Overall, 
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the country experiences its long rains from March to May and short rains in October and November 
(21, 22).  
Administratively, Kenya has two tiers of government as of 2013; the national government, and 
county governments (comprising of forty seven devolved units with semi-autonomous functions). 
Health, which is one of the devolved functions and currently managed by the county governments, 
has three major sources of financing; government (national and county) contributing 33.5%, 
individuals paying 39.8% out-of-pocket, and the rest 26.7% financing from donors and other private 
entities (23). Overall, 48% of the health facilities [hospitals (58%); health centers/nursing homes 
(54%); and dispensaries/clinics (46%)] in Kenya are run by the government (24). Children under five 
years who seek care at public health facilities are exempted from paying medical fees (25, 26). 
As of 2010, Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome 
(AIDS) (accounting for 18% of the deaths), Lower respiratory infections (11%), and malaria (10%), 
were considered the top causes of premature death in Kenya (27). Kenya is among the countries 
with high prevalence of HIV in SSA. A recent population-based survey conducted in Kenya showed 
that the HIV prevalence was 5.6% among persons aged 15-64 years old (28, 29), and 0.9% among 
children aged 18 months to 14 years old (30). Nyanza province, in the Western part of Kenya, had 
the highest HIV prevalence of 15.1% among persons aged 15-64 years. Malaria is reported to 
account for 34% of the outpatient visits in Kenya (31), with a national prevalence of 8% among 
children aged 6 moths to 14 years in 2015. The lake endemic zone of western Kenya has the highest 
prevalence of malaria overall (27%), whereas the prevalence in the low risk areas is as low as <1% 
(32). 
1.2.2 Influenza surveillance in Kenya 
In Kenya, lower respiratory infections are the second largest cause of death in the general 
population after HIV/AIDS (2), and account for 19% of all deaths among children <5 years in 2013 
(33). A large fraction of respiratory tract infections are associated with viruses, quite notably 
influenza A and B, and RSV (34). Whereas seasonal influenza has long been recognized as a cause of 
morbidity and mortality in countries with temperate climates, recent studies have shown that 
influenza causes a significant burden of disease in countries in the tropics as well (35, 36).  
The Kenyan Ministry of Health (KMoH), with the technical support from the United States (US) 
Centers for Disease Control and Prevention (CDC), established a national sentinel surveillance 
system for influenza in 2006 (Figure 1.1). These sentinel surveillance sites are spread across the 
country, and were initially setup to cover each of the eight provinces in the country (now referred 
to as “regions” as of 2013 when a new constitution was implemented in Kenya). The objectives of 
the surveillance system was i) to identify circulating influenza strains, ii) to understand the 
epidemiology and burden of influenza in Kenya, and iii) to serve as a component of an early warning 
system for pandemic influenza (37). Two of these surveillance sites were setup at the two refugee 
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camps in Kenya (one in each of the refugee sites); Kakuma refugee camp located in the 
northwestern Kenya (predominantly hosting Somali and Sudanese refugees); and Dadaab which is 
located in the east (predominantly hosting Somali refugees) (38).  
Besides conducting surveillance for the objectives listed above, three other surveillance sites 
were setup within defined population catchment areas (elsewhere referred to as population-based 
sites). This has provided an important platform for disease burden estimation for influenza and 
other respiratory pathogens, including RSV. The three sites are: Tabitha Clinic, an outpatient facility 
in Kibera (an informal settlement in Nairobi with a study population of 33,881 and covering an area 
of 0.38 km2) (39); and Lwak Mission hospital, and Siaya County hospitals, both located in rural 
western Kenya where the Kenya Medical Research Institute (KEMRI) and CDC implement a heath 
demographic surveillance system covering a population of approximately 220,000 (39, 40). Using 
the same case definitions as for influenza surveillance, specimens collected for influenza testing at 
these three sites (Kibera, Lwak and Siaya) have also previously been tested for RSV and other 
respiratory pathogens including adenovirus, parainfluenza viruses 1, 2, and 3, human 
metapneumovirus, and rhino/enterovirus. 
1.2.3 Transmission and clinical presentation of influenza in Kenya 
Influenza is mainly transmitted from person to person by droplet spread containing up to 105 
virus particles/ml (41), and is largely thought to be transmitted by direct or indirect contact with 
respiratory secretions in the tropics (42). The incubation period is 1-4 days (average: 2 days), and 
people could be infectious even before the onset of symptoms (43). Influenza infection is typically 
characterized by a sudden onset of fever, headache, cough, rhinorrhea, sore throat, myalgia, or 
fatigue (41, 44). Usually, influenza is self-limiting and could last for three to five days (41). However, 
influenza could also result in complications, which are more frequent in the elderly and persons 
with chronic illnesses such as TB, HIV/AIDS, or cardiac disease (12, 13, 15, 45). Some patients may 
develop a primary influenza viral pneumonia, which could result in death. But more commonly, 
influenza infection could result in secondary bacterial pneumonia which may occur up to two weeks 
after the acute viral infection (46, 47).  
In Kenya, the WHO recommended case definition for influenza-like illness (ILI) surveillance was 
used; axillary temperature ≥38°C and cough or sore throat in an outpatient of any age (37). A 
modified version of the WHO’s Integrated Management of Childhood Illness (IMCI) definition for 
pneumonia was used for children aged <5 years; requiring hospitalization and the presence of 
cough or difficulty breathing plus one or more of the following danger signs: chest in-drawing, 
stridor, unable to breastfeed or drink, vomits everything, convulsions, lethargy, or unconsciousness. 
Among persons aged ≥5 years, the case definition used required hospitalization with an axillary 
temperature ≥38°C and cough, difficulty breathing or shortness of breath (37). A recent study in 
Kenya showed that fever and convulsions were significantly associated with increased odds of 
laboratory-confirmed influenza among children <5 years who were hospitalized with SARI, while 
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headache was associated with increased odds of laboratory-confirmed influenza among persons ≥5 
years (37). Malaria is a common comorbidity among patients presenting with ILI or SARI who are 
sampled for influenza testing (48), especially in the malaria endemic areas of western and the 
coastal parts of Kenya, due to the overlap of symptoms included in the case definitions for influenza 
surveillance with the clinical presentation of malaria (49).    
 
1.2.4 Influenza control strategies in Kenya 
Kenya has no national influenza vaccination program in place, and only recently (in 2013) 
developed its first national immunization policy guidelines for all vaccine-preventable diseases, 
which included influenza (50). In these policy guidelines, immunization for influenza, generally 
based on the WHO’s Strategic Advisory Group of Experts (SAGE) recommendations, was 
recommended for young children, healthcare workers, and persons with chronic medical 
conditions. However, the need for more guidance and prioritization of limited vaccination resources 
has recently led to the formation the Kenya National Immunization Technical Advisory Group 
(KENITAG), with a need and preference for data from the Kenyan setting to inform policy 
recommendations and priority setting. In addition, following the experience of the pandemic 
influenza in 2009, the KMoH together with other partners developed pandemic preparedness plans 
which could be activated in the event another pandemic were to emerge. 
 
1.3  Morbidity and mortality burden of influenza in Kenya 
Since 2006 when surveillance for influenza was established in Kenya, there has been limited 
but increasing evidence documenting the burden of influenza-associated morbidity burden (51-53). 
Estimation of the incidence of influenza-associated hospitalizations and outpatient visits has been 
made possible using surveillance platforms with well-defined catchment populations, although 
mostly limited to a few geographical locations in the country; namely Western Kenya, Nairobi, and 
Coastal Kenya. However, there are no existing estimates of the burden of influenza-associated 
mortality from Kenya. 
As in most SSA countries, there is an absence of systematically collected robust vital statistics 
data in Kenya. This is in part because a large fraction of persons who die from respiratory illness 
may not seek care before death (54), and hence are not captured in health facility-based 
surveillance systems.  Moreover, certain age groups such as the elderly may be particularly 
underrepresented in health-facility based surveillance (55, 56).  Many influenza‐associated 
hospitalizations and deaths also occur weeks after a person’s initial infection, either because the 
person may develop a secondary bacterial co‐infection or because influenza can aggravate an 
existing chronic illness (e.g. cardiovascular diseases) (57). Thus, many people that are hospitalized 
13 
 
or die from influenza‐associated complications may seek medical care later in their illness when 
influenza is not suspected, or can no longer be detected from respiratory specimens.  Studies that 
model excess mortality or hospitalizations during periods of known circulation of influenza viruses 
would therefore be useful in evaluating the population-based burden of infections caused by these 
viruses. 
 
1.4 Risk factors for influenza infection and/or severe influenza in Kenya 
 
1.4.1 The impact of HIV/AIDS and TB on influenza disease burden in Kenya 
       Studies conducted outside of tropical Africa and elsewhere have shown persons living with 
HIV/AIDS to be at an elevated risk of infection with the influenza virus (17, 58). Influenza virus 
infections could also lead to the worsening of pre-existing medical conditions such as HIV/AIDS, 
resulting in longer periods of hospitalization and death (12, 59). Additionally, it is believed that 
persons living with HIV/AIDS who are infected with the influenza virus could shed the virus for 
longer periods of time thereby facilitating transmission in the household (60). Studies conducted in 
South Africa had also previously shown a high mortality burden due to influenza among persons 
with HIV/AIDS and/or TB (12, 15, 61). 
1.4.2 Seasonality and meteorological factors associated with influenza activity in Kenya 
In the temperate regions, influenza epidemics exhibit clear seasonality with peaks during 
winter months (62, 63). In these regions lower temperature, lower solar radiation and lower specific 
humidity were shown to be significantly associated with increased influenza activity. This allows for 
a precise timing of influenza vaccination campaigns to precede periods of peak circulation.  In 
contrast, the seasonal characteristics of influenza are more diverse in tropical and subtropical 
regions which are characterized by semi-annual epidemics or year-round influenza activity, often 
without well-defined influenza seasons (64-68).  
Whereas influenza viruses have been shown to circulate for most of the year in Kenya (37), a 
clear description on the weather patterns and how they influence influenza circulation could help 
inform the mechanism of future vaccination campaigns, and highlight seasons when added 
diagnostic, treatment efforts or infection control mechanisms to reduce the burden of influenza 
might be put in place. 
 
1.5  The need for data on Economic burden of influenza in Kenya 
Other than the health impact caused by influenza virus infection, influenza illness has been 
shown to exert a considerable economic burden, although most of the data available come from 
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temperate and resource rich countries (69-72), and none from Africa. Beyond data on the absolute 
burden of influenza, policy-makers require information on the cost of illness to evaluate the cost-
effectiveness of potential interventions. Few data can influence a policy decision to use a vaccine 
more than the cost of an illness to the population and the possibility of an intervention to reduce 
that cost. 
 
1.6  Rationale for this thesis 
The morbidity burden estimates for influenza-associated disease in Kenya are limited, and only 
available for a few geographical locations in the country. There also remain only cursory data on the 
disease burden associated with influenza-associated mortality in Africa, with none available from 
Kenya. Although influenza has been shown to circulate throughout the year in Kenya, the timing 
and meteorological determinants of increased influenza circulation are not described. Additionally, 
the role of chronic medical conditions such as HIV/AIDS on disease burden and transmission of 
influenza are not described; and data on the economic impact of the respiratory tract infections 
associated with influenza in Kenya do not exist.  
Estimation and synthesis of these data will not only help to quantify the magnitude of the 
disease burden and describe the timing of influenza activity in Kenyan populations, but also will 
provide a basis for quantifying its economic impact, and identifying and prioritizing the segments of 
the population which are in need of the limited vaccination resources. These data could also be 
used by other tropical countries in Africa with similar cultural and geographical contexts to inform 
influenza prevention and control policies. 
 
1.7  Research questions 
This thesis addresses the following research questions: 
i) What is the morbidity and mortality burden of influenza-associated disease in Kenya, 
and which segments of the population are most affected? 
ii) What are the risk factors for influenza infection and/or severe influenza in Kenya? 
iii)  What is the cost and overall economic burden of influenza-associated disease in Kenya? 
 
1.8  Thesis outline 
The research questions listed above were addressed through several studies that were 
conducted in Kenya and presented in the chapters described below. 
1.8.1 Morbidity and mortality burden of influenza in Kenya 
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       In chapter 2, we review and summarize published data describing the disease burden associated 
with influenza in Kenya. We also discuss the various disease burden estimation methods used and 
provide suggestions for future research strategies that will help to generate additional data needed 
to inform influenza control strategies. In chapter 3, we estimate the age-specific burden, including 
rates for children aged <6 months, of medically-attended, and non-medically attended influenza 
and RSV using data collected from a population-based disease surveillance site in Western Kenya. In 
chapter 4, we use verbal autopsy data collected through a health demographic surveillance system 
(HDSS) in Western Kenya to estimate the overall and age-specific excess mortality rates associated 
with influenza virus and RSV during the period 2007 to 2013. We also estimate mortality rates 
associated with influenza and RSV among persons with respiratory illness (including pneumonia), 
HIV/AIDS and pulmonary TB related deaths. 
1.8.2 Risk factors for influenza infection and/or severe influenza in Kenya 
In chapter 4, we present data on the mortality burden due to influenza among persons with 
HIV/AIDS and PTB. In chapter 5, we present findings from a household-based study that was 
conducted in an informal settlement in Nairobi (Kibera) that examined i) the association between 
the HIV status of household members and their risk of introducing influenza to the home, and ii) 
whether the HIV status of index cases of influenza impacts the risk of developing secondary 
influenza-like illness (ILI) among their household contacts. 
In chapter 6, we describe the patterns of periods of increased influenza circulation, over the 
period 2007-2013, for different regions (based on different “climatic” zones) and for Kenya as a 
whole. We also provide suggestions on the possible implications for future vaccination programs, 
and assess the relationship between three meteorological variables (temperature, rainfall, and 
specific humidity) and the onset of influenza activity. 
1.8.3 Economic burden of influenza in Kenya 
       In chapter 7, we estimate the cost-per-episode, from a societal perspective, of laboratory-
confirmed influenza-associated illness in Kenya using data collected from interviews with case-
patients or their care-takers. Using the cost-per-episode, we estimate the annual economic burden 
of influenza-associated illness in Kenya by applying these costs to the annual national morbidity 
burden using previously published data on burden of influenza-associated disease. 
1.8.4 General discussion 
Finally, we provide an overall synthesis of the key findings from the studies presented in this 
thesis in a summary discussion in chapter 8. Here, we also discuss the possible implications of the 
findings presented in this thesis for other countries in East Africa and conclude with the 
recommendations for further research. 
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Abstract 
Background:  In Kenya data on the burden of influenza disease are needed to inform influenza 
control policies. 
Methods: We conducted a systematic review of published data describing the influenza disease 
burden in Kenya using surveillance data collected until December 2013. We included studies with 
laboratory confirmation of influenza, well-defined catchment populations, case definitions used to 
sample patients for testing and a description of the laboratory methods used for influenza testing. 
Studies with or without any adjustments on the incidence rates were included. 
Results: Ten studies reporting the incidence of medically-attended and non-medically attended 
influenza were reviewed. For all age groups, the influenza positive proportion ranged from 5-10% 
among hospitalized patients, and 5-27% among all medically-attended patients (a combination of 
in- and outpatients). The adjusted incidence rate of hospitalizations with influenza among children 
<5 years ranged from 2.7-4.7 per 1,000 [5.7 per 1,000 in children <6 months old], and were 7-10 
times higher compared to persons aged ≥5 years. The adjusted incidence of all medically-attended 
influenza among children aged <5 years ranged from 13.0-58.0 per 1,000 compared to 4.3-26.0 per 
1,000 among persons aged ≥5 years.  
Conclusions: Our review shows an expanding set of literature on disease burden associated with 
influenza in Kenya, with a substantial burden in children under five years of age. Hospitalizations 
with influenza in these children were 2-3 times higher than reported in the United States. These 
findings highlight the possible value of an influenza vaccination program in Kenya, with children <5 
years and pregnant women being potentially important targets.  
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2.1 Introduction 
Human influenza infections are a major cause of morbidity and mortality worldwide (1-3). 
Although risk factor data from tropical climates are limited, young children (<5 years), pregnant 
women, the elderly, and persons with underlying medical conditions have been shown to be at 
increased risk of severe disease (1, 4). A recent study estimated that there were 20 million cases of 
influenza associated with pneumonia; 1 million cases of influenza associated with severe 
pneumonia; and 28000–111500 deaths associated with influenza among children aged <5 years 
globally in 2008, with 99% of these deaths occurring in the developing world (5). A summary of 
existing direct estimates of influenza disease burden in tropical and developing countries is needed 
to validate global modeling efforts that suggest a disproportionate burden in these countries. 
In Kenya, influenza surveillance was established partly in response to the global emerging threat 
of avian influenza A(H5N1) (6, 7). As is the case with other tropical and sub-tropical countries, 
influenza viruses circulate in Kenya for most of the year (7-9) and morbidity (hospitalization and 
outpatient) burden of influenza have only recently been described (10-18).  
An improved understanding of disease burden in Kenya relating to morbidity, mortality, and 
economic losses is needed to support decisions involving the allocation of limited resources toward 
influenza control programs. The Kenyan Ministry of Health (KMoH) has released its first ever 
influenza vaccination policy (19) and this has necessitated the publication of an overview of the 
burden of influenza in Kenya to inform initial vaccination pilot activities.   
In this article, we review existing data on the influenza disease burden in Kenya using data 
collected until December 2013. We summarize published data describing the health burden of 
human influenza collected through population-based influenza surveillance systems in Kenya. We 
also discuss the various disease burden estimation methods used and provide suggestions for 
future research strategies that will help to generate additional data needed to inform influenza 
control strategies. 
 
2.2 Methods 
 
2.2.1 Search strategy and selection criteria 
Our objective is to provide a comprehensive overview of the disease burden of influenza in 
Kenya. We carried out a literature review with specific search terms; "Kenya" and each of the 
following words "Influenza", "Respiratory", "Pneumonia", "Severe Acute Respiratory Illness", and 
"Influenza-like Illness". We searched PubMed and EMBASE (Ovid) for studies – with no language 
restrictions - that contained original data and were conducted until December 2013. The search was 
last conducted on March 23, 2015. We created a master list of the search results from these two 
search databases with two variables; author names and study title. We then removed duplicates. 
Titles from these search results were reviewed for the presence of any of the following key words; 
“Kenya”, “Influenza”, “respiratory”, “pneumonia”,  “influenza-like illness”, “acute lower respiratory 
infection”, “acute upper respiratory infection”, “mortality”, “deaths”, “hospitalization”, “hospital 
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admission”, and “outpatient”.   Abstracts of articles that contained at least one of these search 
words were then reviewed by one researcher (GOE) and included if they contained information on 
disease burden of influenza in Kenya.  
Only studies with original data collected before December 2013 were included. We considered 
studies for inclusion: (i) if they reported incidence rates of hospitalization and/or outpatient visits 
associated with influenza-like illness (ILI), acute respiratory illness (ARI), acute lower respiratory 
illness (ALRI), severe respiratory illness (SARI), and severe or very severe pneumonia using 
laboratory confirmed influenza cases ;  (ii) if they had well-defined catchment populations or 
estimations of the population-at-risk [using any of population-based disease surveillance systems, 
health demographic surveillance systems (HDSS), national population census data, or population 
registration records]; (iii) if they provided the case definition used to sample patients for testing; 
and (iv) if they provided a description of the laboratory testing methods used.  Studies that 
presented adjusted or unadjusted (crude) incidence rates were included in the review (see 
Appendix File 2.1, for a summary of the formulae used for the adjustments). All reported rate 
adjustments are indicated for each study.  Additionally, we scanned the reference lists and titles of 
articles selected for review using the criteria defined above.  
A flow chart with details of the process followed in selecting the articles that were reviewed, 
and the number of articles included –and excluded from this review is provided in Figure. 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 2.1: Overview of the different phases of literature selection. The inclusion criteria was: Studies that reported incidence 
rates of influenza-associated illness; with well-defined catchment populations; that provided the case definition used for testing 
influenza; and that provided a description of the laboratory methods used for testing influenza. 
Records after duplicates removed (n=715) 
Articles assessed for eligibility 
(n=160) 
Articles excluded from initial 
screening (n=555) 
(Title subject not on Kenya, or 
influenza, or respiratory disease, 
or pneumonia) 
 
Excluded for not meeting inclusion 
criteria (n=150) 
Articles included in review (n=10) 
Records screened (n=715) 
Articles identified from literature 
searches (n=1,273) 
 PubMed (n=739) 
 EMBASE (n=534) 
 
Articles identified from 
references of selected articles 
(n=0) 
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2.2.2 Data extraction, analysis and reporting 
Data extraction was performed by one researcher (GOE) using a template that collected details 
on study characteristics [title, author(s), publication year, place of study, study participants age 
group, syndromes used for case identification, and adjustment factors used for calculating 
incidence rates]. The adjustments applied to the rates were limited to one or more of the following: 
(i) patients who met the swabbing criteria but were not tested for influenza; (ii) cases in the 
community who met the specific case definition but did not seek healthcare at the study 
hospital/clinic; and (iii) asymptomatic detection of influenza using controls to determine illness 
attributable to influenza. In this review, we reported both adjusted and unadjusted influenza 
burden disease rates, but our primary measure was the adjusted rates as these were more accurate 
estimates of the disease burden.  
The outcome measures that we considered were incidence of: (i) hospitalizations with influenza; 
(ii) medically-attended influenza (outpatient and inpatient combined); and (iii) non-medically 
attended influenza. We also, as a secondary measure, reported on the proportion of those who 
tested positive for influenza if data on incidence of influenza illness were reported. Other than the 
conditions defined in the inclusion criteria, no further quality assessments were applied to the 
reviewed articles.  All incidence rates were reported per 1,000 persons or person-years. Adjusted 
rates reported in our paper included at least an adjustment for patients who met the swabbing 
criteria but were not tested, which was the most commonly applied adjustment in the studies that 
we reviewed. 
Data from the articles reviewed were summarized as ranges (minimum - maximum), where two 
or more studies were involved, and presented in tables by the following domains: (i) proportions 
testing positive for influenza; (ii) hospitalizations with influenza; (iii) medically-attended influenza; 
and (iv) non-medically attended influenza. 
 
2.3 Results 
 
2.3.1 Search results and description of methods used 
There were a total of 1,273 search records returned, including duplicates (PubMed=739; and 
EMBASE=534) (Figure. 2.1). After removing duplicates, there were 715 unique articles that were 
returned from the search and among these were 555 (78%) were on subjects not related to 
influenza or respiratory illness and were excluded in the first round of screening. Of the remaining 
160 articles, there were 51 articles on an influenza related subject; 67 on pneumonia, and 42 on a 
broader respiratory subject other than influenza and pneumonia. Of these 160 articles, 10 met the 
inclusion criteria for this review. 
Figure. 2.2 shows the location of the study sites that generated the data that were used in the 
analysis for articles that we reviewed. Eight of the 10 articles reviewed were based on surveillance 
data collected by the Kenya Medical Research Institute (KEMRI) and the Centers for Disease Control 
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and Prevention (CDC) (10-14, 17, 18, 20). The remaining two articles were based on data collected 
by the KEMRI and Wellcome Trust Research Program (15, 16). Of the ten articles reviewed, one was 
published in 2010 (15), five in 2012 (11-13, 16, 17), two in 2013 (10, 14), one in 2014 (18) and one 
in 2015 (20). Case definitions used in two of these articles included data on severe or very severe 
pneumonia (15, 16); six included data on severe acute respiratory illness (SARI) or acute lower 
respiratory illness (ALRI) (10, 11, 14, 17, 18, 20); two included data on influenza-like illness (ILI) (11, 
18); and two included data on acute respiratory illness (ARI) (12, 13). 
                                            
Figure. 2.2: Map of Kenya showing the study sites which generated data that was used in the reviewed 
papers 
 
The case definitions for the respiratory syndromes used in identifying the cases to be tested for 
influenza varied (Appendix Table 2.1). Six of the articles reviewed used mid-year population data 
from well-defined catchment areas as denominators, either from a HDSS, refugee camp records, or 
national census data for estimation of incidence while the rest used person-time years of follow-up 
calculated from a population-based surveillance system. All ten articles that reported influenza A 
and/or B testing, used reverse transcriptase polymerase chain reaction (RT-PCR) testing methods. 
The data reported in all the papers reviewed were collected year-round, and all (except one (15)) of 
27 
 
the papers had multiple years of data included. All – except one (15) - of the articles included data 
collected during the 2009 pandemic period.  
Most (9/10) of the articles reported data on the proportions of patients who tested positive for 
influenza (Appendix Table 2.2). Six of the nine articles reported rates of hospitalization with 
influenza (Table 2.1), four reported rates of medically-attended influenza (both in- and outpatients) 
(Table 2.2), and two reported incidence of non-medically attended SARI or ILI (10, 18) (Table 2.3). 
None of the studies reviewed had data on influenza mortality in Kenya. 
2.3.2 Proportions testing positive for influenza 
      The proportions of those who tested positive for influenza A and/or B varied among the studies 
included (Appendix Table 2.2). These ranged from 4.9% to 26.7% for all medically-attended patients 
[4.9% to 13.7% among children <5 years; 14.0% to 20.5% among persons ≥5 years; and 9.8% to 
26.7% in studies that reported proportions among patients of all ages]. Among hospitalized patients 
who were tested, the proportion of those who tested positive for influenza A and/or B ranged from 
5% to 10%.   
2.3.3 Incidence rate of hospitalization with influenza 
Incidence rates of hospitalization with influenza varied among the studies, which were 
implemented during different years, and used varying case definitions, and adjustments factors 
(Table 2.1 and Appendix Table 2.3). There were six studies that reported incidence rates of 
hospitalization with influenza. Two studies conducted among children with severe or very severe 
pneumonia reported similar incidence rates among children <5 years [0.8 cases per 1,000 in the 
first study, and 0.6 cases per 1,000 (95% CI 0.5-0.7) in the second study] (15, 16). No adjustments 
for people with pneumonia who were not tested were reported in these two studies. Unadjusted 
rates of influenza among hospitalized children in the age group <5 years were also reported in a 
study conducted in two refugee sites. These unadjusted rates ranged 4.2-5.6 cases per 1,000 for 
influenza A viruses and 1.1- 1.4 for influenza B viruses.  
Adjusted incidence rates of hospitalization with influenza among children of the age group of <5 
years who presented with SARI ranged from 2.7-4.7 per 1,000 (10, 18). Adjusted incidence rates of 
hospitalization with influenza among persons aged ≥5 years who presented with SARI ranged from 
0.2-0.4 per 1,000 among persons aged ≥5 years, and were lower compared to those of children in 
the age group of <5 years. In Western Kenya there was a high incidence rate of hospitalization with 
influenza among children <6 months [5.7(95% CI 2.4-13.8) per 1,000] (18). 
2.3.4 Incidence rate of medically-attended influenza 
Over the study period covered in our review, there were three publications that reported 
broader medically-attended (combining in- and outpatients) influenza incidence rates. Two of the 
publications were based on medically-attended ALRI (11, 14); and another on medically-attended 
ARI (13). Two studies reported medically-attended influenza incidence rates only for outpatients 
(18, 20). The adjusted incidence rates of medically-attended influenza ranged from 21.8-58.0 per 
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1,000 child-years for children in the age group of <5 and 4.3-26.0 for persons aged ≥5 years (Table 
2.2 and Appendix Table 2.4).  
A study that was conducted in a peri-urban informal settlement in Nairobi (Kibera) and a rural 
site in Western Kenya (Lwak) among patients who sought care for ALRI as inpatients and/or 
outpatients, reported higher adjusted incidence rates for influenza among children <5 years in the 
rural site [40.5 (95% CI 31.2-52.6)] compared to the urban site [22.0 (95% CI 17.7-26.6)]. However, 
similar results were reported among persons ≥5 years [15.8 (95% CI 14.1-17.7) vs. 12.0 (95% CI 
10.3-13.3)] in the rural and urban sites respectively (11) (Appendix Table 2.4).  
2.3.5 Incidence rate of non-medically attended influenza 
Only two of the studies reviewed (both conducted in Western Kenya) estimated non-medically 
attended incidence rates of influenza (two reported non-medically attended SARI in Siaya (10, 18); 
and one reported non-medically attended ILI (18)). The incidence of influenza with non-medically 
attended severe ARI ranged from 2.9-5.1 per 1,000 among children <5 years, and 0.4-0.8 among 
persons aged ≥5 years. In the one study that estimated incidence of influenza among non-medically 
attended ILI cases, there were an estimated 30.1 cases of influenza per 1,000 (95% CI 27.3-33.3) 
among children <5 years and 5.4 cases per 1,000 (95% CI 4.9-6.0) among persons aged ≥5 years (18) 
(Table 2.3 and Appendix Table 2.5). 
 
2.4 Discussion 
We have provided a comprehensive summary of available data on disease burden of influenza 
in Kenya and we show that influenza is an important cause of respiratory infection-associated 
morbidity, especially among younger children under the age of five years. Indeed, both adjusted 
and unadjusted incidence rates of hospitalization with influenza (10, 17, 18), and outpatient visits 
(18) were higher than those that have been reported in United States and European countries 
during similar time periods (21-32).   
We also note that the published literature on the burden of influenza in Kenya is limited but 
expanding. Eight of the ten papers that we reviewed were published within the last three years 
(2012 - 2014) – including two studies that published data on the post- pandemic A(H1N1) period. 
This could be attributed to the interest generated by the threat of avian and pandemic influenza.   
Our review showed that there were an estimated 2.7-4.7 cases of influenza per 1,000 among 
children <5 years who were hospitalized with severe acute respiratory illness (SARI). These were 7-
10 times higher compared to those in persons aged ≥5 years. A study that estimated disease burden 
among hospitalized children <6 months in Western Kenya reported that there were 5.7 cases of 
influenza per 1,000 (18). This is consistent with data from several other countries (22, 23, 33), and 
shows a considerable burden of disease in young infants for whom influenza vaccination is not 
recommended, and also highlights the rationale for targeting pregnant mothers for influenza 
vaccination (34). Whereas pregnant mothers have been shown to be at increased risk of 
complications associated with influenza (35), vaccinating them may not only be beneficial to them 
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but could also offer protection to their young infants - for whom no influenza vaccine is currently 
licensed - through breastfeeding and trans-placental antibody transfer (36, 37). 
The incidence rates of hospitalization with influenza among children <5 years reported at the 
two refugee sites (Kakuma and Dadaab) – without adjustments for eligible cases who were not 
tested - were higher than rates reported elsewhere in Kenya. This could be due to the unique 
challenges experienced by the populations in refugee settings, such as population density, which 
could make them more vulnerable to exposure to respiratory infections (38, 39). While the 
incidence rates of hospitalization with influenza are similar to those reported in South Africa (40), 
Asia (41-46), Latin America (47), some of the reported rates were up to seven times higher than 
rates reported in the United States (21-26) and Europe (27, 28).  The incidence rates of 
hospitalization with influenza children <6 months in Kenya, for example, were 2-3 times higher than 
rates reported in the United States (23).  
The adjusted incidence of medically-attended (outpatient + inpatient) influenza among children 
<5 years ranged from 21.8 to 58.0, and 4.3 to 26.0 per 1,000 among persons aged ≥5 years in 
different studies. These rates were similar to rates reported in Asia (48), but up to 2-4 times higher 
than annual estimates reported in Europe (29-31), and up to 2-8 times higher than rates reported in 
the United States (32).  
The incidence of non-medically attended severe ARI associated with influenza suggested a 
burden of disease that was similar to the medically-attended burden. As reported in the health 
utilization survey conducted in Western Kenya, 52% of children <5 years and 66% of persons ≥5 
years who reported to have had pneumonia did not seek care at a hospital (49). The similarity 
between the medically-attended and non-medically attended incidence not only underscores the 
fact that there is a considerable burden of non-medically attended influenza, but also highlights the 
low levels of health-care seeking for respiratory illness in Kenya (49). These findings also suggest 
that surveillance limited to the health care setting will not capture the entire burden of influenza 
severe respiratory illness in contexts such as Kenya. 
The studies reviewed included various adjustments for patients who met the case definitions 
but were not tested for influenza (10-12, 18);  for those who sought health-care at a facility other 
than the one used for estimating the incidence rates (13, 14); and for asymptomatic detection of 
influenza among controls (13, 14). The first two adjustments would serve to increase the crude 
incidence to account for persons who met the case definition and were not tested for influenza or 
those who did not seek care; while the latter would drive the rate downwards by only accounting 
for the cases for which the virus was the likely cause disease. Other than the case definition for ILI 
developed by the World Health Organization (WHO) which was more commonly applied across the 
different studies (50), the case definitions used for SARI, ALRI and ARI also substantially varied 
across the studies reviewed.  In order to facilitate disease burden comparisons over time, it would 
have been helpful if researchers also presented their data using standard case definitions as 
recommended by WHO (51); and unadjusted rates in addition to those where adjustments were 
applied. These standardizations, in addition to presenting data in age groups that may be 
aggregated  to WHO recommended age categories [<2, 2-4, 5-14, 15-49, 50-64, and ≥65 years] (51) 
would help to facilitate comparisons across studies and across countries (52).  
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All the articles reviewed utilized data generated from well-defined catchment areas managed by 
either the KEMRI and CDC, or the KEMRI and Wellcome Trust research collaboration; indeed a 
majority of the articles reviewed included KEMRI and CDC co-authors who are also authors on this 
paper. Additionally, all the papers that we reviewed included in their analysis data that were 
collected year-round and a majority of them had multiple years of data used in estimating incidence 
rates. This consideration is important because – other than considering that influenza circulates in 
Kenya year-round (7) – it minimizes the risk of overestimating the disease burden by only sampling 
during epidemic periods.  
Six of the ten studies reviewed utilized mid-year population denominators, derived from HDSS 
or National census data (12), for the estimation of incidence rates. As opposed to using 
denominators derived from individual follow-up (person-time) in population-based surveillance 
systems, denominators based on mid-year population could potentially underestimate the 
incidence rates as they may not accurately reflect the actual population dynamics relating to births, 
migrations and deaths, especially if smaller populations are involved (53). However, using either of 
these two denominator types to estimate incidence rates would normally yield nearly identical 
results for large populations. Taken in the context of the resources required to set-up and run a 
population-based surveillance system, denominators derived from mid-year population numbers 
may be useful for disease burden estimation in Kenya for the foreseeable future.  
Only one study reported rates among children <6 months, and a few reported data on those 
aged ≥50 years (11, 12) which is in part explained by the lower health-seeking behavior among 
older persons in Kenya (49), and perhaps also by a diminished likelihood that older patients will 
report the fever required to meet the WHO SARI case definition. Understanding the disease burden, 
especially in the high risk groups which include pregnant women, and people with underlying 
medical conditions; as well as understanding the socio-economic (direct and in-direct) burden of 
influenza in Kenya would be helpful to public-health and influenza control programs and 
understanding the impact of influenza. For example a recent study conducted in Western Kenya 
showed a substantial burden of influenza (3-times higher) among HIV-infected adults aged ≥18 
compared to their HIV-negative counterparts (13). Another study in South Africa reported 4–8 times 
greater incidence of acute lower respiratory tract infection (LRTI) with influenza among HIV-infected 
compared to HIV-uninfected persons (40). 
Our study was subject to limitations. First, we may have missed some articles as we limited our 
review to only published data searched the PubMed and EMBASE databases. However, we believe 
that the likelihood of finding additional data relevant to our study in other databases is very low. 
Second, most of the published data summarized in our review included data from the 2009 
pandemic influenza period and may have served to overestimate the seasonal influenza disease 
burden. Third, the reviewed papers were limited to respiratory surveillance only. For some 
populations (particularly young infants) presentation may be fever without respiratory symptoms. 
As such, the true burden among children may have been underestimated. Fourth, the clinical 
threshold to hospitalize in Kenya may not be comparable to US or Europe and therefore 
hospitalization rates should be interpreted with caution when making these comparisons. Fifth, 
most of the studies presented data on incidence of influenza without presenting either the age-
specific denominators or age-specific numbers of cases.  Taken together with the fact that there 
were varied case definitions and adjustments applied, this made it difficult for us to calculate meta-
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analytic rates of influenza disease burden in Kenya.  Lastly, while not a direct limitation of our 
methods, the absence of data on influenza mortality remains a gap that needs to be addressed in 
order to inform influenza vaccine policy. 
In conclusion, our literature review provides a comprehensive summary of available data on the 
disease burden of influenza in Kenya over the past 8 years, and shows a substantial medically- and 
non-medically attended disease burden among children aged <5 years. Additional research gaps 
identified in the review include the lack of influenza mortality and socio-economic disease burden 
data.   While these additional data would be very helpful to policy makers and other stakeholders to 
inform prevention and treatment policies, the current data in Kenya indicate an important burden 
of influenza in young children that might be reduced with a targeted vaccination program including 
children and pregnant women. However, any decision about influenza vaccination must look at its 
burden relative to other respiratory pathogens such as respiratory syncytial virus – when a vaccine 
becomes available - and even non-respiratory vaccine preventable diseases. 
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Table 2.1: Average annual incidence rates of hospitalization with influenza for different respiratory 
syndromes (per 1,000 persons or person-years) in Kenya 
Author(s) 
Syndrome 
type 
Adjustment used Study site Age group 
Incidencea 
Rangeb            
Berkley et al. (2010)(15) 
and Onyango et al. 
(2012)(16) 
Hospitalized 
Severe or 
very severe 
pneumonia 
None stated Kilifi < 1 year 1.5-2.4 
    <5 years 0.6-0.8 
Ahmed et al. (2012)(17) 
Hospitalized 
SARI 
None stated 
Kakuma & Dadaab 
refugee camp 
< 1 year 10.3-12.3 
    < 5 years 4.2-5.6 
Fuller et al. (2013)(10) 
and  Emukule et al. 
(2014)(18) 
Hospitalized 
SARI 
Healthcare seeking; those 
with syndrome who did not 
have swabs tested for 
influenza virus 
Siaya, Western 
Kenya 
<6 months 5.7 
    <5 years 2.7-4.7 
    ≥5 years 0.2-0.4 
    All ages 0.7-1.1 
Feikin et al. (2012)(12) 
Hospitalized 
ARI 
Rates adjusted for those 
hospitalized with ARI who did 
not have swabs tested for 
influenza 
Bondo, Western 
Kenya 
<1 year 1.4 
    <5 years 1.4 
    All ages 0.6 
All studies 
All 
syndromes 
With or without any 
adjustment 
All study sites <6 months 5.7 
    <1 year 1.4-12.3 
    <5 years 0.6-5.6 
    ≥5 years 0.2-0.4 
    All ages 0.6-1.1 
Abbreviations: SARI=Severe acute respiratory illness; ARI=Acute respiratory illness.  
aIncidence reported per 1,000 persons or person-years; bRange is the minimum-maximum in cases where two or more studies were 
involved 
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Table 2.2: Average annual incidence rates of medically-attended influenza A and/or B (hospitalized and 
outpatient) per 1,000 persons or person-years in Kenya 
Author(s) 
Syndrome 
type 
Adjustment used Study site Age group 
Incidencea 
Rangeb 
Katz et al. 
(2012)(11) 
In- and 
outpatient 
ALRI 
Adjusted for those with ALRI who 
were not tested for influenza 
Kibera and 
Lwak 
< 1 year 32.8-42.1 
    <5 years 22.0-40.5 
    ≥5 years 12.0-15.8 
    All ages 13.7-23.0 
Feikin et al. 
(2013)(14) 
In- and 
outpatient 
SARI 
Adjusted for healthcare seeking by 
extrapolating from those with ARIǂ 
at household visit who sought care 
at a clinic besides the study clinic 
and for the pathogen-attributable 
fraction (PAF¥) 
Lwak, Western 
Kenya 
<5 years 58.0 
Breiman et al. 
(2015)(20) 
Outpatient 
SARI 
Adjusted for healthcare seeking for 
SARI at the study clinic and for the 
pathogen-attributable fraction 
(PAF¥). 
Kibera <5 years 13.0 
Feikin et al. 
(2012)(13) 
In- and 
outpatient 
ARI 
Adjusted for healthcare seeking by 
extrapolating from those with ARIǂ 
at household visit who sought care 
at a clinic besides the study clinic 
and for the pathogen-attributable 
fraction (PAF¥) 
Lwak, Western 
Kenya 
≥5 years 26.0 
Emukule et al. 
(2014)(18) 
Outpatient ILI 
Adjusted for those with ILI who 
were not tested for influenza 
Ting'wang'i, 
Western 
Kenya 
<6 months 16.2 
    <5 years 21.8 
    ≥5 years 4.3 
    All ages 7.2 
All studies All syndromes With any adjustment All study sites <6 months 16.2 
    < 1 year 32.8-42.1 
    <5 years 21.8-58.0 
    ≥5 years 4.3-26.0 
    All ages 7.2-23.0 
Abbreviations: SARI=Severe acute respiratory illness; ALRI=Acute lower respiratory illness; ILI=influenza-like illness; ARI=Acute 
respiratory illness  
aIncidence reported per 1,000 persons or person-years; bRange is the minimum-maximum in cases where two or more studies were 
involved; ǂARI in home was defined as cough, difficulty breathing or chest pain and reported fever; ¥Adjusted rates downward for 
asymptomatic detection of influenza in controls. 
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Table 2.3: Non-medically attended average annual incidence rates of Influenza reported for different 
respiratory syndromes (per 1,000 persons or person-years) in Kenya 
Author(s) Syndrome type Adjustment used Study site Age group 
Incidencea 
Rangeb 
Fuller et al. 
(2013)(10); Emukule 
et al. (2014)(18) 
Non-medically 
attended  SARI 
Adjusted for persons with 
pneumonia who did not seek 
care from health utilization 
survey (HUS) 
Siaya <6 months 6.2 
    <5 years 2.9-5.1 
    ≥5 years 0.4-0.8 
    All ages 0.9-1.4 
Emukule et al. 
(2014)(18) 
Non-medically 
attended ILI 
Adjusted for persons with 
ARI who did not seek care 
from HUS 
Ting'wang'i <6 months 22.3 
    <5 years 30.1 
    ≥5 years 5.4 
    All ages 9.1 
aIncidence reported per 1,000 persons or person-years; bRange is the minimum-maximum in cases where two or more studies were 
involved 
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Appendix File 2.1: Summarized equations for the adjustment factors accounting for persons who 
were not tested for influenza, those who did not seek healthcare, and for asymptomatic detection of 
influenza 
 
Equation 1. Incidence rate of influenza-associated hospitalization/outpatient visit  
 
𝐼𝑅 =
𝐹𝑙𝑢𝑐𝑎𝑠𝑒𝑠
𝑃𝑜𝑌
 
 
Where:  
𝐼𝑅 = Unadjusted incidence rate of influenza-associated hospitalizations/outpatient visits  
𝐹𝑙𝑢𝑐𝑎𝑠𝑒𝑠 = Total number of cases who tested positive for influenza 
 PoY= Person-time of surveillance in years/Mid-year population 
 
 
Equation 2a. Adjustment for those who met the specific case definition but were not tested for influenza 
 
𝐴𝑑𝑗𝐼𝑅 = (𝐼𝑅 ×
1
𝑃𝑓𝑙𝑢𝑡𝑒𝑠𝑡
) 
Where:  
 𝐴𝑑𝑗𝐼𝑅 = Incidence adjusted for those who were not tested for influenza 
 𝐼𝑅 = Unadjusted (crude) incidence rate of influenza-associated hospitalizations/outpatient visits 
𝑃𝑓𝑙𝑢𝑡𝑒𝑠𝑡   = Proportion of hospitalized patients who met the specific case definition and were tested for influenza 
 
Equation 2b. Adjustment for those who did not seek healthcare 
 
𝐴𝑑𝑗𝐼𝑅 = (𝐼𝑅 ×
1
𝑃𝑐𝑎𝑠𝑒
) 
Where:  
 𝐴𝑑𝑗𝐼𝑅 = Incidence adjusted for those who were not tested for influenza 
 𝐼𝑅 = Unadjusted (crude) incidence rate of influenza-associated hospitalizations/outpatient visits 
𝑃𝑐𝑎𝑠𝑒 = Proportion of cases in the community who met the specific case definition and sought healthcare at the study 
hospital/clinic 
 
 
Equation 2c. Adjustment for asymptomatic detection of influenza  
 
𝐴𝑑𝑗𝐼𝑅 = (𝐼𝑅 × 𝑃𝐴𝐹) 
Where:  
 𝐴𝑑𝑗𝐼𝑅 = Incidence adjusted for those who were not tested for influenza 
 𝐼𝑅 = Unadjusted (crude) incidence rate of influenza-associated hospitalizations/outpatient visits 
𝑃𝐴𝐹 = Pathogen-attributable fraction defined as (OR-1)/OR 
𝑂𝑅 = The odds ratio of detection of influenza among cases compared to asymptomatic controls from a case-control 
analysis 
 
Note: Refer to the individual published papers for further details on specific adjustments used. 
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Appendix Table 2.1: Case definitions use for respiratory syndromes in reviewed articles 
Authors(s) Syndrome Case definitions used 
Berkley et al. (2010) Hospitalized Severe or very 
severe pneumonia 
Severe pneumonia was defined as cough OR difficult breathing AND lower chest wall in-drawing and no signs of very severe pneumonia.                                                                                                  
 
Very severe pneumonia was defined as cough OR difficult breathing AND at least one of (hypoxia, inability to drink or breast feed, inability to sit, or 
impaired consciousness at admission). 
Onyango et al. (2012) Hospitalized Severe or very 
severe pneumonia  
Severe pneumonia was defined as cough OR difficulty breathing AND lower-chest-wall in-drawing. 
 
Very severe pneumonia was defined as cough OR difficulty breathing AND one or more of (cyanosis, prostration, unconsciousness, or an oxygen 
saturation level <90%). 
Ahmed et al. (2012) 
 
Hospitalized SARI For children > 1 week and < 2 months old, SARI was defined as an admission to the pediatric ward with any of the following: respiratory rate > 60 
per minute, severe chest in-drawing, nasal flaring, grunting, fever ≥ 38°C, hypothermia < 35.5°C, or pulse oxygenation < 90%. 
 
For children 2 months to < 5 years of age, SARI was defined as cough or difficulty breathing and any one of the following: respiratory rate > 50/min 
for infants 2 months to < 1 year old or > 40/min for children 1 to < 5 years old, chest in-drawing or stridor in a calm child, unable to drink or breast 
feed, vomiting, convulsions, lethargic or unconscious, or pulse oxygen saturation < 90%. 
 
For older children and adults ≥ 5 years of age, SARI was defined as fever ≥ 38°C, and cough or sore throat, and shortness of breath or difficulty 
breathing.  
Fuller et al. (2013) Hospitalized SARI For children <5 years as cough or difficulty breathing and any one of the following: IMCIǂ danger sign, tachypnea for age group, nasal flaring, 
grunting, oxygen saturation <90%, chest in-drawing, or stridor in a calm child.                                                                                                     In patients 
aged ≥5 years, SARI was defined as any hospitalized case with cough, difficulty breathing, or chest pain during the previous 14 days. 
Emukule et al. (2014) Hospitalized SARI Defined as cough or difficulty breathing or pleural chest pain within the last 14 days for persons of all ages. 
Feikin et al. (2012) Hospitalized ARI Acute cough, difficulty in breathing or pleuritic chest pain. 
Feikin et al. (2013) In- and outpatient ALRI For patients aged ≥5 years, ALRI was defined as cough, difficulty breathing or chest pain and either documented axillary temperature ≥38°C or 
oxygen saturation <90%.                                                                    
Katz et al. (2012) 
 
 
In- and outpatient ALRI For in- and out-patient children <5 years ALRI was defined as cough OR difficulty breathing, AND at least one of (maternal report of IMCIǂ danger 
sign, lower-chest wall in-drawing, stridor, oxygen saturation <90%).     
For in- and out-patients aged ≥5 years, ALRI was defined as cough OR difficulty breathing OR chest pain, AND a documented axillary temperature 
of ≥38.0°C OR and oxygen saturation level of ≤90%. 
Breiman et al. (2015) Outpatient SARI For in- and out-patient children <5 years SARI was defined as cough OR difficulty breathing, AND at least one of (unable to drink/breastfeed, vomits 
everything, convulsions, lethargic or unconscious, stridor when calm, and lower chest wall in-drawing, as well as an additional criterion of oxygen 
saturation <90%).   
Katz et al. (2012) In- and outpatient ILI Defined as axillary temperature ≥38°C AND cough or sore throat in an outpatient within the past 14 days for persons of all ages. 
Emukule et al. (2014) Outpatient ILI Defined as axillary temperature ≥ 38°C and cough or sore throat for persons of all ages. 
Feikin et al. (2012) In- and outpatient ARI Cough or difficulty breathing or chest pain and documented axillary temperature ≥38°C or oxygen saturation <90% or hospitalization. 
Fuller et al. (2013) Non-hospitalized SARI Those with pneumonia who did not seek care in health utilization survey (HUS). In this HUS, pneumonia was defined as: cough or difficulty 
breathing for more than two days or a diagnosis of ‘pneumonia’ by a healthcare worker. 
Emukule et al. (2014) Non-hospitalized SARI Those with pneumonia who did not seek care in health utilization survey (HUS). In this HUS, pneumonia was defined as: cough and difficulty in 
breathing for more than two days (excluding the past 14 days) within the preceding 12 months or a diagnosis of ‘pneumonia’ by a healthcare 
worker. 
Emukule et al. (2014) Non-medically attended ILI Those with acute respiratory illness (ARI) who did not seek care in a HUS. In this HUS, ARI was defined as: cough and difficulty in breathing within 
the last 14 days. 
ǂInability to drink or breastfeed, vomiting everything, convulsions, lethargy or unconscious
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Appendix Table 2.2: Proportion testing positive for influenza A and/or B among hospitalized patients and in- and 
outpatients seen with different respiratory syndromes in Kenya 
Author(s) Study period Syndrome type Study site Age group 
Influenza positive        
n/N(%) 
Berkley et al. 
(2010) 
Jan to Dec, 
2007 
Hospitalized severe or very 
severe pneumonia 
Kilifi <5 years 44/779(5.8)a 
Onyango et al. 
(2012) 
Jan, 2007 to 
Dec, 2010 
Hospitalized severe or very 
severe pneumonia. 
Kilifi <5 years 99/2,002(4.9) 
Ahmed et al. 
(2012) 
Sep, 2007 to 
Aug, 2010 
Hospitalized SARI 
Kakuma and 
Dadaab 
<5 years 410/4,449(9.2)a 
Emukule et al. 
(2014) 
Aug, 2009 to 
Jul, 2012 
Hospitalized SARI Siaya All ages 348/5,507(7.9) 
Feikin et al. 
(2012) 
Mar, 2007 
to Feb 2010 
Hospitalized ARI Bondo 
<5 years 83/1,213(6.8) 
≥5 years 121/866(14.0) 
All ages 204/2079(9.8) 
Katz et al. (2012) 
Mar, 2007 
to Feb 2010 
In- and outpatient ALRI 
Kibera All ages 319/1197(26.7) 
Lwak All ages 359/1,641(21.9) 
Feikin et al. 
(2013) 
Mar, 2007 
to Feb 2010 
In- and outpatient SARI Lwak <5 years 27/408(6.6)a 
Breiman et al. 
(2015) 
Mar, 2007 
to Feb 2011 
Outpatient SARI Kibera <5 years 112/818(13.7) 
Feikin et al. 
(2012) 
Mar, 2007 
to Feb 2010 
In- and outpatient ARI Lwak ≥5 years 249/1216(20.5)a 
Emukule et al. 
(2014) 
Aug, 2009 to 
Jul, 2012 
Outpatient ILI Ting'wang'i All ages 206/1,632(13.7) 
Abbreviations: SARI=Severe acute respiratory illness; ALRI=Acute lower respiratory illness; ILI=influenza-like illness; ARI=Acute respiratory illness  
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Appendix Table 2.3: Average annual incidence rates of influenza-associated hospitalizations for different respiratory 
syndromes (per 1,000 persons or person-years) in Kenya 
Author(s) 
Study 
period 
Syndrome 
type 
Adjustment used Study site Age group 
Incidence*  
(95% CI) 
Berkley et al. 
(2010) 
Jan to 
Dec, 2007 
Hospitalized 
Severe or very 
severe 
pneumonia 
None stated. Kilifi¢ 
< 1 year 2.40a 
1-<2 years 1.00a 
2-4 years 0.40a 
<5 years 0.80a 
Onyango et al. 
(2012) 
Jan, 2007 
to Dec, 
2010 
Hospitalized 
severe or very 
severe 
pneumonia. 
None stated. Kilifi 
<1 years 1.5(1.2-2.0) 
<5 years 0.6(0.5-0.7) 
Ahmed et al. 
(2012) 
Sep, 2007 
to Aug, 
2010 
Hospitalized 
SARI 
None stated. 
Kakuma 
refugee camp 
< 1 year 12.3(7.7-19.5)a 
1-4 years 4.2(2.9-6.1)a 
< 5 years 5.6(4.2-7.5)a 
Dadaab 
refugee camp 
< 1 year 10.3(6.8-15.6)a 
1-4 years 2.9(2.1-4.2)a 
< 5 years 4.2(3.2-5.5)a 
Fuller et al. 
(2013) 
Aug, 2009 
to Jul, 
2010 
Hospitalized 
SARI 
Rates adjusted for risk 
factor and healthcare-
seeking for SARI (See the 
online appendix of the 
published paper). 
Siaya  
<5 years 3.9(3.1-4.7) 
≥5 years 0.3(0.2-0.4) 
Kenya 
<5 years 4.7(3.5-6.2) 
≥5 years 0.2(0.2-0.3) 
All ages 1.1(0.9-1.6) 
Aug, 2010 
to Jul, 
2011 
Hospitalized 
SARI 
Rates adjusted for risk 
factor and healthcare-
seeking for SARI (See the 
online appendix of the 
published paper). 
Siaya 
<5 years 3.0(2.2-3.7) 
≥5 years 0.4(0.3-0.5) 
Kenya 
<5 years 3.0(2.3-3.9) 
≥5 years 0.2(0.2-0.4) 
All ages 0.7(0.5-0.9) 
Emukule et al. 
(2014) 
Aug, 2009 
to Jul, 
2012 
Hospitalized 
SARI 
Rates adjusted for those 
hospitalized with SARI who 
did not have swabs tested 
for influenza virus. 
Siaya 
<6 months 5.7(2.4-13.8) 
6-11 months 4.7(1.8-11.9) 
12-23 months 4.5(2.3-8.6) 
2-4 years 1.4(0.7-2.8) 
<5 years 2.7(1.8-3.9) 
≥5 years 0.3(0.2-0.4) 
All ages 0.7(0.5-0.9) 
Feikin et al. 
(2012) 
Mar, 2007 
to Feb 
2010 
Hospitalized 
ARI 
Rates adjusted for those 
hospitalized with ARI who 
did not have swabs tested 
for influenza. 
Bondo 
<1 year 1.4(0.9-1.8) 
<5 years 1.4(1.2-1.7) 
All ages 0.6(0.5-0.6) 
Abbreviations: SARI=Severe acute respiratory illness; ARI=Acute respiratory illness.  
*Incidence reported per 1,000 persons or person-years; £SARI in the community was defined as: cough or difficulty breathing AND one of (chest wall 
in-drawing, vomiting everything, lethargic, convulsions, or inability to drink or breast feed); aInfluenza A; ¢95% CI not provided. 
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Appendix Table 2.4: Average annual incidence rates of medically-attended influenza A and/or B (hospitalized and 
outpatient) per 1,000 persons or person-years in Kenya 
Author(s) Study period 
Syndrome 
type 
Adjustment used Study site Age group 
Incidence*  
(95% CI) 
Katz et al. 
(2012) 
Mar, 2007 to 
Feb 2010 
In- and 
outpatient 
ALRI 
Rates adjusted for those 
with ALRI at the study 
clinic who were not tested 
for influenza. 
Kibera 
< 1 year 32.8(21.4-50.2) 
1-<2 years 26.2(18.3-37.5) 
2-4 years 17.1(12.6-23.1) 
<5 years 22.0(17.7-26.6) 
≥5 years 12.0(10.3-13.3) 
All ages 13.7(12.2-15.2) 
Lwak 
< 1 year 42.1(22.7-78.3) 
1-<2 years 43.9(26.0-74.1) 
2-4 years 40.1(28.3-56.7) 
<5 years 40.5(31.2-52.6) 
≥5 years 15.8(14.1-17.7) 
All ages 23.0(20.8-25.5) 
Feikin et al. 
(2013) 
Mar, 2007 to 
Feb 2010 
In- and 
outpatient 
SARI 
Rates were adjusted for 
healthcare seeking by 
extrapolating from those 
with ARIǂ at household 
visit who sought care at a 
clinic besides the study 
clinic and for the 
pathogen-attributable 
fraction (PAF¥). 
Lwak <5 years 58.0(38.0-78.0) 
Breiman et 
al. (2015) 
Mar, 2007 to 
Jul, 2011 
Outpatient 
SARI 
Adjusted for healthcare 
seeking for SARI at the 
study clinic and for the 
pathogen-attributable 
fraction (PAF¥). 
Kibera <5 years 13.0(6.0-20.0) 
Feikin et al. 
(2012) 
Mar, 2007 to 
Feb 2010 
In- and 
outpatient ARI 
Rates were adjusted for 
healthcare seeking by 
extrapolating from those 
with ARIǂ at household 
visit who sought care at a 
clinic besides the study 
clinic and for the 
pathogen-attributable 
fraction (PAF¥). 
Lwak ≥5 years 26.0(22.8-29.2)a 
Emukule et 
al. (2014) 
Aug, 2009 to 
Jul, 2012 
Outpatient ILI 
Rates adjusted for those 
with ILI at the outpatient 
clinic who did not have 
swabs tested for influenza. 
Ting'wang'i 
<6 months 16.2(3.5-73.8) 
6-11 months 37.7(14.7-96.7) 
12-23 months 31.8(15.6-64.4) 
2-4 years 17.2(10.3-28.9) 
<5 years 21.8(15.1-31.6) 
≥5 years 4.3(2.8-6.4) 
All ages 7.2(5.5-9.4) 
Abbreviations: SARI=Severe acute respiratory illness; ALRI=Acute lower respiratory illness; ILI=influenza-like illness; ARI=Acute respiratory illness  
*Incidence reported per 1,000 persons or person-years; ǂARI in home was defined as cough, difficulty breathing or chest pain and reported fever; 
¥Adjusted rates downward for asymptomatic detection of influenza in controls; aInfluenza A. 
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Appendix Table 2.5: Non-medically attended average annual incidence rates of Influenza reported for different 
respiratory syndromes (per 1,000 persons or person-years) in Kenya 
Author(s) Study period 
Syndrome 
type 
Adjustment used Study site Age group 
Incidence*         
(95% CI) 
Fuller et al. 
(2013) 
Aug, 2009 to 
Jul, 2010 
Non-medically 
attended SARI 
Percent of pneumonia 
case hospitalized from 
health utilization 
survey (HUS). 
Siaya 
<5 years 4.2(2.7-7.3) 
≥5 years 0.6(0.3-1.2) 
Kenya 
<5 years 5.1(3.5-8.1) 
≥5 years 0.4(0.2-0.8) 
All ages 1.4(0.9-2.4) 
Aug, 2010 to 
Jul, 2011 
Non-medically 
attended SARI 
Percent of pneumonia 
case hospitalized from 
HUS. 
Siaya 
<5 years 3.2(2.1-5.5) 
≥5 years 0.8(0.5-1.6) 
Kenya 
<5 years 3.3(2.4-5.2) 
≥5 years 0.5(0.3-0.9) 
All ages 0.9(0.6-1.6) 
Emukule et al. 
(2014) 
Aug, 2009 to 
Jul, 2012 
Non-medically 
attended  
SARI 
Adjusted for persons 
with pneumonia who 
did not seek care, 
using the results of a 
2005 HUS. 
Siaya 
<6 months 6.2(2.9-13.2) 
6-11 months 5.0(2.2-11.4) 
12-23 months 4.8(2.7-8.6) 
2-4 years 1.6(0.9-2.7) 
<5 years 2.9(2.1-4.0) 
≥5 years 0.5(0.4-0.7) 
All ages 1.2(0.9-1.4) 
Emukule et al. 
(2014) 
Aug, 2009 to 
Jul, 2012 
Non-medically 
attended ILI 
Adjusted for persons 
with ARI who did not 
seek care, using the 
results of a 2005 HUS. 
Ting'wang'i 
<6 months 22.3(15.0-33.2) 
6-11 months 52.1(40.4-67.1) 
12-23 months 43.8(36.3-53.0) 
2-4 years 23.8(20.7-27.4) 
<5 years 30.1(27.3-33.3) 
≥5 years 5.4(4.9-6.0) 
All ages 9.1(8.5-9.8) 
*Incidence reported per 1,000 persons or person-year. 
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Abstract 
Background:  In Kenya, detailed data on the age-specific burden of influenza and RSV are essential 
to inform use of limited vaccination and treatment resources. 
Materials and Methods: We analyzed surveillance data from August 2009 to July 2012 for 
hospitalized severe acute respiratory illness (SARI) and outpatient influenza-like illness (ILI) at two 
health facilities in western Kenya to estimate the burden of influenza and respiratory syncytial virus 
(RSV).  
Incidence rates were estimated by dividing the number of cases with laboratory-confirmed virus 
infections by the mid-year population. Rates were adjusted for healthcare-seeking behavior, and to 
account for patients who met the SARI/ILI case definitions but were not tested.  
Results: The average annual incidence of influenza-associated SARI hospitalization per 1,000 
persons was 2.7 (95% CI 1.8-3.9) among children <5 years and 0.3 (95% CI 0.2-0.4) among persons 
≥5 years; for RSV-associated SARI hospitalization, it was 5.2 (95% CI 4.0-6.8) among children <5 
years and 0.1 (95% CI 0.0-0.2) among persons ≥5 years. 
The incidence of influenza-associated medically-attended ILI per 1,000 was 24.0 (95% CI 16.6-34.7) 
among children <5 years and 3.8 (95% CI 2.6-5.7) among persons ≥5 years. The incidence of RSV-
associated medically-attended ILI was 24.6 (95% CI 17.0-35.4) among children <5 years and 0.8 
(95% CI 0.3-1.9) among persons ≥5 years. 
Conclusions: Influenza and RSV both exact an important burden in children. This highlights the 
possible value of influenza vaccines, and future RSV vaccines, for Kenyan children. 
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3.1 Introduction 
Acute lower respiratory tract infections account for an estimated 1.9 million deaths in children 
<5 years of age annually, up to 90% of which occur in the developing world (1-3).  In Africa and Asia, 
acute lower respiratory tract infections are two to ten times more common than in the USA (4), and 
have three to seven-fold worse outcomes than in the industrialized world (5).  A large fraction of 
human respiratory tract infections are associated with viruses including influenza A and B, and 
respiratory syncytial virus (RSV) (6). Safe and effective vaccines for influenza are available (7, 8), but 
very limited quantities of influenza vaccine are currently being used in Kenya, and elsewhere in 
Africa (9). Efforts are on-going to develop a vaccine for RSV (10). However additional and more 
detailed data on burden of disease may be required before these vaccines are used more widely. 
While some data suggest a significant burden of hospitalized influenza in Kenya, many of the 
data come from persons seeking medical care during the period of the 2009 influenza 
A(H1N1)pdm09 pandemic with few data from either the pre- or post-pandemic periods (11-13). The 
age-specific burden of influenza has also not clearly been defined among infants <6 months, or 
among those aged 6-12 months. Such data could be used to inform whether vaccination of 
pregnant women to protect infants <6 months of age (for whom no influenza vaccine is currently 
licensed) through maternal antibody transfer and/or vaccination of children older than six months 
of age may be viable vaccination strategies for Kenya. Data on the burden of RSV have also been 
limited to those seeking medical care – focused on children <5 years - at the Coastal and Western 
areas of Kenya (14-17).  
To address these gaps we estimated the age-specific burden and seasonality of medically-
attended, and non-medically attended influenza and RSV in western Kenya during the period 2009-
2012. 
 
3.2 Methods 
Since August 2009 the Kenya Medical Research Institute and the Centers for Disease Control 
and Prevention (KEMRI/CDC) have conducted hospital-based surveillance for severe acute 
respiratory illness (SARI) at Siaya District Hospital (SDH) and outpatient surveillance for influenza-
like illness (ILI) at Ting’wang’i Health Centre (THC) in western Kenya. Both facilities are located in 
Karemo Division, where KEMRI/CDC implements a Health Demographic Surveillance System (HDSS), 
with an approximate population of 80,000 (18). Karemo’s population is culturally homogenous, and 
almost entirely rural (19). The area is endemic for malaria with a high child mortality rate (212 
deaths per 1000 live births in 2008) (19) and a high HIV prevalence, which in 2008 was estimated at 
14% among persons aged ≥18 years (20).  
3.2.1 Data collection and case definitions 
       From August 2009 to July 2012, trained nurses and clinical officers enrolled all consenting 
patients who were admitted to SDH with SARI or sought outpatient healthcare at THC for ILI. ILI was 
defined as axillary temperature ≥38°C and cough or sore throat with an onset with the past 14 days 
in an outpatient for persons of all ages. SARI was defined as hospitalization with cough or difficulty 
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breathing or pleural chest pain with an onset within the last 14 days. Hospitalized SARI patients 
were followed up for the duration of their hospitalization until they were discharged, transferred or 
died. We also estimated rates of non-medically attended ILI and SARI using the proportion of 
persons that sought care for acute respiratory infections (ARI), and pneumonia, respectively, from a 
health utilization survey implemented in Western Kenya in 2005 (21). In this survey, ARI was 
defined more narrowly than ILI as cough and difficulty in breathing within the last 14 days (21). 
Pneumonia was defined as ARI lasting for more than two days (excluding the past 14 days) within 
the preceding 12 months or a diagnosis of ‘pneumonia’ by a healthcare worker. Data processing 
and management procedures have been described previously (13). 
3.2.2 Specimen collection and laboratory methods 
Patients meeting SARI and ILI case definitions were enrolled in medical facility-based 
surveillance and nasopharyngeal (NP) and oropharyngeal (OP) swabs were collected, combined into 
a single viral transport media, and tested by real-time reverse transcription polymerase chain 
reaction (rtRT-PCR) for influenza A and B viruses and RSV (12, 13). 
Patients admitted to the hospital for any reason were offered voluntary counseling and testing 
for HIV. Details of HIV testing at SDH have also been described previously (22).  
3.2.3 Data analysis 
3.2.3.1 Descriptive Analyses 
      We used univariate analysis methods including mean, median and proportions to describe 
demographic characteristics and laboratory outcomes of patients. Chi-square tests were used to 
assess associations for categorical variables. Mann-Whitney rank sum tests were used to test for 
differences in the age distribution between patients who were tested and those who were not 
tested for influenza viruses and RSV.  
3.2.3.2 Estimating the incidence rates of hospitalized SARI, and influenza and RSV-associated SARI 
       As SDH is the only hospital located within Karemo Division, age-specific incidence rates (for 11 
age groups: <6 months, 6-11 months, 12-23 months, 2-4 years, 5-17 years, 18-34 years, 35-49 
years,  ≥50 years, <5 years, ≥5 years, all ages) of hospitalized SARI were estimated by dividing the 
number of cases enrolled in the HDSS for each age group, by the mid-year population in each age 
group residing in the Karemo Division who were enrolled in HDSS. Similarly, the age-specific 
incidence rates of Influenza and RSV-associated SARI hospitalizations were calculated by dividing 
the number laboratory-confirmed influenza or RSV cases enrolled in the HDSS for each age group, 
by the mid-year population in each age group. Rates of influenza and RSV-associated SARI were 
adjusted for patients who met the SARI case definition but from whom NP/OP swabs were not 
collected and tested (for each age group, the adjusted number of cases was equal to the number of 
laboratory-confirmed cases divided by the proportion of patients with SARI who were tested). We 
compared incidence rates of influenza and RSV for residents living within 0-5 kilometers (KM), 0-10 
KM, and 0-20 KM of the hospital. We did this in order to assess whether rates of hospitalized 
influenza and RSV declined with inclusion of persons who lived within Karemo Division but farther 
from the hospital (Figure 3.1). 
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3.2.3.3 Estimating the incidence rates of outpatient ILI, and Influenza and RSV-associated ILI 
       We estimated age-specific incidence of outpatient influenza and RSV virus infections for the 11 
aforementioned age groups. To do this we examined the outpatient registers for children <5 years 
and persons ≥5 years at all seven outpatient facilities in Karemo Division to obtain the area of 
residence (village and sub-location) for each outpatient visit for a two-year period. From each 
outpatient facility we calculated the number and proportion of patients seen who were residents of 
Karemo Division by month and age (< 5 years and ≥5 years). We summed the number of patients 
seen at the seven facilities who were residents of Karemo and calculated the proportion of those 
who visited THC. We determined that approximately 10% (12,464/128,967) of outpatient visits 
among Karemo residents between 2010 and 2011 occurred at THC (11% and 9% for children <5 
years and persons ≥5 years, respectively).  The crude incidence rates (outpatient medically-
attended ILI; influenza-associated ILI; and RSV-associated ILI) were calculated by dividing the 
number of cases by the mid-year population in each age group residing in the Karemo Division who 
were enrolled in HDSS.    
       After calculating crude rates by age group, we calculated adjusted rates by dividing the crude 
rates by the proportions of patients who visited THC in each age group (0.11 for children <5 years 
and 0.09 for persons ≥5 years).  Influenza and RSV-associated incidence rates were then further 
adjusted for ILI patients who did not have NP/OP swabs collected (for each age group, the adjusted 
number of cases was equal to the number of laboratory-confirmed cases divided by the proportion 
of patients with ILI who were tested) (Figure 3.1). 
3.2.3.4 Estimating non-medically attended incidence rates of influenza and RSV 
We calculated the total (hospitalized and non-hospitalized) incidence of influenza and RSV-
associated SARI by dividing the hospitalized SARI-associated incidence rates by the proportion of 
reported cases of pneumonia who went to hospital based on data from a 2005 Health Utilization 
Survey.  In this survey, health utilization was reported for two age groups – children <5 years and 
persons ≥5 years. Forty eight percent (95% CI 35-62) of the children aged <5 years and 34% (95% CI 
23-48) of persons aged ≥5 years were reported to have sought care for pneumonia at a hospital. As 
there was no health utilization reported for the finer age categories among children <5 years and 
persons ≥5 years, we used the same adjustment factor reported in the survey for children <5 years 
(48%) for all the age categories under five years (<6 months, 6-11 months, 12-23 months, 2-4 years, 
and <5 years). Similarly, we used the same health utilization adjustment factor (34%) reported for 
persons ≥5 years for all the age groups among persons aged five years or older (5-18 years, ≥18 
years, and ≥5 years). The incidence of non-hospitalized SARI associated with influenza and RSV was 
then calculated by subtracting the hospitalized influenza and RSV-associated SARI incidence from 
the total incidence of influenza and RSV-associated SARI calculated using health utilization survey 
data for each age group (Figure 3.1).  
We took a similar approach to estimate non-medically attended ILI associated with influenza 
and RSV. In this survey, 42% (95% CI 33-51) of the children aged <5 years and 44% (95% CI 40-53) of 
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persons aged ≥5 years reported to have sought care for ARI at a health facility. We used an 
adjustment factor of 42% for all the age groups under the age of five years and 44% for the age 
groups among patients aged five years or older.  Total age-specific incidence rates of influenza and 
RSV-associated ILI were calculated by dividing the medically-attended ILI incidence rates by the 
proportion of reported cases of ARI in the health utilization survey who went to any facility.  
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Figure 3.1: Flow diagram of the steps used for the calculation of incidence rates.
A: SARI and ILI Syndromes 
Step 2: Adjust for patients hospitalized with SARI 
without pathogen testing. 
B: Pathogen-associated (Influenza, and RSV) 
SARI hospitalizations 
C: Pathogen-associated (Influenza, and RSV) 
outpatient ILI visits 
Step1: Calculate crude incidence as number of 
laboratory confirmed pathogen cases divided by the 
age-specific mid-year population. 
Step 3: Incidence rate of pathogen-associated 
hospitalized SARI. 
Step 2: Incidence rate of SARI hospitalization or 
ILI outpatient visits. 
Step1: Calculate crude incidence as number of 
SARI hospitalized cases or ILI outpatient cases 
divided by the age-specific mid-year population. 
Step 4: Apply age group-specific (<5 years and ≥5 
years) adjustment for pneumonia cases who did seek 
care at a hospital using results from a 2005 HUS.  
Step 5: Total pathogen-associated (hospitalized and 
non-medically attended) SARI. 
Step 7: Pathogen-specific incidence of non-medically 
attended SARI. 
 
Step 6: Subtract incidence in Step 3 from Step 5. 
Step1: Calculate crude incidence as number of laboratory 
confirmed pathogen cases divided by the age-specific mid-
year population. 
Step 2: Adjust for outpatients with ILI without pathogen 
testing. 
 
Step 4: Incidence rate of pathogen-associated outpatient ILI. 
Step 3: Adjust for residents of Karemo who sought outpatient 
care at a facility other than the study facility. 
Step 5: Apply age group-specific (<5 years and ≥5 years) 
adjustment for ARI cases who did seek care at a health 
facility using results from a 2005 HUS. 
 
Step 6: Total pathogen-associated (outpatient and non-
medically attended) ILI. 
Step 8: Pathogen-specific incidence of non-medically 
attended ILI. 
Step 7: Subtract incidence in Step 4 from Step 6. 
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The age-specific incidence of non-medically attended ILI associated with influenza and RSV was 
calculated by subtracting the adjusted incidence of medically-attended influenza and RSV estimated 
from ILI surveillance at THC from the total incidence of influenza and RSV-associated ILI calculated 
using health utilization survey data, for each age group (Figure 3.1). Incidence rates were reported 
per 1000 persons, and the Poisson approximation method was used to calculate the 95% 
confidence intervals (CIs) around point estimates (23), separately for each age group. Data analysis 
was performed using Stata version 12.1 (Stata Corp, College Station, Texas). 
 
3.3 Ethical considerations 
This study was approved by both the Ethical Review Committee of the Kenya Medical Research 
Institute (KEMRI SSC-1801) and Institutional Review Board of CDC-Atlanta (CDC IRB #3308). Written 
informed consent was obtained from all participants or caretakers/guardians of all minors prior to 
enrolment in the study and sample collection. 
 
3.4 Results 
 
3.4.1 Descriptive analyses 
We enrolled 5507 patients hospitalized with SARI at SDH, and 1632 patients with ILI at THC. 
Most (SARI=75%, ILI=77%) were children <5 years old. Although the study case definition was 
different from the current WHO case definition for SARI, seventy percent of the SARI cases included 
in this study also met the new  WHO case definition [25% among children <5 years (30% in children 
< 6 months); and 47% in persons ≥5 years] (24). The median age was 1.6 years and 2.4 years for 
SARI and ILI patients, respectively, and 50% of the SARI patients and 53% of the ILI patients were 
female. Of the enrolled patients, 4387 (80%) of those with SARI and 1508 (92%) of those with ILI 
were tested for influenza and RSV (Table 3.1). When we compared SARI patients who were tested 
with those who were not, those tested were more likely to be male (50% vs. 46%; p<0.05), and the 
median age among those tested was 1.6 years compared to 1.5 years among those not tested 
(p<0.001).  Similarly, ILI patients who were tested for influenza viruses or RSV were significantly 
older than those not tested (median age 2.4 years vs. 1.8 years; p<0.001). Case-fatality was 
significantly higher in SARI patients who were not tested for influenza or RSV than in those who 
were tested (18% vs. 4%; p<0.001).  
Influenza viruses were detected in 348/4387 (8%) of the SARI patients (Table 3.1); 253 (6%) 
were positive for influenza A, 97 (2%) were positive for influenza B and 2 (0.1%) were positive for 
positive for both influenza A and B. The most commonly detected subtypes during the study period 
were influenza A(H1N1)pdm09 and influenza A(H3N2). RSV was detected in 437 (10%) of the SARI 
patients who were tested (12% in children <5 years; 4% in persons ≥5 years old). HIV-infected 
patients were as likely as non-HIV infected patients to test positive for these viral pathogens when 
we adjusted for age (p=0.284 for influenza; and p= 0.957 for RSV).  The case-fatality proportion was 
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similar for SARI patients who tested positive compared to those who tested negative for influenza 
[13/348 (4%) vs. 171/4039 (4%); p=0.66] and RSV [14/437 (3%) vs. 170/3950 (4%); p=0.28], 
respectively. The median age among the SARI patients was significantly higher in influenza positive 
patients compared to RSV positive patients [3.0 vs. 1.1 years; p<0.001].  
Of the 1508 ILI patients tested, 206 (14%) tested positive for influenza viruses; [159 (11%) were 
positive for influenza A; 51 (3%) for influenza B; and 4 (0.3%) were positive for both influenza A and 
B]. The most commonly detected subtypes during the three years were influenza A(H1N1)pdm09 
and influenza A(H3N2). RSV was detected in 138 out of 1,508 patients (10%) [11% in children <5 
years; 6% in persons ≥5 years old] (Table 3.1).  Similarly, the median age among ILI patients was 
significantly higher in the influenza positive patients compared to RSV positive patients [4.4 vs. 2.4; 
p<0.001].   
Influenza-virus-positive cases were detected throughout the study period with the influenza-
positive proportions observed to be lower in the hotter months between December and January 
every year. RSV peaked more predictably during May-July of each year (Figure 3.2). Influenza 
A(H1N1)pdm09 was the dominant influenza virus in circulation during late 2009 and early 2010, and 
again during late 2010 and early 2011. Influenza A(H3N2) was the dominant influenza virus in 
circulation during the periods May 2010 to October 2010 and also from January 2012 to July 2012. 
Influenza B viruses were detected mostly between April 2011 and December 2011 (Figure 3.3). 
3.4.2 Incidence of hospitalized SARI, and influenza and RSV-associated SARI 
The estimated average annual incidence rate of SARI hospitalizations among children <5 years 
of age was 43.6(95% CI 40.1-47.3) [106.2(95% CI 88.6-127.3) in children < 6 months; 120.2(95% CI 
101.7-142.0) in children 6-11 months; 67.6(95% CI 58.1-78.8) in children 12-23 months; and 
16.9(95% CI 14.3-20.0) in children 2-4 years] and 2.4(95% CI 2.0-2.8) among persons aged ≥5 years 
cases per 1000 persons (Table 3.2).  The average annual adjusted incidence of influenza-associated 
hospitalized SARI was 0.7 per 1000 persons (95% CI 0.5-0.9) and was higher among children aged <5 
years [2.7 (95% CI 1.8-3.9)] compared to persons aged ≥5 years [0.3 (95% CI 0.2-0.4)] (Table 3.3).  
Influenza-associated hospitalizations were 5.7(95% CI 2.4-13.8) in children <6 months; 4.7(95% CI 
1.8-11.9) in children aged 6-11 months; and 4.4(95% CI 2.3-8.5) in children aged 12-23 months. The 
incidence of influenza-associated SARI hospitalizations was not significantly different among 
residents of Karemo living within 5 KM of SDH [2.6 (95% CI 1.5-4.7)] compared to residents living 
within 10 KM of SDH [2.4 (95% CI 1.6-3.7)] and those living with 20 KM of SDH [2.7 (95% CI 1.8-3.9)] 
(Figure 3.4). 
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                           Figure 3.2: Seasonality of Influenza and RSV in Western Kenya, Aug 2009 - Jul 2012 
 
 
                       
                  Figure 3.3: Seasonality of influenza and circulating subtypes in Western Kenya, Aug 2009 - Jul 2012 
 
Incidence rates of RSV-associated hospitalized SARI were 0.9 (95% CI 0.7-1.2) and were higher in 
children aged <5 years [5.2 (95% CI 4.0-6.8)] than in persons aged ≥5 years [0.1 (95% CI 0.0-0.2)] 
(Table 3.3). RSV-associated hospitalizations were highest in children <2 years old [13.4(95% CI 7.5-
23.8) in children <6 months; 14.0(95% CI 8.1-24.1) in children aged 6-11 months; and 8.1(95% CI 
5.0-13.1) in children aged 12-23 months]. As was the case with influenza, incidence of RSV-
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associated SARI was not significantly different in residents of Karemo living within 5 KM of SDH [0.9 
(95% CI 0.6-1.3)] compared with those living within 10 KM of SDH [0.9 (95% CI 0.7-1.2)] and 
compared to those with 20 KM of SDH [0.9 (95% CI 0.7-1.2)] (Figure 3.4). More detailed age-specific 
incidence rates of hospitalizations associated with influenza and RSV are presented in Table 3.3. 
Incidence rates of hospitalizations associated with influenza or RSV were higher in the first year 
(August 2009 – July 2010) compared to the other two years included in this analysis (Table 3.4). 
                 
             Figure 3.4: Rates of influenza and RSV associated SARI by distance from SDH, Aug 2009 –Jul 2012. 
 
3.4.3 Incidence of medically-attended outpatient ILI and influenza and RSV-associated ILI 
      The estimated incidence of medically-attended outpatient visits associated with ILI among 
children <5 years of age was 214.9(95% CI 207.1-223.1), and 16.1(95% CI 15.1-17.1) among persons 
aged ≥5 years cases per 1000 persons (Table 3.2).  The average annual adjusted incidence of 
medically-attended ILI associated with influenza was 7.2 (95% CI 5.5-9.4) and was significantly 
higher in children aged <5 years [21.8(95% CI 15.1-31.6)] compared to those aged ≥5 years 
[4.3(95% CI2.8-6.4)]. The average annual incidence of medically-attended ILI associated with RSV 
was 4.7 (95% CI 3.3-6.6) and was significantly higher among children <5 years [22.3(95% CI15.5-
32.2)] compared to persons aged ≥5 years [0.9(95% CI 0.4-2.2)] (Table 3.2).  The age-specific 
incidence rates of outpatient visits associated with influenza and RSV are presented on Table 3.3. 
3.4.4 Non-medically attended incidence rates of influenza and RSV SARI and ILI 
The incidence of non-hospitalized SARI attributable to influenza was 1.2 (95% CI 0.9-1.4) [2.9 
(95% CI 2.1-4.0) in persons <5 years; and 0.5 (95% CI 0.4-0.7) in persons ≥5 years]. The incidence of 
non-hospitalized SARI attributable to RSV was 1.6 (95% CI 1.4-2.0) [5.6 (95% CI 4.5-7.1) in persons 
<5 years; and 0.2 (95% CI 0.1-0.3) in persons ≥5 years] after adjusting for persons who reported 
cases of pneumonia but did not go to hospital.  
The overall incidence of non-medically attended ILI attributable to influenza was 9.1 (95% CI 
8.5-9.8); 30.1(95% CI27.3-33.3) in persons <5 years; and  5.4(95% CI4.9-6.0) in persons ≥5 years. 
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The incidence of non-medically attended ILI associated with RSV was 6.0 (95% CI 5.4-6.5) [30.8(95% 
CI27.9-34.0) in persons <5 years; and 1.1(95% CI0.9-1.4) in persons ≥5 years] after adjusting for 
persons who reported ARI in the 2005 health utilization survey but did not go to any facility (Table 
3.3). 
 
3.5 Discussion 
These findings suggest an important burden of both influenza and RSV among persons with 
hospitalized SARI and outpatient ILI in western Kenya, particularly among children aged <5 years. 
There is also likely an important burden of illness associated with these viral pathogens in persons 
with SARI and ILI who do not seek medical care.  
The burden of severe respiratory disease associated with both influenza and RSV was highest in 
children less than 23 months of age, suggesting young children are an important potential target 
group for current or future vaccines and other interventions in Kenya. While pregnant women are a 
high risk group for influenza-associated complications in their own right (25), our additional finding 
that the burden of influenza associated SARI was highest in those under six months of age further 
suggests the potential value of vaccination of pregnant women as a way of protecting (via maternal 
antibody transfer) those very young children for whom no influenza vaccine is currently licensed 
(26).  These data therefore support the 2012 recommendations by the WHO Strategic Advisory 
Group of Experts on Immunization that suggest pregnant women to be a high priority group for 
influenza vaccination (27). 
The rates of influenza-associated hospitalizations presented here are comparable to the 
incidence reported in Kenya during the period August 2010 to July 2011 (11). These rates of 
hospitalized influenza are also comparable to rates published for other locations in Kenya (11), and 
to those reported in Bangladesh and Thailand (28, 29). However these estimates of influenza-
associated hospitalizations in children <5 years are nearly two times higher than rates in the pre-
pandemic period before 2009 in the same region (13). Importantly, they are also 3-7 times higher 
than those reported recently in the United States (30, 31).  
Our adjusted incidence of hospitalizations associated with RSV among children <5 years [i.e. 5.2 
(95% CI 4.0-6.8)] is nearly 2-fold higher than the incidence reported in Kilifi, in the Coastal part of 
Kenya (14), but is lower than rates published in a five-year cohort study in South Africa.  Even 
without adjustment, our observed incidence rates of RSV in children under 24 months of age also 
appear to be nearly twice those reported in the United States (32). We also observe that the 
incidence of RSV-associated hospitalizations was higher than the incidence of influenza 
hospitalizations in younger ages, but lower in older ages, which is consistent with findings from 
other studies (31, 33). 
Our observed incidence of outpatient ILI-associated influenza was only one-tenth of the rate 
reported in Bangladesh (28) but over 2-fold higher than rates reported in England and Netherlands 
among children <5 years (34). As was the case with influenza, our estimated incidence of ILI-
associated RSV in children <5 years was over 5-times higher than the incidence published in Europe 
(34).  
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Using adjustments for health seeking behaviors, our estimates of the incidence of non-
medically-attended SARI and ILI associated with influenza and RSV were higher than comparable 
rates of medically-attended illness in this community.  This highlights the need to consider burden 
of disease beyond the health care facility to best inform public health policy in this setting. Indeed, 
the 2005 survey indicated that only 48% of children <5 years and 34% of persons ≥5 years who 
reported having pneumonia sought care at a hospital. Similarly, only 42% of children <5 years and 
44% of persons ≥5 years who reported having ARI in the two weeks preceding the health utilization 
survey  sought healthcare at any health facility (21). These direct estimates therefore support 
international indirect modeling efforts that have suggested influenza and RSV-associated severe 
disease rates are substantially higher in Africa and other lower resourced countries than elsewhere 
(2, 3, 5).  
Our study was subject to several limitations. The SARI case definition did not include wheezing, 
nasal flaring, tachypnea, shortness of breath, and lethargy which have been associated with RSV 
elsewhere, and may have resulted in an under estimation of incidence of RSV, especially in very 
young children (3, 16, 35). This might explain why our RSV rates were similar between infants aged 
<6 months and 6-11 months, which is inconsistent with other studies that report much higher rates 
in younger infants (32). Conversely, the SARI case definition that we used is broader than the new 
case definition recommended by WHO which requires a history of fever or measured fever (24). 
There were an additional 30% SARI cases identified using this case definition compared to what 
would have been identified using the new WHO case definition. This may have served to improve 
sensitivity and thus helped to better estimate disease burden, in the very young children (<6 
months) and older persons who may be less likely to present with fever as a component of influenza 
virus infections. Similarly, the ILI case definition – requiring a measured temperature of ≥ 38°C - was 
used to estimate the burden of RSV among outpatients. This also may have possibly led to an under 
estimation of the burden of RSV in outpatients, which may be less likely than influenza to result in 
presentation with fever (36, 37).  The case definitions for ARI and pneumonia in this survey were 
also both narrower in scope than the ILI and SARI case definitions used in facility-based surveillance, 
respectively. This could have led to an underestimation of the incidence of illness in the community.   
Another limitation was that to estimate the burden of non-hospitalized and non-medically-
attended illness we used adjustment factors from a health utilization survey that was conducted in 
2005 - four years earlier than the study period. Health seeking behaviors could have changed over 
that period of time. Additionally, the survey was powered to estimate health utilization among for 
both children <5 years and persons ≥5 years (21). In this respect, the health utilization adjustments 
may not have been as robust as ideal for the finer age-specific rate adjustments that we undertook. 
For example, we applied the same adjustment factor reported for health utilization among under-
fives for all age categories in children <5 years (<6 months, 6-11 months, 12-23 months, 2-4 years). 
If the utilization rates differ across these age groups, then this could bias our estimates. Conducting 
health utilizations surveys with sufficient power in narrower age groups would serve to improve 
future estimates.  
There was also minimal testing for HIV especially among younger persons and thus our study 
was not able to effectively estimate incidence specifically in HIV positive and negative populations.  
Lastly, we did not conduct a record review at hospitals in the area other than SDH to determine the 
proportion of residents of Karemo who went to other hospitals. Instead, we assumed that every 
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resident of Karemo who required hospitalization would go to SDH. We felt this was a reasonable 
approach given that the next nearest hospital was located 17 KM away.   To support this there were 
also no observed differences between calculated incidence for persons who lived within 5KM, 
10KM, and 20 KM of SDH. The assumption behind this validation approach was that people within 
very close proximity would seek care at SDH rather than elsewhere and so we would have expected 
the incidence to decline significantly with an increase in distance.  
In conclusion, influenza and RSV both exact an important disease burden in rural western Kenya, 
particularly in children <5 years old. These data suggest that a future RSV vaccine could have 
important implications for child health in Kenya. The immunization of children and pregnant women 
with currently licensed influenza vaccines also has important potential to reduce a significant cause 
of respiratory morbidity and mortality in Kenya. 
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Table 3.1: Characteristics of patients who were admitted at SDH with SARI and those who presented to THC 
with ILI and were tested for respiratory pathogens, August 2009 - July 2012 
  In-patients (SARI patients) Out-patients (ILI patients) 
 
Total Number 
(N=5,507) 
Enrolled in 
Karemo HDSS  
(N=2,136) 
Total Number 
(N=1,632) 
Enrolled in 
Karemo HDSS  
(N=1,186) 
  n (%) n (%) n (%) n (%) 
Sex 
    
Male 2,800(50.8) 1,097(51.4) 779(47.7) 567(47.8) 
Female 2,707(49.2) 1,039(48.6) 853(52.3) 619(52.2) 
Age Group     
<6 months 918(16.7) 351(16.4) 134(8.2) 85(7.2) 
6-11 months 1,040(18.9) 414(19.4) 207(12.7) 140(11.8) 
12-23 months 1,134(20.6) 495(23.2) 339(20.8) 248(20.9) 
2-4 years 1,018(18.5) 411(19.2) 570(34.9) 431(36.3) 
5-17 years 417(7.6) 174(8.2) 311(19.1) 236(19.9) 
18-34 years 493(9.0) 133(6.2) 53(3.3) 35(3.0) 
35-49 years 223(4.1) 74(3.5) 11(0.7) 7(0.6) 
≥50 years 264(4.8) 84(3.9) 7(0.4) 4(0.3) 
Median age years (Range) 1.6(0.01-90.0) 1.6(0.01-90.0) 2.4(0.1-0  63.4) 2.4(0.02-63.4) 
Died in the hospital 390(7.1) 103(4.8) - - 
HIV status     
Negative 2,917(53.0) 1,190(55.7) 482(29.5) 337(28.4) 
Positive¥ 654(11.9) 230(10.8) 28(1.7) 12(1.0) 
Unknown 1,936(35.2) 716(33.5) 1,122(68.8) 837(70.6) 
Sampled and tested for influenza and RSV 4,387(79.7) 1730(81.0) 1,508(92.4) 1,092(92.1) 
Respiratory pathogen isolated     
Influenza A or B* 348(7.9) 124(7.2) 206(13.7) 155(14.2) 
Influenza A* 253(5.8) 93(5.4) 159(10.5) 119(10.9) 
Seasonal A (H1N1)** 2(0.8) 0(0.0) 1(0.6) 1(0.8) 
Seasonal A (H3N2)** 63(24.9) 16(17.2) 52(32.7) 42(35.3) 
Pandemic H1N1** 93(36.8) 39(41.9) 82(51.6) 59(49.6) 
Unsubtypable** 10(4.0) 3(3.2) 3(1.9) 3(2.5) 
Not subtyped** 81(32.0) 32(34.4) 18(11.3) 14(11.8) 
Influenza B* 97(2.2) 32(1.9) 51(3.4) 38(3.5) 
Influenza A and B* 2(0.1) 1(0.1) 4(0.3) 2(0.2) 
Respiratory syncytial virus (RSV)* 437(10.0) 176(10.2) 138(9.7) 101(9.7) 
Influenza-RSV co-infection* 18(0.4) 7(0.4) 14(0.9) 11(1.0) 
¥18% of those with known HIV status were HIV infected; *Denominator is the number of those who tested for Influenza and RSV; **Denominator            
in the number of influenza A cases. 
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Table 3.2: Age-specific average annual rates of SARI hospitalizations and ILI outpatient visits (per 1,000 
persons) in Western Kenya, August 2009 - July 2012 
  
Karemo 
Populationa 
Proportion of 
hospitalizationsb 
with SARI                        
n(%) 
Average annual 
SARI 
hospitalization 
rates                 
(95% CI) 
Proportion of 
outpatientsc with   
ILI                        
n(%) 
 Average annual 
medically-attended 
ILI ratesd                    
(95% CI) 
Age Group      
<6 months 1,102 351/821(42.8) 106.2(88.6-127.3) 85/896(9.5) 233.7(206.9-264.1) 
6-11 months 1,148 414/1,050(39.4) 120.2(101.7-142.0) 140/858(16.3) 369.5(336.0-406.4) 
12-23 months 2,440 495/1,287(38.5) 67.6(58.1-78.8) 249/1,436(17.3) 309.2(287.9-332.1) 
2-4 years 8,097 411/1,267(32.4) 16.9(14.3-20.0) 433/2,435(17.8) 162.1(153.5-171.1) 
5-17 years 28,326 174/708(24.6) 2.0(1.6-2.6) 237/2,456(9.6) 31.0(29.0-33.1) 
18-34 years 18,270 133/1,452(9.2) 2.4(1.8-3.3) 35/1,152(3.0) 7.1(6.0-8.4) 
35-49 years 8,272 74/758(9.8) 3.0(2.0-4.4) 7/461(1.5) 3.1(2.1-4.6) 
≥50 years 10,397 84/944(8.9) 2.7(1.9-3.9) 4/749(0.5) 1.4(0.9-2.4) 
<5 years 12,787 1,671/4,425(37.8) 43.6(40.1-47.3) 907/5,625(16.1) 214.9(207.1-223.1) 
≥5 years 65,265 465/3,862(12.0) 2.4(2.0-2.8) 283/4,818(5.9) 16.1(15.1-17.1) 
      All ages 78,052 1,978/8,287(23.9) 8.4(7.8-9.1) 1,179/10,443(11.3) 50.4(48.8-52.0) 
         aMid-study-period population for Karemo (Aug 2009 – Jul 2012); bTotal hospitalizations among residents of Keremo over three years (Aug 2009 -     
       Jul 2012); cTotal outpatient visits to Ting'wang'i by residents of Karemo over three years (Aug 2009 - Jul 2012); dAdjusted for outpatient visits to  
       other health facilities in Karemo other than Ting'wang'i. 
 
 
61 
 
Table 3.3:  Age-specific average annual rates for hospitalizations and outpatient visits attributable to influenza and RSV (per 1,000 persons) in Western 
Kenya, August 2009 - July 2012 
    SARI      ILI 
  
Proportion 
positivea                        
n(%) 
Unadjusted 
hospitalized 
rates             
(95% CI) 
Adjusted 
Hospitalized 
ratesb                    
(95% CI) 
Non-
hospitalized 
ratesc                     
(95% CI) 
  Proportion 
positivea                        
n(%) 
Unadjusted 
medically-
attended rates                    
(95% CI) 
Adjusted 
Medically-
attended ratesb                     
(95% CI) 
Non-medically 
attended ratesd                     
(95% CI) 
Influenza A or B          
<6 months 15/279(5.4) 4.5(1.9-10.9) 5.7(2.4-13.8) 6.2(2.9-13.2)  5/72(6.9) 1.5(0.3-6.9) 16.2(3.5-73.8) 22.3(15.0-33.2) 
6-11 months 13/337(3.9) 3.8(1.5-9.7) 4.7(1.8-11.9) 5.0(2.2-11.4)  13/128(10.2) 3.8(1.5-9.7) 37.7(14.7-96.7) 52.1(40.4-67.1) 
12-23 months 27/409(6.6) 3.7(1.9-7.1) 4.4(2.3-8.5) 4.8(2.7-8.5)  23/223(10.3) 3.1(1.5-6.4) 31.7(15.6-64.4) 43.8(36.3-53.0) 
2-4 years 27/319(8.5) 1.1(0.6-2.1) 1.4(0.7-2.7) 1.5(0.9-2.7)  43/402(10.7) 1.8(1.1-3.0) 17.3(10.3-29.0) 23.9(20.8-27.5) 
5-17 years 13/126(10.3) 0.2(0.1-0.4) 0.2(0.1-0.5) 0.4(0.2-0.7)  54/221(24.4) 0.6(0.4-1.0) 6.1(3.9-9.8) 7.8(6.9-8.9) 
18-34 years 15/117(12.8) 0.3(0.1-0.7) 0.3(0.1-0.7) 0.6(0.3-1.1)  12/35(34.3) 0.2(0.1-0.6) 2.0(0.7-5.3) 2.5(1.9-3.4) 
35-49 years 8/67(11.9) 0.3(0.1-1.1) 0.4(0.1-1.2) 0.7(0.3-1.6)  * * * * 
≥50 years 6/76(7.9) 0.2(0.0-0.8) 0.2(0.1-0.9) 0.4(0.2-1.1)  * * * * 
<5 years 82/1344(6.1) 2.1(1.5-3.1) 2.7(1.8-3.9) 2.9(2.1-4.0)  84/825(10.2) 2.2(1.5-3.2) 21.8(15.1-31.6) 30.1(27.3-33.3) 
≥5 years 42/386(10.9) 0.2(0.1-0.4) 0.3(0.2-0.4) 0.5(0.4-0.7)  71/267(26.6) 0.4(0.2-0.5) 4.3(2.8-6.4) 5.4(4.9-6.0) 
      All ages 124/1730(7.2) 0.5(0.4-0.7) 0.7(0.5-0.9) 1.2(0.9-1.4)  155/1092(14.2) 0.7(0.5-0.9) 7.2(5.5-9.4) 9.1(8.5-9.8) 
RSV          
<6 months 35/279(12.5) 10.6(6.0-18.8) 13.4(7.5-23.8) 14.5(8.9-23.7)  2/72(2.8) 0.6(0.1-6.7) 6.5(0.6-71.4) 8.9(4.8-16.7) 
6-11 months 39/337(11.6) 11.3(6.6-19.5) 14.0(8.1-24.1) 15.1(9.5-24.2)  14/128(10.9) 4.1(1.6-10.1) 40.6(16.4-100.6) 56.1(43.9-71.6) 
12-23 months 49/409(12.0) 6.7(4.1-10.9) 8.1(5.0-13.1) 8.7(5.7-13.4)  21/223(9.4) 2.9(1.4-6.0) 29.0(13.8-60.8) 40.0(32.8-48.8) 
2-4 years 37/319(11.6) 1.5(0.9-2.7) 2.0(1.1-3.4) 2.1(1.3-3.4)  49/402(12.2) 2.0(1.2-3.3) 19.7(12.1-32.0) 27.2(23.9-31.1) 
5-17 years 7/126(5.6) 0.1(0.0-0.3) 0.1(0.0-0.4) 0.2(0.1-0.5)  13/221(5.9) 0.2(0.1-0.4) 1.5(0.6-3.8) 1.9(1.4-2.5) 
18-34 years 7/117(6.0) 0.1(0.0-0.5) 0.1(0.0-0.5) 0.3(0.1-0.7)  1/35(2.9) 0.0(0.0-0.5) 0.2(0.0-4.9) 0.2(0.1-0.6) 
35-49 years 1/67(1.5) 0.0(0.0-1.2) 0.0(0.0-1.3) 0.1(0.0-0.9)  * * * * 
≥50 years 1/76(1.3) 0.0(0.0-1.0) 0.0(0.0-1.1) 0.1(0.0-0.7)  * * * * 
<5 years 160/1344(11.9) 4.2(3.2-5.5) 5.2(4.0-6.8) 5.6(4.5-7.1)  86/825(10.4) 2.2(1.6-3.2) 22.3(15.5-32.2) 30.8(27.9-34.0) 
≥5 years 16/386(4.1) 0.1(0.0-0.2) 0.1(0.0-0.2) 0.2(0.1-0.3)  15/267(5.6) 0.1(0.0-0.2) 0.9(0.4-2.2) 1.1(0.9-1.4) 
      All ages 176/1730(10.2) 0.8(0.6-1.0) 0.9(0.7-1.2) 1.6(1.4-2.0)   101/1092(9.2) 0.4(0.3-0.6) 4.7(3.3-6.6) 6.0(5.4-6.5) 
aIncludes only data for residents of the HDSS area of Keremo Division (2009-2012); bAdjusted for those that met the case definition for SARI/ILI without laboratory test results; cAdjusted for  persons with 
pneumonia who did not seek care, using the results of a 2005 HUS; 48% (95% CI 35-62) of children <5 years and 34% (95% CI 23-48) of persons ≥5 years sought care for pneumonia at a hospital (Burton et al, 
2005); dAdjusted for persons with ILI who did not seek care, using the results of a 2005 HUS; 42%(95% CI 33-51) of children <5 years and 44%(95% CI 40-53) of persons ≥5 years sought care at any facility for 
ARI (Burton et al, 2005). * Estimates not calculated because there were fewer than 30 specimens tested in this age-specific stratum..  
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Table 3.4:  Annual ratesa for hospitalizations and outpatient visits attributable to influenza and RSV by year (per 1,000 persons) in Western Kenya, Aug 
2009 - Jul 2012 
  SARI    ILI 
  
Year 1b Year 2c Year 3d 
Average 
annual rates 
Year 1b Year 2c Year 3d 
Average          annual 
rates 
Influenza A or B         
<5 years 3.8(2.8-5.1) 3.2(2.2-4.5) 1.1(0.6-2.0) 2.7(1.8-3.9) 32.9(24.4-44.4) 15.3(9.9-23.7) 17.6(11.5-26.9) 21.8(15.1-31.6) 
≥5 years 0.3(0.2-0.5) 0.2(0.1-0.4) 0.3(0.2-0.4) 0.3(0.2-0.4) 8.5(6.4-11.4) 3.1(1.9-5.0) 1.5(0.8-2.9) 4.3(2.8-6.4) 
      All ages 0.9(0.7-1.1) 0.7(0.5-1.0) 0.4(0.3-0.6) 0.7(0.5-0.9) 12.7(10.3-15.6) 5.0(3.6-6.9) 4.1(2.9-5.9) 7.2(5.5-9.4) 
RSV         
<5 years 8.8(7.2-10.8) 4.8(3.6-6.4) 1.8(1.1-2.9) 5.2(4.0-6.8) 42.9(33.0-55.7) 13.8(8.7-21.9) 10.0(5.7-17.7) 22.3(15.5-32.2) 
≥5 years 0.2(0.1-0.4) 0.1(0.0-0.2) 0.1(0.0-0.2) 0.1(0.0-0.2) 2.4(1.4-4.1) 0.2(0.0-1.4) 0.2(0.0-1.2) 0.9(0.4-2.2) 
      All ages 1.7(1.4-2.0) 0.8(0.6-1.1) 0.3(0.2-0.5) 0.9(0.7-1.2) 9.8(7.8-12.5) 2.6(1.7-4.1) 1.8(1.0-3.1) 4.7(3.3-6.6) 
aAdjusted for those that met the case definition for SARI/ILI without laboratory test results; bAugust 2009 - July 2010;  cAugust 2010 - July 2011;  dAugust 2011 - July 2012. 
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Abstract 
Background: Influenza viruses and respiratory syncytial virus (RSV) associated mortality has not been 
well-established in tropical Africa.  
Methods: We used the negative binomial regression method and the rate-difference method (i.e., 
deaths during low and high influenza/RSV activity months), to estimate excess mortality attributable to 
influenza and RSV using verbal autopsy data collected through a health and demographic surveillance 
system in Western Kenya, 2007-2013. Excess mortality rates were calculated for a) all-cause mortality, 
b) all-respiratory deaths (including pneumonia), c) HIV-related deaths, and d) pulmonary tuberculosis 
(PTB) related deaths. 
Results: Using the negative binomial regression method, the mean annual all-cause excess mortality rate 
associated with influenza and RSV was 14.1 (95% confidence interval [CI] 0.0-93.3) and 17.1 (95% CI 0.0-
111.5) per 100,000 person-years (PY) respectively; and 10.5 (95% CI 0.0-28.5) and 7.3 (95% CI 0.0-27.3) 
per 100,000 PY for all-respiratory deaths, respectively. Highest mortality rates associated with influenza 
were among ≥50 years, particularly among persons with PTB (41.6 [95% CI 0.0-122.7]); and with RSV 
were among <5 years.  Using the rate-difference method, the excess mortality rate for influenza and RSV 
was 44.8 (95% CI 36.8-54.4) and 19.7 (95% CI 14.7-26.5) per 100,000 PY, respectively, for all-cause 
deaths; and 9.6 (95% CI 6.3-14.7) and 6.6 (95% CI 3.9-11.0) per 100,000 PY, respectively, for all-
respiratory deaths. 
Conclusions: Our study shows an important role of influenza and RSV on excess mortality in Western 
Kenya, especially among children <5 years and older persons, supporting recommendations for 
influenza vaccination and efforts to develop RSV vaccines.  
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4.1 Introduction 
Influenza viruses and respiratory syncytial virus (RSV) cause substantial morbidity globally (1-5). 
Disease severity associated with influenza and RSV has been well described in temperate countries as 
pronounced among young children (3, 6, 7), older persons (3, 7, 8), and among persons with chronic 
medical conditions (4-6, 9). In Kenya, influenza virus and RSV circulate year round and although limited 
morbidity data exist (10-15), associated mortality has not been established. Influenza and RSV 
associated mortality can inform policy makers in low and middle income countries to prioritize segments 
of the population that are most in need of the potentially limited vaccination and treatment resources. 
Conceptually, excess mortality can be estimated as the difference between observed mortality 
(during the periods of influenza or RSV circulation) and expected mortality (if the pathogens are not 
circulating) (16-20).  In Kenya, as in most sub-Saharan African countries, there is an absence of 
systematically collected and robust vital statistics data. Furthermore, hospital-based data could under-
represent the number of those who die from respiratory illness as care-seeking is low, particularly 
among adults who are often underrepresented in health-facility based surveillance systems (21, 22).  
Here, we used verbal autopsy (VA) data collected through a health and demographic surveillance 
system (HDSS) in Western Kenya (23-25) to estimate the overall and age-specific excess mortality rates 
associated with influenza virus and RSV during the period 2007 to 2013. We also explore and discuss the 
merits and challenges of using two different estimation methods: (i) the negative binomial regression 
method which has been used in temperate countries to estimate excess mortality associated with 
influenza and RSV (16-19), and (ii) the rate-difference method which has previously been recommended 
as the method of choice when estimating excess mortality for countries without a clear disease 
seasonality pattern (16, 20). 
 
4.2 Methods 
 
4.2.1 Study site and population 
      The Western Kenya HDSS has been in existence since 2001 and currently comprises three 
geographical sites in Nyanza Province: Asembo, Gem and Karemo, (23, 25). These three areas cover an 
estimated area of 700 km2 with a culturally homogenous rural population of approximately 220,000 
(Figure 4.1) (23). Nyanza Province also has a high burden of malaria, pulmonary tuberculosis (PTB) (26) 
and human immunodeficiency virus (HIV) which has prevalence of 15% compared to 6% overall in Kenya 
(27).  
4.2.2 Mortality and population data sources 
Our study-participants included HDSS residents, i.e., lived in the site for at least four consecutive 
months, and their infants (23).  Participants live in compounds (or households) that are geo-spatially 
mapped, and each person receives a unique identification number allowing record linkage. A household 
census is conducted throughout the study area every four months to capture births, pregnancies, 
deaths, in- and out- migration, and economic data (23, 28). If a death is reported, at least one month 
after the death trained interviewers use a standardized World Health Organization (WHO) questionnaire 
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(29) endorsed by International Network for the Demographic Evaluation of Populations and Their Health 
(INDEPTH) to collect information on the decedent’s illness and care seeking behavior (30). The cause of 
death is assigned using the InterVA-4 method with corresponding ICD-10 codes (Appendix 4.1). 
                 
Figure 4.1: Map showing the location of the Health and Demographic Surveillance System (HDSS) in Western Kenya 
(Source: Odhiambo et al [23]) 
 
4.2.3 Influenza, RSV and malaria activity and data sources 
       Indices of influenza, RSV and malaria activity were defined using the monthly positive proportion of 
tested samples from our hospital-based active surveillance sites. Malaria was considered a priori as a 
potential confounder because it is endemic in the study region and has demonstrated seasonal mortality 
that sometimes overlaps with influenza and RSV activity. Malaria test result, as well as influenza and RSV 
virological data, were collected from three HDSS surveillance sites [Siaya County Referral Hospital 
(SCRH), Lwak Mission Hospital (Lwak), and Ting’wang’i Health Center (THC)] (Figure 4.1). Patients at 
these facilities were screened for malaria using methods previously described (31). Nasopharyngeal (NP) 
and oropharyngeal (OP) swabs were collected from patients (of all ages) with influenza-like illness (ILI) 
who presented as outpatients at Lwak or at THC, or patients hospitalized with severe acute respiratory 
illness (SARI) at Lwak or SCRH. (See Appendix 4.1 for case definitions). Laboratory testing for influenza A 
and B viruses and RSV was performed by real-time reverse transcription polymerase chain reaction (rRT-
PCR) using CDC protocols (32, 33).  
4.2.4 Data analyses 
      Estimates of deaths associated with influenza and RSV were calculated for four mortality outcomes: 
(i) all-cause deaths, (ii) all-respiratory deaths, including pneumonia, (iii) HIV-related deaths, and (iv) PTB-
related deaths. All-respiratory, HIV-, and PTB-related cause of death was considered for each individual 
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if it was listed as a cause of death. We did not estimate excess mortality for circulatory deaths 
associated with influenza and RSV because of the relatively low number of deaths recorded. 
4.2.4.1 Descriptive analyses and handling of missing VA data 
      The demographic characteristics of those who died were described using medians and ranges. 
Wilcoxon rank-sum and Chi-square tests were used to assess if there were differences between the age 
and sex distributions of cases with VA-coded underlying cause of death and those without. Influenza and 
RSV circulation patterns were described using monthly percentages of positive results.  We adjusted for 
missing VA data (age groups: <5, 5-49, ≥50 years, all ages), by dividing the monthly number of outcome-
specific (all-causes, all-respiratory, HIV-, and PTB-related) deaths by the monthly proportion of deaths 
with VA done.  
4.2.4.2 Estimating excess deaths using the negative binomial regression method 
Negative-binomial regression models which incorporated monthly influenza and RSV circulation data 
and adjusted for malaria activity were used to estimate the age-specific and pathogen-associated 
deaths. For each age group and mortality outcome, we explored a range of models with varying 
combinations of time polynomial terms (up to the 6th order) and seasonal cyclical terms (starting with a 
full model that incorporated time polynomials, the quarterly, semiannual and annual seasonal cyclical 
terms). The general model equation was of the form: 
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Where E(Yt) is the age-specific number of deaths; t is the running time variable; 0 is the model 
constant; 1 to 6 are the coefficients for the linear and polynomial time trends;  7 to 12  are the 
coefficients corresponding to the cyclical terms for the annual, semiannual and quarterly background 
seasonal variations; 13 , 14 and 15 are the coefficients representing the contribution of influenza, 
RSV and malaria respectively, and t is the error term. The final model that was selected was the one 
for which the Akaike Information Criterion (AIC) values were minimized.  
We explored using the natural cubic spline smoothing functions of time to model the background 
mortality as opposed to using the polynomial time trends and sinusoidal curves but the estimates were 
not significantly different. However, as our time series data were monthly and only analyzed over a 
period of seven years, we were concerned about overfitting the models when we used the spline 
method. The mortality estimates that we report here are based on models that incorporated sinusoidal 
curves to model the background mortality. 
To estimate the excess mortality associated with a specific pathogen (influenza or RSV), we first 
calculated the predicted monthly deaths from the model that included a term for the detection of the 
pathogen (full model) and then subtracted the predicted deaths from the baseline model (where the 
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term for the detection of the pathogen was set to zero) (6, 16, 19, 34). Only positive differences 
between the full and the baseline model were considered. We then calculated the age-specific excess 
mortality rates per 100,000 person-years (PY) by dividing the average annual number of excess deaths 
by the population at risk. The 95% confidence intervals (CI) were estimated using bootstrap sampling 
(with replacement) on blocks of calendar years over 1,000 replications (34). 
4.2.4.3 Estimating excess deaths using the baseline rate-difference method 
In this approach, we calculated the excess deaths attributable to influenza and RSV by taking the 
positive difference between age-specific deaths occurring each month when there was high pathogen 
circulation and the monthly average of deaths that occurred during the months of low pathogen 
circulation (baseline months) (16, 20). Months when the percentage of influenza and RSV cases were 
less than 15% and 12%, respectively, were considered as the baseline months (Figure 4.2). These 
baselines were defined based on the upper limit of the 95% CI on the mean pathogen detection rate 
over the study period (Appendix 4.1).  
To avoid double counting deaths for months where both influenza and RSV activity exceed these 
thresholds, we apportioned excess deaths for each pathogen proportionate to how the pathogen 
activity deviated from the stated thresholds (15% and 12%) (Appendix 4.1). Excess mortality rates were 
calculated as the mean annual number of excess deaths divided by the age-specific population at risk. 
The Poisson approximation method was used to calculate the 95% CI around point estimates (35). In this 
analysis, malaria and diarrheal deaths were excluded from the all-cause death estimates as they tended 
to follow a seasonal pattern similar to the RSV activity pattern (Appendix Figure 4.1). 
    
Figure 4.2: Monthly percentage of influenza and respiratory syncytial virus (RSV) positive results with cut-offs for the 
rate-difference method.  
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4.3 Ethical considerations 
The HDSS protocol and consent procedures, were approved by the Ethical Review Committee of the 
Kenya Medical Research Institute (KEMRI SSC-1801) and the Institutional Review Board of CDC-Atlanta 
(CDC IRB #3308).  
4.4 Results 
 
4.4.1 Descriptive analyses 
From January 2007 through December 2013, the Western Kenya HDSS population increased by 14% 
from 218,985 to 249,470. Over this period, there were a total of 22,899 deaths reported. Of these, 
19,991 (87%) had VA conducted and a cause of death assigned. The median age of death was 32 years 
[interquartile range (IQR) 2-63 years]. There were no differences between those with a VA-coded cause 
of death and those without by sex (χ=0.8692, p=0.351). However, those without a VA-coded cause of 
death were younger [median age 27 years (IQR=2-46) vs. 33 years (IQR=2-65); p<0.001]. The proportion 
of deaths without VA data also varied by year and was highest in 2007 (17%) and lowest in 2012 (8%). 
A total of 13,677 and 10,001 samples were collected and tested for influenza and RSV, respectively, 
over the study period. Of these, 1,620 (12%) tested positive for influenza viruses and 1,022 (10%) tested 
positive for RSV.  The average monthly percentage of tested patients who were positive for influenza 
was 12% (95% CI 10-14) and for RSV was 9% (95% CI 7-11) (Figure 4.2, and Appendix Figure 4.1). Malaria 
parasites were detected in 43% of all patients evaluated over the entire study period. 
4.4.2 Overall mortality rates and trends 
Over the study period, the mean annual all-causes mortality rate was 1,446 (95% CI 1,397-
1,497)/100,000 PY.  Among children <5 years the annual all-causes mortality rate ranged from 1,827 to 
5,059 deaths per 100,000 PY (lowest in 2012 and highest in the 2008), for a mean of 2,965 (95% CI 
2,791-3,150)/100,000 (Table 4.1 and Figure 4.3). Among persons aged ≥5 years, the annual all-causes 
mortality rate ranged from 953 to 1,456 per 100,000 PY for a mean of 1,163 (95% CI 1,115-
1,212)/100,000 PY. The mean annual all-respiratory mortality rate was 148 (95% CI 133-164)/100,000 
PY, and among children <5 years was 513 (95% CI 443-593)/100,000 PY]. The mean annual mortality 
rates for HIV- and PTB-related deaths were 275 (95% CI 254-298) and 186 (95% CI 169-204) per 100,000 
PY, respectively.  
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Figure 4.3: Age-specific trends in all-causes mortality rates in Western Kenya, 2007-2013 
 
4.4.3 Influenza- and RSV-associated deaths using the negative binomial regression method 
Using the negative binomial regression method, the mean annual excess all-causes mortality rate 
associated with influenza activity was 14.1 (95% CI 0.0-93.3)/100,000 PY; and was highest among 
persons aged ≥50 years (74.0 [95% CI 0.0-310.4]/100,000 PY) (Table 4.2 and Figure 4.4). Similarly, the 
mean annual excess mortality rate for all-respiratory deaths was highest among persons aged ≥50 years 
(34.6 [95% CI 0.0-81.0]/100,000 PY). Among children aged <5 years, the mean annual excess mortality 
rate of all-respiratory deaths associated with influenza was 16.7 (95% CI 0.0-78.2)/100,000 PY. The 
mean annual excess PTB related mortality rate was highest among persons aged ≥50 years (41.6 [95%CI 
0.0-122.7]/100,000 PY).  
The mean annual excess all-causes mortality rate associated with RSV was 17.1 (95% CI 0.0-
111.5)/100,000 PY. In contrast to influenza, the mean annual excess RSV mortality rate for all-
respiratory deaths was highest among children aged <5 years (38.5 [95% CI 0.0-109.9]/100,000 PY) 
(Table 4.3 and Figure 4.5).  
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Figure 4.4: Excess deaths estimated using the negative binomial regression model that were associated with influenza 
among children aged <5 years and persons aged ≥50 years, 2007-2013 
                 
Figure 4.5: Excess deaths estimated using the negative binomial regression model that were associated with RSV among 
children aged <5 years and persons aged ≥50 years, 2007-2013 
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4.4.4 Excess deaths using the rate-difference method 
The mean annual excess all-causes mortality rate using the rate difference method was 44.8 (95% CI 
36.8-54.4)/100,000 PY. All-respiratory influenza-associated mortality among <5 years was 62.7 (95% CI 
41.3-95.1) compared to 17.7 (95% CI 7.6-41.1)/100,000 PY among ≥50 year olds. Of HIV-related deaths, 
the mean annual excess influenza-associated mortality rate was highest among <5 years (40.9 [95% CI 
24.4-68.6] /100,000 PY), whereas PTB related mortality rate associated with influenza was highest 
among persons aged ≥50 years (41.8 [95% CI24.1-72.3] /100,000 PY) (Table 4.2).  
The mean annual excess all-causes mortality rate associated with RSV was highest among <5 years 
(90.3 [95% CI 63.8-127.8]/100,000 PY) (Table 4.3). Rate estimates of all-respiratory deaths associated 
with RSV was highest among children <5 years (38.1 [95% CI 22.3-65.0]/ 100,000 PY), whereas among 
persons aged ≥50 years was 4.7 (95% CI 0.9-24.1) /100,000 PY).  
 
4.5 Discussion 
Using two different methods (negative binomial regression and the rate-difference), our study 
showed that both influenza and RSV are associated with mortality among children <5 years, and adults 
≥50 years. The two estimation methods were consistent, for most of the mortality outcomes and age 
groups considered, in showing the segments of the population with high mortality burden.  
The rate-difference estimation approach has been suggested for estimating excess deaths where 
there are multiple peaks with no clear seasonality patterns, or where there is only a limited time series 
of data available (less than five years of data) (16). However, its major drawback is its inability to account 
for the effect of other pathogens that co-circulate with the pathogen investigated. In a region like 
Western Kenya where malaria is endemic and RSV sometimes overlaps with influenza activity (13), the 
rate-difference method could potentially overestimate influenza-associated excess deaths. Unlike the 
case with the rate-difference method, the negative binomial regression models were adjusted for the 
effect of RSV/influenza and malaria. This could partially explain the consistently lower estimates using 
this method when compared to estimates obtained using the rate-difference method.   
Our estimates of all-causes excess mortality associated with influenza are comparable to estimates 
from Singapore (36), Hong Kong (37-39), and New Zealand (40) among persons of all ages.  Estimates of 
all-respiratory excess deaths associated with influenza among children <5 years were comparable to the 
estimates reported in South Africa (6), but over ten-fold higher than rates reported in the United States 
(7, 41). The PTB related excess mortality that was associated with influenza was higher among persons 
≥50 years compared to children, consistent with other studies (34), highlighting the risk for influenza-
associated complications among PTB patients and the potential impact of influenza vaccination in areas 
of high prevalence of PTB. Because of the relatively low number of deaths, we were not able to estimate 
the excess HIV-related deaths that were associated with influenza for various age groups using the 
negative binomial regression method. However, estimates from the rate-difference method suggest an 
important HIV-related mortality associated with influenza among children aged <5 years. Further 
analysis may be warranted when more data become available as studies conducted in South Africa have 
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suggested a higher mortality rate associated with influenza among persons with HIV compared to those 
without (6, 8).  
Although the confidence intervals suggest comparable all-respiratory mortality rates associated with 
influenza and RSV among children aged <5 years, using the negative binomial regression method, our 
study found relatively higher point estimates for mortality rates in this age group associated with RSV 
compared to influenza, which is consistent with findings from studies conducted elsewhere (7, 41). The 
estimates of excess mortality associated with RSV were higher than rates reported in South Africa (6), 
and in the United States (7, 41). We also noted a high all-cause mortality associated with RSV among 
persons aged ≥50 years, which was similar to that associated with influenza and consistent with other 
studies that have suggested RSV as an important cause of morbidity and mortality among older adults 
(41, 42).  
It is not clear which death outcome category is more appropriate to characterize excess mortality 
associated with influenza or RSV in countries where these diseases have no marked seasonality and 
where there are competing causes of deaths such as malaria, PTB, and HIV. As in other studies (8, 17, 
39, 43), our estimates for all-causes excess mortality were higher than estimates for all-respiratory 
excess mortality for both influenza and RSV due to its low specificity. In appreciation of this challenge, 
most of studies try to make estimates available using several death outcomes including pneumonia and 
influenza and cardiovascular disease (7, 8, 17); however, the underlying characteristics of the population 
in sub-Saharan Africa may differ from that in temperate countries which may limit the utility of this 
approach.  
Our study was subject to several limitations. First, our study was underpowered to estimate 
mortality using regression methods for finer age groups, and due to few data points (particularly for 
RSV), estimates had wide confidence intervals, particularly when using negative-binomial of which all 
overlapped with zero.  This could also be the reason why we did not observe statistically significant 
excess mortality estimates associated with influenza and RSV using regression methods and supports a 
need for more robust datasets for estimation using negative binomial regression models. Second, we 
used VA data and not clinician certified cause-of-death data and thus estimates may vary as a function 
of the true cause of death composition in the population. Indeed, a study conducted elsewhere 
estimated the cause-specific mortality fraction accuracy at 0.625 and 0.629 for adults and children 
respectively, using verbal autopsy with the cause of death assigned using the InterVA-4 method (44). 
Lastly, we could not evaluate the impact of different virus subtypes on excess mortality due to limited 
data available.  
In conclusion, our study suggests a role of influenza and RSV on excess mortality in Western Kenya, 
especially among children <5 years and persons ≥50 years. These data suggest that future RSV vaccines 
(45, 46), and vaccination of children, older adults and persons with chronic medical conditions against 
seasonal influenza has the potential to reduce mortality rates in Western Kenya.  
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Table 4.1: Age-specific mean annual mortality rates in Western Kenya, January 2007 - December 2013 
Age group 
Person-
years 
All-cause mortality*         
(95% CI) 
Respiratory mortality 
(including pneumonia)* 
(95% CI) 
HIV-related 
mortality*                 
(95% CI) 
Pulmonary TB 
(PTB) related 
mortality*                   
(95% CI) 
    0-11 months 6,956 7,690 (7,065-8,370) 1,896 (1,598-2,249) 704 (532-932) 0 (-) 
    12-23 months 7,059 3,908 (3,473-4,397) 403 (279-582) 1,139 (916-1,418) 18 (3-103) 
    24-59 months 21,271 1,107 (975-1,258) 97 (63-150) 203 (151-274) 6 (1-34) 
    <5 years 35,286 2,965 (2,791-3,150) 513 (443-593) 489 (422-568) 7 (2-25) 
    5-14 years 65,209 213 (181-252) 21 (13-36) 39 (26-57) 8 (3-19) 
    15-49 years 93,149 1,025 (962-1,092) 54 (41-71) 340 (304-379) 254 (223-288) 
    50-64 years 17,847 1,923 (1,730-2,137) 138 (93-204) 395 (313-499) 364 (286-464) 
    ≥65 years 12,737 5,964 (5,554-6,403) 482 (376-619) 253 (180-358) 840 (695-1,015) 
    ≥50 years 30,584 3,606 (3,399-3,825) 281 (228-347) 336 (277-408) 562 (484-653) 
    ≥5 years 188,943 1,163 (1,115-1,212) 79 (68-93) 235 (214-258) 219 (199-241) 
    Total 224,228 1,446 (1,397-1,497) 148 (133-164) 275 (254-298) 186 (169-204) 
*Deaths per 100,000 person-years; CI-Confidence intervals; HIV-Human immunodeficiency virus 
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Table 4.2: Age-specific mean annual excess mortality rate associated with influenza in Western Kenya, 2007 - 2013 
Cause of death by age 
Negative-binomial  
regression method 
Rate-difference method 
(Higha activity vs. baselineb) 
  
Estimated 
deaths 
Mortality Rate*            
(95% CI) 
Estimated 
deaths 
Mortality Rate*                  
(95% CI) 
All causes     
    <5 years 8 22.2 (0.0-145.2) 44 125.5 (93.4-168.4) 
    5-49 years 1 0.8 (0.0-40.0) 37 23.6 (17.1-32.5) 
    ≥50 years 23 74.0 (0.0-310.4) 29 95.1 (66.1-136.7) 
    All ages 32 14.1 (0.0-93.3) 100 44.8 (36.8-54.4) 
All respiratory, including 
pneumonia  
    
    <5 years 6 16.7 (0.0-78.2) 22 62.7 (41.3-95.1) 
    5-49 years 7 4.5 (0.0-7.2) 4 2.2 (0.8-6.3) 
    ≥50 years 11 34.6 (0.0-81.0) 5 17.7 (7.6-41.1) 
    All ages 24 10.5 (0.0-28.5) 22 9.6 (6.3-14.7) 
HIV/AIDS     
    <5 years 1 3.6 (0.0-27.3) 14 40.9 (24.4-68.6) 
    5-49 years NE NE 9 6.3 (3.4-11.7) 
    ≥50 years NE NE 4 13.4 (5.1-35.2) 
    All ages NE NE 25 11.3 (7.7-16.7) 
Pulmonary Tuberculosis (PTB)     
    <5 years 1 2.2 (0.0-8.2) 1 2.8 (0.4-20.1) 
    5-49 years 10 6.5 (0.0-31.6) 27 17.4 (11.9-25.2) 
    ≥50 years 13 41.6 (0.0-122.7) 13 41.8 (24.1-72.3) 
    All ages 24 10.6 (0.0-40.2) 39 17.5 (12.8-23.9) 
     aMonthly percentage of influenza positive cases ≥15%; bMonthly percentage of influenza cases <15%; NE-Not estimated 
    *Deaths per 100,000 person-years. 
 
  
79 
 
 Table 4.3: Age-specific mean annual excess mortality rate associated with respiratory syncytial virus (RSV) in Western Kenya, 
2007 - 2013 
Cause of death by age 
Negative-binomial  
regression method 
Rate-difference method 
(Higha activity vs. baselineb) 
  
Estimated 
deaths 
Mortality Rate*                 
(95% CI) 
Estimated 
deaths 
Mortality Rate*               
(95% CI) 
All causes     
    <5 years 12 32.6 (0.0-397.1) 32 90.3 (63.8-127.8) 
    5-49 years 6 3.7 (0.0-28.7) 9 5.5 (2.8-10.6) 
    ≥50 years 21 68.7 (0.0-208.0) 15 48.2 (28.9-80.3) 
    All ages 39 17.1 (0.0-111.5) 44 19.7 (14.7-26.5) 
All respiratory, including pneumonia     
    <5 years 14 38.5 (0.0-109.9) 13 38.1 (22.3-65.0) 
    5-49 years 1 0.6 (0.0-8.4) 2 1.0 (0.2-4.8) 
    ≥50 years 2 5.9 (0.0-29.0) 1 4.7 (0.9-24.1) 
    All ages 17 7.3 (0.0-27.3) 15 6.6 (3.9-11.0) 
HIV/AIDS  
   
    <5 years 1 3.7 (0.0-87.0) 19 53.7 (34.2-84.2) 
    5-49 years NE NE 11 6.7 (3.6-12.2) 
    ≥50 years NE NE 3 10.9 (3.7-31.9) 
    All ages NE NE 29 13.1 (9.1-18.8) 
Pulmonary Tuberculosis (PTB)  
   
    <5 years 1 1.8 (0.0-160.3) 1 2.1 (0.2-20.5) 
    5-49 years 2 1.4 (0.0-31.4) 7 4.3 (2.0-9.1) 
    ≥50 years 11 35.1 (0.0-73.4) 9 28.3 (14.5-55.1) 
    All ages 14 6.0 (0.057.6) 12 5.2 (2.9-9.2) 
aMonthly percentage of RSV positive cases ≥12%; bMonthly percentage of RSV cases <12%; NE-Not estimated 
*Deaths per 100,000 person-years. 
  
  
80 
 
References 
1. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections 
due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 
2011;378(9807):1917-30. 
2. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower 
respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-
analysis. Lancet. 2010;375(9725):1545-55. 
3. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et al. Hospitalizations 
associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America. 
2012;54(10):1427-36. 
4. Madhi SA, Schoub B, Simmank K, Blackburn N, Klugman KP. Increased burden of respiratory viral 
associated severe lower respiratory tract infections in children infected with human immunodeficiency 
virus type-1. The Journal of pediatrics. 2000;137(1):78-84. 
5. Moyes J, Cohen C, Pretorius M, Groome M, von Gottberg A, Wolter N, et al. Epidemiology of 
respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-
infected and HIV-uninfected South African children, 2010-2011. The Journal of infectious diseases. 
2013;208 Suppl 3:S217-26. 
6. Tempia S, Walaza S, Viboud C, Cohen AL, Madhi SA, Venter M, et al. Mortality associated with 
seasonal and pandemic influenza and respiratory syncytial virus among children <5 years of age in a high 
HIV prevalence setting--South Africa, 1998-2009. Clinical infectious diseases : an official publication of 
the Infectious Diseases Society of America. 2014;58(9):1241-9. 
7. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated 
with influenza and respiratory syncytial virus in the United States. JAMA : the journal of the American 
Medical Association. 2003;289(2):179-86. 
8. Tempia S, Walaza S, Viboud C, Cohen AL, Madhi SA, Venter M, et al. Deaths associated with 
respiratory syncytial and influenza viruses among persons >/=5 years of age in HIV-prevalent area, South 
Africa, 1998-2009(1). Emerg Infect Dis. 2015;21(4):600-8. 
9. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly 
and high-risk adults. The New England journal of medicine. 2005;352(17):1749-59. 
10. Emukule GO, Paget J, Velden K, Mott JA. Influenza-Associated Disease Burden in Kenya: A Systematic 
Review of Literature. PloS one. 2015;10(9):e0138708. 
11. Katz MA, Lebo E, Emukule G, Njuguna HN, Aura B, Cosmas L, et al. Epidemiology, seasonality, and 
burden of influenza and influenza-like illness in urban and rural Kenya, 2007-2010. The Journal of 
infectious diseases. 2012;206 Suppl 1:S53-60. 
12. Katz MA, Muthoka P, Emukule GO, Kalani R, Njuguna H, Waiboci LW, et al. Results from the first six 
years of national sentinel surveillance for influenza in Kenya, July 2007-June 2013. PLoS One. 
2014;9(6):e98615. 
13. Emukule GO, Khagayi S, McMorrow ML, Ochola R, Otieno N, Widdowson MA, et al. The burden of 
influenza and RSV among inpatients and outpatients in rural western Kenya, 2009-2012. PLoS One. 
2014;9(8):e105543. 
14. Nokes DJ, Okiro EA, Ngama M, Ochola R, White LJ, Scott PD, et al. Respiratory syncytial virus 
infection and disease in infants and young children observed from birth in Kilifi District, Kenya. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America. 2008;46(1):50-
7. 
81 
 
15. Bigogo GM, Breiman RF, Feikin DR, Audi AO, Aura B, Cosmas L, et al. Epidemiology of respiratory 
syncytial virus infection in rural and urban Kenya. The Journal of infectious diseases. 2013;208 Suppl 
3:S207-16. 
16. Thompson WW, Weintraub E, Dhankhar P, Cheng PY, Brammer L, Meltzer MI, et al. Estimates of US 
influenza-associated deaths made using four different methods. Influenza and other respiratory viruses. 
2009;3(1):37-49. 
17. Goldstein E, Viboud C, Charu V, Lipsitch M. Improving the estimation of influenza-related mortality 
over a seasonal baseline. Epidemiology. 2012;23(6):829-38. 
18. Serfling RE, Sherman IL, Houseworth WJ. Excess pneumonia-influenza mortality by age and sex in 
three major influenza A2 epidemics, United States, 1957-58, 1960 and 1963. American journal of 
epidemiology. 1967;86(2):433-41. 
19. Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, et al. Global mortality 
estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study. PLoS medicine. 
2013;10(11):e1001558. 
20. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among 
persons with acquired immunodeficiency syndrome. Archives of internal medicine. 2001;161(3):441-6. 
21. Burton DC, Flannery B, Onyango B, Larson C, Alaii J, Zhang X, et al. Healthcare-seeking behaviour for 
common infectious disease-related illnesses in rural Kenya: a community-based house-to-house survey. 
J Health Popul Nutr. 2011;29(1):61-70. 
22. Kenya National Bureau of Statistics (KNBS) and ICF Macro. Kenya Demographic and Health Survey 
2008-09. 2010. 
23. Odhiambo FO, Laserson KF, Sewe M, Hamel MJ, Feikin DR, Adazu K, et al. Profile: the KEMRI/CDC 
Health and Demographic Surveillance System--Western Kenya. Int J Epidemiol. 2012;41(4):977-87. 
24. van Eijk AM, Adazu K, Ofware P, Vulule J, Hamel M, Slutsker L. Causes of deaths using verbal autopsy 
among adolescents and adults in rural western Kenya. Tropical medicine & international health : TM & 
IH. 2008;13(10):1314-24. 
25. Adazu K, Lindblade KA, Rosen DH, Odhiambo F, Ofware P, Kwach J, et al. Health and demographic 
surveillance in rural western Kenya: a platform for evaluating interventions to reduce morbidity and 
mortality from infectious diseases. The American journal of tropical medicine and hygiene. 
2005;73(6):1151-8. 
26. van't Hoog AH, Laserson KF, Githui WA, Meme HK, Agaya JA, Odeny LO, et al. High prevalence of 
pulmonary tuberculosis and inadequate case finding in rural western Kenya. American journal of 
respiratory and critical care medicine. 2011;183(9):1245-53. 
27. Kimanga DO, Ogola S, Umuro M, Ng'ang'a A, Kimondo L, Murithi P, et al. Prevalence and incidence of 
HIV infection, trends, and risk factors among persons aged 15-64 years in Kenya: results from a 
nationally representative study. Journal of acquired immune deficiency syndromes. 2014;66 Suppl 
1:S13-26. 
28. Phillips-Howard PA, Odhiambo FO, Hamel M, Adazu K, Ackers M, van Eijk AM, et al. Mortality trends 
from 2003 to 2009 among adolescents and young adults in rural Western Kenya using a health and 
demographic surveillance system. PloS one. 2012;7(11):e47017. 
29. World Health Organization (WHO). The 2012 WHO verbal autopsy instrument. Available at: 
http://www.who.int/healthinfo/statistics/WHO_VA_2012_RC1_Instrument.pdf. Accessed Nov 16th 
2015. 
30. INDEPTH. Available: http://www.indepth-network.org/. Accessed  Nov 16th 2015. 
82 
 
31. Odhiambo FO, Hamel MJ, Williamson J, Lindblade K, ter Kuile FO, Peterson E, et al. Intermittent 
preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, 
double-blind placebo-controlled trial. PloS one. 2010;5(4):e10016. 
32. WHO collaborating centre for influenza. CDC protocol of realtime RTPCR for influenza A(H1N1). 
Available at: 
http://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-
2009_20090430.pdf. Accessed on May 11th 2016, . 2009. 
33. Feikin DR, Ope MO, Aura B, Fuller JA, Gikunju S, Vulule J, et al. The population-based burden of 
influenza-associated hospitalization in rural western Kenya, 2007-2009. Bulletin of the World Health 
Organization. 2012;90(4):256-63A. 
34. Walaza S, Cohen C, Nanoo A, Cohen AL, McAnerney J, von Mollendorf C, et al. Excess Mortality 
Associated with Influenza among Tuberculosis Deaths in South Africa, 1999-2009. PloS one. 
2015;10(6):e0129173. 
35. Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). 
American journal of epidemiology. 1990;131(2):373-5. 
36. Chow A, Ma S, Ling AE, Chew SK. Influenza-associated deaths in tropical Singapore. Emerging 
infectious diseases. 2006;12(1):114-21. 
37. Wong CM, Chan KP, Hedley AJ, Peiris JS. Influenza-associated mortality in Hong Kong. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America. 
2004;39(11):1611-7. 
38. Park M, Wu P, Goldstein E, Joo Kim W, Cowling BJ. Influenza-Associated Excess Mortality in South 
Korea. American journal of preventive medicine. 2015. 
39. Wu P, Goldstein E, Ho LM, Yang L, Nishiura H, Wu JT, et al. Excess mortality associated with influenza 
A and B virus in Hong Kong, 1998-2009. The Journal of infectious diseases. 2012;206(12):1862-71. 
40. Kessaram T, Stanley J, Baker MG. Estimating influenza-associated mortality in New Zealand from 
1990 to 2008. Influenza and other respiratory viruses. 2015;9(1):14-9. 
41. Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of mortality attributable 
to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of 
death, and risk status. Influenza and other respiratory viruses. 2014;8(5):507-15. 
42. Jansen AG, Sanders EA, Nichol KL, van Loon AM, Hoes AW, Hak E. Decline in influenza-associated 
mortality among Dutch elderly following the introduction of a nationwide vaccination program. Vaccine. 
2008;26(44):5567-74. 
43. Nunes B, Viboud C, Machado A, Ringholz C, Rebelo-de-Andrade H, Nogueira P, et al. Excess mortality 
associated with influenza epidemics in Portugal, 1980 to 2004. PloS one. 2011;6(6):e20661. 
44. Murray CJ, Lozano R, Flaxman AD, Serina P, Phillips D, Stewart A, et al. Using verbal autopsy to 
measure causes of death: the comparative performance of existing methods. BMC medicine. 2014;12:5. 
45. World Health Organization (WHO). Status of Vaccine Research and Development of Vaccines for RSV. 
Available at:http://www.who.int/immunization/research/meetings_workshops/WHO_PDVAC_RSV.pdf. 
Accessed on Dec 1st 2015. 2014. 
46. Beeler JA, Eichelberger MC. Influenza and respiratory syncytial virus (RSV) vaccines for infants: 
safety, immunogenicity, and efficacy. Microbial pathogenesis. 2013;55:9-15. 
  
83 
 
Appendix 4.1: Supplementary Methods 
 
Case definitions 
 Influenza-Like Illness  
For patients of all ages, influenza-like illness was defined as an axillary temperature ≥38oC and 
cough or sore throat in an outpatient (1, 2). 
Severe Acute Respiratory Illness (SARI) 
SARI was defined differently for children under five years and for persons aged ≥5 years. Among 
children aged <5 years, SARI was defined using a modified version of the World Health Organization’s 
Integrated Management of Childhood Illness (IMCI) definition for pneumonia. This was defined as 
hospitalization with cough OR difficulty breathing, AND at least one of (maternal report of lower-chest 
wall in-drawing, stridor in a calm child, unable to drink or breast feed, vomiting, convulsions, lethargic or 
unconscious, oxygen saturation <90%). Among persons aged 5 years, SARI was defined as hospitalization 
with cough OR difficulty breathing OR shortness of breath AND a documented fever (≥38oC) (1, 2). At 
Lwak Mission hospital, a modified “SARI” case definition that did not require hospitalization was used. 
Among children <5 years, SARI was defined as defined as cough OR difficulty breathing, AND at least one 
of (inability to drink or breastfeed, vomiting everything, convulsions, lethargy or unconscious, lower-
chest wall in-drawing, stridor, oxygen saturation <90%). For persons aged ≥5 years, SARI was defined as 
cough OR difficulty breathing OR chest pain, AND a documented axillary temperature of ≥38.0°C OR and 
oxygen saturation level of ≤90% (1). 
 
Verbal autopsy data 
The InterVA-4 model software which was introduced in the year 2009 was used to assign the 
possible cause of death. To maintain uniformity, data that were collected prior to its introduction were 
re-assigned a cause of death using the InterVA-4 software. It is important to mention that data from this 
HDSS area were included in a multi-country study that compared the physician–coded verbal autopsy 
(PCVA) cause of death to the cause of death as determined by the InterVA-4 model (3). Results from this 
analysis showed a very strong correlation 0.83 (95% CI 0.75 to 0.91) among the five participating 
countries. Specifically for the Western Kenya HDSS data (with 21,236 deaths), the correlation was 0.85 
(95% CI 0.79 - 0.92) (3). Table 1 below shows the cause-of-death list for the mortality outcomes that we 
considered with the corresponding ICD-10 codes (4). 
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Appendix Table 4.1: Cause-of-death list for verbal autopsy with corresponding broad ICD-10 codes 
Verbal autopsy title ICD code ICD title 
Tuberculosis 
  
  
  
  
A159 Respiratory tuberculosis, unspecified, confirmed bacteriologically and 
histologically 
A169 Respiratory tuberculosis, unspecified, without mention of 
bacteriological or histological confirmation 
A179 Tuberculosis of nervous system, unspecified 
A192 Acute miliary tuberculosis, unspecified 
A199 Miliary tuberculosis, unspecified 
HIV/AIDS 
  
  
  
  
B209 HIV disease resulting in unspecified infectious or parasitic disease 
B219 HIV disease resulting in unspecified malignant neoplasm 
B227 Human immunodeficiency virus [HIV] disease resulting in multiple 
diseases classified elsewhere 
B238 Human immunodeficiency virus [HIV] disease resulting in other 
specified conditions 
B24 Unspecified human immunodeficiency virus [HIV] disease 
Acute lower respiratory infections 
(including pneumonia and acute 
bronchitis) 
  
  
  
  
  
J129 Viral pneumonia, unspecified 
J159 Bacterial pneumonia, unspecified 
J180 Bronchopneumonia, unspecified 
J181 Lobar pneumonia, unspecified 
J182 Hypostatic pneumonia, unspecified 
J189 Pneumonia, unspecified 
 
Defining influenza and RSV ‘baseline’ and ‘activity months’ 
Contrary to temperate countries which are characterized by distinct seasons (5, 6), influenza and 
RSV are detected in Kenya almost throughout the year (1, 2, 7) without distinct periods of activity, which 
is particularly true for influenza. We therefore used a cut-off defined using the average monthly 
percentage of cases detected to define the ‘baseline’ and ‘increased activity’ months for influenza and 
RSV that were used for the estimation of excess mortality using the rate-difference method. From the 
distribution of the monthly percentage of influenza positive cases over the entire study period, we 
determined that the average was 12% (95% CI 10-14).  Months where ≥15% (higher than the upper 
confidence limit on the average percentage) cases of influenza were detected were classified as 
increased influenza activity months. Similarly, the average monthly percentage of RSV cases was 9% 
(95% CI 7-11) and months where ≥12% cases of RSV were detected were classified as increased RSV 
activity months.   
 
Dealing with potential double counting of deaths in the rate-difference method 
The following steps were applied in calculating excess deaths associated with influenza and RSV 
for months when the activity index of both pathogens exceeded the stated thresholds (15% and 12% for 
influenza and RSV respectively): 
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1. We standardized the activity index variables (based on the monthly percentage of influenza and 
RSV cases) 
2. The excess deaths were then calculated as the positive difference between the monthly number 
of deaths and the average monthly number of deaths that occurred when the pathogen 
circulation was low (<15% and <12% for influenza and RSV respectively).  
3. Excess deaths were then apportioned on the basis of pathogen activity, as indicated by the 
standardized pathogen index as shown below: 
𝐸𝑥𝑐𝑒𝑠𝑠𝑑𝑒𝑎𝑡ℎ𝑠𝑓𝑙𝑢 = (𝐸𝑥𝑐𝑒𝑠𝑠𝑑𝑒𝑎𝑡ℎ𝑠 ×
𝑍𝑓𝑙𝑢
𝑍𝑓𝑙𝑢 + 𝑍𝑟𝑠𝑣
) 
 
Where:  
𝐸𝑥𝑐𝑒𝑠𝑠𝑑𝑒𝑎𝑡ℎ𝑠𝑓𝑙𝑢 = Excess deaths associated with influenza activity for a specific month 
𝐸𝑥𝑐𝑒𝑠𝑠𝑑𝑒𝑎𝑡ℎ𝑠 = Excess deaths for a specific month over the average monthly number of deaths that occurred during the 
months of low influenza activity 
𝑍𝑓𝑙𝑢  = Standardized index for influenza activity for a specific month 
𝑍𝑟𝑠𝑣 = Standardized index for RSV activity for a specific month 
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Appendix Figure 4.1: Influenza, RSV and malaria activity patterns in Western Kenya, 2007-2013 
 
        
Appendix Figure 4.2: Graph showing the observed all-respiratory deaths, predicted deaths, and baseline for children 
aged <5 years, 2007–2013 
 
0
.0
0
2
0
.0
0
4
0
.0
0
6
0
.0
0
M
o
n
th
ly
 p
ro
p
o
rt
io
n
 p
o
s
it
iv
e
2007m1 2008m1 2009m1 2010m1 2011m1 2012m1 2013m1 2014m1
Time (in months)
% Influenza cases
% RSV cases
% Malaria cases
0
1
0
2
0
3
0
4
0
5
0
6
0
R
e
s
p
ir
a
to
ry
 d
e
a
th
s
2007m1 2008m1 2009m1 2010m1 2011m1 2012m1 2013m1 2014m1
Time (in months)
Observed respiratory deaths Predicted deaths Excess flu deaths
Children aged <5 years
87 
 
                 
Appendix Figure 4.3: Graph showing the observed all-respiratory deaths, predicted deaths, and baseline for persons 
aged 5-49 years, 2007-2013 
 
                
Appendix Figure 4.4: Graph showing the observed all-respiratory deaths, predicted deaths, and baseline for persons 
aged ≥50 years, 2007-2013 
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Appendix Figure 4.5: Graph showing the observed all-respiratory deaths, predicted deaths, and baseline for persons 
of all ages, 2007-2013 
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Abstract 
Background: Little is known about how HIV infection affects influenza transmission within homes in sub-
Saharan Africa. 
Methods: We used respiratory illness surveillance and HIV testing data gathered in Kibera, an urban 
slum in Nairobi, Kenya to examine the impact of HIV status on  i) introducing influenza to the home and 
ii) transmission to household contacts. 
Results: While HIV status did not affect the likelihood of being an influenza index case, household 
contacts of HIV-infected influenza index cases had twice the risk of developing secondary ILI than 
contacts of HIV-negative index cases. 
Conclusions: HIV-infected influenza index cases may facilitate transmission of influenza within the home. 
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5.1 Introduction 
Studies of household influenza transmission dynamics have mostly taken place outside of densely-
populated, urban settings in sub-Saharan Africa (1-3). However, this region may have distinct influenza 
transmission patterns due to the high prevalence of HIV infection (4). 
We conducted a retrospective cohort study of 176 households in an urban slum in Nairobi, Kenya 
using household and clinic data gathered during 2008 -2011 to examine i) the association between the 
HIV status of household members and their risk of introducing influenza to the home, and ii) whether 
the HIV status of index cases of influenza impacts risk of developing secondary influenza-like illness (ILI) 
among their household contacts. 
 
5.2 Methods 
 
5.2.1 Study site 
We analyzed respiratory illness data and HIV testing data from a Kenya Medical Research 
Institute (KEMRI) and Centers for Disease Control and Prevention-Kenya (CDC) active population-based 
infectious disease surveillance (PBIDS) site in the urban slum of Kibera, Nairobi, Kenya (5).  
5.2.2 Household and clinic data collection 
Approximately 28,000 PBIDS enrollees with a median (IQR) follow-up time of 2.5 (1.0-3.8) person-
years in 6,000 households are being followed prospectively. Trained community interviewers regularly 
visit and interview all participating households for persons reporting symptoms of diarrhea, fever, 
jaundice, and respiratory illness occurring within the past two weeks. These interviewers encourage 
participants who report illnesses to go to the Tabitha Clinic, a local medical facility owned by Carolina for 
Kibera Inc. (Chapel Hill, NC) and supported by KEMRI and CDC. (5).  
In 2008, all adult PBIDS enrollees (≥18 years) were offered the option to consent and participate in a 
home-based HIV testing and counseling (HBTC) program (6), while more restricted enrollment was 
offered to enrollees <18 years of age. Among 10,673 individuals who were offered HBTC, 83% accepted. 
Participants not accepting HBTC at PBIDS enrollment and those enrolled after 2008 had access to 
voluntary clinic-based testing at the free medical facility (6). 
 
5.2.3 Case Definitions Used for Influenza Testing at Tabitha Clinic 
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All persons with severe acute respiratory infection (SARI) and the first five daily cases of 
influenza-like illness (ILI) reporting to Tabitha clinic were tested for influenza. ILI was defined as an acute 
onset (<14 days) with a recorded temperature ≥ 38.0°C or home-reported “hotness of body” and cough 
or sore throat in a patient of any age. For children <5 years, SARI was defined as acute onset (<14 days) 
of cough or difficulty breathing and ≥1 of the following danger signs: chest in-drawing; stridor in a calm 
child; oxygen saturation <90%; unable to breastfeed or drink; vomits everything; convulsions; lethargy; 
unconsciousness; admitted with respiratory illness. For persons ≥5 years of age, SARI was defined as 
cough or difficulty breathing or chest pain with acute onset (<14 days) and either temperature ≥38.0°C 
or oxygen saturation <90%. 
5.2.4 Clinic-based testing for influenza 
Consenting patients provided verbal responses to a standardized questionnaire and had 
nasopharyngeal and oropharyngeal (NP/OP) specimens collected by trained medical personnel at the 
study clinic. Specimens were tested at the KEMRI-CDC laboratory in Nairobi by real time reverse 
transcription polymerase chain reaction (PCR) for influenza A and B with additional influenza A 
subtyping (7).  
5.2.5 Influenza index cases and secondary cases in the household 
Laboratory-confirmed influenza cases were linked to their households by study identification 
numbers. Household index cases of influenza were then identified as the first study participants with 
laboratory-confirmed influenza in a household of known HIV status where no other member had 
reported or been diagnosed with ILI or SARI within the past two weeks. Only households with influenza 
index cases and known household HIV status were included in the study.  
After the influenza index cases were identified, we defined a secondary ILI case as any household 
contact of the index case that developed ILI within two weeks. Over 95% of cases were home reported. 
All secondary ILI cases were also secondary SARI cases. We selected a two-week follow-up period to 
account for approximately two influenza infectious periods (8). The overall secondary attack rate (SAR) 
for ILI was defined as the proportion of household contacts developing ILI within 14 days after index 
case identification. 
5.2.6 Individual and household-level HIV status 
      Individual HIV status was defined as the most recent result of an HIV test conducted up to 18 months 
after household influenza index case identification. Persons whose HIV status was not determined by 
the HBTC in 2008 or by voluntary testing at the study clinic during the study period were regarded as 
having unknown HIV status. Among study participants with known HIV status, 24% had their most recent 
test via HBTC.  An HIV-positive household was defined as one in which ≥1 member was found to be HIV-
infected by a test conducted up to 18 months after influenza index case identification. An HIV-negative 
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household was defined as a household that had ≥3 members who tested HIV-negative, or a household 
where ≥ 50% of the household tested negative for HIV, and no one was HIV-infected. 
 
5.2.7 Bivariate analysis 
     We used bivariate log-binomial generalized estimating equation (GEE) models accounting for 
household clustering to assess crude relative risks between independent variables and i) the influenza 
index case status of household members, as well as ii) development of ILI among household contacts of 
influenza index cases (9). Independent variables included individual HIV status of the index cases and 
household contacts, age group of each household member at time of index case identification, 
household size, and gender. 
5.2.8 Multivariate analysis 
The variables included in the two multivariate log-binomial GEE models, also accounting for 
household clustering, demonstrated a significant association with the respective outcomes in bivariate 
analyses and substantially changed the regression parameter of the primary exposure variable (by 
≥10%) after being added to the model. The first multivariate model compared 176 influenza index cases 
to their 874 household contacts in 176 households; predictors of influenza index case status included 
individual HIV status, age group of household members, and their respective household sizes. The 
second model compared 72 household contacts with ILI to the 802 household contacts without ILI; 
predictors of secondary ILI development included age groups of all household contacts and HIV status of 
their respective household index cases. Statistical analysis was performed using SAS 9.3 for Windows 
(SAS Institute, Cary, NC) and Stata 12 for Mac OS 10.7.5 (StataCorp, College Station, TX). 
 
5.3 Ethical considerations 
The protocol for data collection and written consent forms were reviewed and approved by the 
ethical review committees of the Centers for Disease Control and Prevention (Atlanta, GA; protocol 
number 4566) and the Kenya Medical Research Institute (Nairobi, Kenya; protocol number 932).  
 
5.4 Results 
 
5.4.1 Description of the Study Population 
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After exclusions, our sample (n=1,050) consisted of 176 households, each with an influenza index 
case and a known household HIV status (Appendix Table 5.1). In addition to the 176 laboratory-
confirmed influenza index cases, there were 874 household contacts in these households. Of the 
influenza index cases, 10 (6%) were HIV-infected, 57 (32%) HIV-negative, and 109 (62%) were HIV status 
unknown. Of the 874 household contacts, 55 (6%) were HIV-infected, 398 (46%) HIV-negative, and 421 
(48%) were HIV status unknown. Among the 874 household contacts, there were 72 (8%) secondary ILI 
cases (5 HIV-infected, 31 HIV-negative, and 36 HIV unknown) and 802 household contacts with no ILI (50 
HIV-infected, 367 HIV-negative, and 385 HIV unknown) (Appendix Figure 5.1). 
Influenza types and subtypes for the household index cases are summarized in Appendix Table 5.2. 
The median (range) age of index cases was 8.3 (0.2 – 48.1) years; 49% were male. Among those with 
known HIV status, HIV seroprevalence (95% CI) was 15% (7 – 26).  
The median (range) age among secondary ILI cases was 6.3 (0.3 – 52.4) years; 46% were male. 
Among those with known HIV status, HIV seroprevalence (95% CI) was 14% (2 – 26). Household contacts 
with no secondary ILI had a median (range) age of 19.2 (0.1 – 66.1) years and 47% were male. Among 
those with known HIV status, HIV seroprevalence (95% CI) was 12% (9 – 15). 
The average (95% CI) household secondary attack rates (SARs) due to influenza by year during 2008, 
2009, 2010, and 2011 were 9% (1-17), 6% (4-9), 10% (4-15), and 6% (2-11), respectively. The unadjusted 
SAR was significantly higher in the 8 homes with an HIV-infected index case and no HIV-positive 
household contacts (26%) than in the 45 homes with an HIV-negative index case and no HIV-positive 
household contacts (8%) (7/27 vs. 18/239, p=0.002). 
5.4.2 Risk factors for influenza introduction to the household 
     In the multivariate model, being HIV infected was not significantly associated with household 
influenza index case status (as compared to having known HIV-negative status from testing) when 
controlling for age of each household member and household size. However, younger age and smaller 
household size remained significantly associated with index case status (Table 5.1). 
5.4.3 Risk factors for secondary transmission within the household 
In the multivariate model, the risk of being a secondary ILI case when the household influenza index 
case was HIV-infected was about two times the risk of being a secondary ILI case when the household 
index case was HIV-negative, adjusting for age group of the household contacts (aRR: 2.36, 95% CI: 1.19, 
4.66). Being an HIV-infected household contact of the index case was not significantly associated with 
the development of secondary ILI, compared to being an HIV-negative household contact (Table 5.2). 
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5.5 Discussion 
To our knowledge, this is the first study to investigate the effects of HIV infection on household 
influenza transmission dynamics in a densely-populated, urban setting in sub-Saharan Africa. After age-
adjustment, household contacts of HIV-infected influenza index cases were about twice as likely to 
develop ILI as household contacts of HIV-negative influenza index cases—a finding that may be 
explained by prior observations that HIV-infected individuals shed infectious pathogens in general (10) 
and influenza viruses in particular in higher titers and for longer periods of time than HIV-negative 
individuals (11, 12).  
Children were more likely to be index cases than adults. While our findings may simply reflect an 
increased burden of influenza in younger children in general, these results are consistent with studies 
that suggest young and school-aged children are most likely to become infected with influenza due to 
increased socially-mediated exposure and biologic susceptibility (1), and that they often introduce 
influenza into their homes (13).  
Using a relatively conservative window of two weeks, we observed an unadjusted SAR for ILI of 8% in 
exclusively HIV-negative homes in Kibera. Overall influenza-associated SARs during each year of our 
study were not substantially different than the recent comparative observational study conducted in 
Hong Kong that found average (95% CI) SARs of 8% (3-14) and 9% (5-15) from pandemic and seasonal 
influenza viruses, respectively (2). 
There were multiple limitations to this study. We lacked the influenza virus shedding data for our 
index cases to quantitatively support prior observations of high titer and prolonged pathogen shedding. 
Another limitation was sub-optimal coverage of HIV testing and counseling, especially among younger 
individuals, which led to significant numbers of study participants with unknown HIV status. However, a 
relatively low overall estimated HIV seroprevalence of 3% for persons <18 years (14) would somewhat 
limit the number of missed HIV-positive children. Limited testing and refusal of testing likely reduced our 
power to evaluate the impact of HIV on influenza transmission, and perhaps also limited the 
representativeness of our study population. Finally, data on median CD4 counts and on highly active 
anti-retroviral treatment (HAART) among HIV-infected individuals were not available. Therefore, we 
assumed HIV-infected individuals had all progressed to a state of meaningful immunosuppression.  
Despite these limitations, this study suggests that an ancillary benefit of HIV control prevention and 
programs may be to reduce the spread of influenza in homes. Furthermore, coupled with the knowledge 
that HIV-infected individuals are at an elevated risk for severe clinical symptoms and mortality (15, 16), 
our findings highlight the potential value of thoughtful delivery of effective influenza vaccines to HIV-
infected individuals. 
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Table 5.1: Risk Factors for Introducing Influenza to the Household as an Index Case Among 1050 Household Members, Kibera, 
Kenya, 2008–2011 
Risk Factor 
All Household 
members 
Index casesa 
Index case status,                                    
RR (95% CI)b 
n(%) n(%) Unadjusted Adjusted 
Individual HIV status     
     Positive 65 (6) 10 (15) 3.30 (2.00–5.46) 1.23 (.55–2.75) 
     Unknown 530 (51) 109 (21) 1.21 (.65–2.24) 1.05 (.74–1.48) 
     Negative 455 (43) 57 (13) 1.00 1.00 
Age (years)     
     <2 66 (6) 26 (39) 17.66 (10.19–30.62 5.69 (3.67–8.82) 
     2–4 109 (10) 30 (28) 7.88 (3.87–16.05) 3.83 (2.40–6.11) 
     5–17 380 (36) 74 (19) 4.10 (1.84–9.12) 3.08 (2.02–4.71) 
     ≥18 495 (47) 46 (9) 1.00 1.00 
Persons/household ( number)     
     ≤6 412 (39) 102 (25) 3.44 (3.18–3.72) 3.14 (2.73–3.61) 
     >6 638 (61) 74 (12) 1.00 1.00 
Sex     
     Male 496 (47) 87 (17) 1.15 (.64–2.06) - 
     Female 554 (53) 89 (16) 1.00   
Abbreviation: HIV, human immunodeficiency virus. 
aIndex cases are defined as study participants who had laboratory-confirmed influenza in a household with a known HIV status where no 
other member had reported or received a diagnosis of influenza-like illness or severe acute respiratory infection within the past 2 weeks. In 
households with >1 laboratory-confirmed influenza case within a 2-week period, the first with a nasopharyngeal or oropharyngeal swab 
specimen testing positive for influenza virus by reverse transcription–polymerase chain reaction analysis was designated as the index case. 
bUnadjusted relative risks (RRs) and 95% confidence intervals (CIs) were computed using a generalized estimating equations (GEE) log-
binomial bivariate model, and adjusted RRs and 95% CIs were computed using a GEE log-binomial multivariate model. 
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Table 5.2: Risk Factors for Secondary Influenza-Like Illness (ILI) Among 874 Household Contacts of Influenza Virus–Positive 
Index Cases, Kibera, Kenya, 2008–2011 
Risk Factor 
All household contacts 
Secondary ILI 
casesa 
Secondary ILI status,                      
RR(95% CI)b 
n(%) n(%) Unadjusted Adjusted 
HIV status of household index case    
     Positive 33 (4) 8 (24) 3.40 (1.52–7.63) 2.36 (1.19–4.66) 
     Unknown 538 (62) 43 (8) 1.14 (.65–2.00) 1.27 (.72–2.21) 
     Negative 303 (35) 21 (7) 1.00 1.00 
HIV status of household contact     
     Positive 55 (6) 5 (9) 1.22 (.54–2.76) - 
     Unknown 421 (48) 36 (9) 1.12 (.71–1.77) - 
     Negative 398 (46) 31 (8) 1.00  
Age of household contact 
(years)     
     <2 40 (5) 16 (40) 6.73 (3.99–11.35) 6.56 (3.96–10.85) 
     2–4 79 (9) 14 (18) 3.20 (1.87–5.50) 3.02 (1.73–5.27) 
     5–17 306 (35) 17 (6) 1.00 (.61–1.64) 1.01 (.61–1.66) 
     ≥18 449 (51) 25 (6) 1.00 1.00 
Age of household index case (years)    
    <18 661 (76) 48 (7) 0.64 (.38–1.08) - 
     ≥18 213 (24) 24 (11) 1.00  
Persons/household ( number)     
     ≤6 310 (35) 31 (10) 1.39 (.81–2.36) - 
     >6 564 (65) 41 (7) 1.00  
Sex     
     Male 409 (47) 33 (8) 0.89 (.60–1.32) - 
     Female 465 (53) 39 (8) 1.00   
Abbreviation: HIV, human immunodeficiency virus.  
aSecondary ILI cases are defined as any member of the same household as the index case who had home reported or clinically diagnosed ILI 
within 2 weeks of index case identification. 
bUnadjusted relative risks (RRs) and 95% confidence intervals (CIs) were computed using a generalized estimating equations (GEE) log-
binomial bivariate model, and adjusted RRs and 95% CIs were computed using a GEE log-binomial multivariate model.  
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Appendix Table 5.1: Characteristics of 176 Households Meeting Study Inclusion Criteria, Kibera, Kenya, 2008-2011 
Household characteristics 
Median (range) size, persons 
 
6 (2-15) 
Mean (95% CI) household age, years 
 
19.4 (18.6-20.2) 
HIV-positive households (n) 
 
32 
    With 1 HIV-infected person 
 
26 
    With 2 HIV-infected persons 
 
6 
Median (range) persons tested for HIV   3 (1-7) 
 
Appendix Table 5.2: Influenza types and subtypes cultured from household index cases of influenza, Kibera, Kenya, 2008-2011 
Type, Subtype       n (%) 
Influenza A  
Pandemic H1N1 59  (33) 
H3N2 47  (26) 
H1N1 21  (12) 
Subtype Inconclusive 14    (8) 
Influenza B 38  (21) 
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Appendix 5.1: Supplemenary Figures 
 
             
 Appendix Figure 5.1: Number of Surveillance Participants and Exclusions from Study Analysis – Kibera, Kenya, 2008-     
2011. Individuals in gray boxes were subject of analyses. 
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Appendix Figure 5.2: Number of Laboratory-confirmed Influenza Index Cases by Sample Confirmation Date – Kibera, 
Kenya, 2008-2011. 
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Abstract 
Background: Information on the timing of influenza circulation remains scarce in Tropical regions of 
Africa.  
Objectives: We assessed the relationship between influenza activity and several meteorological factors 
(temperature, specific humidity, precipitation), and characterized the timing of influenza circulation, and 
its implications to vaccination strategies in Kenya.  
Methods: We analyzed virologically-confirmed influenza data for outpatient influenza-like illness (ILI), 
hospitalized for severe acute respiratory infections (SARI), and cases of severe pneumonia over the 
period 2007-2013. Using logistic and negative binomial regression methods, we assessed the 
independent association between climatic variables (lagged up to 4 weeks) and influenza activity.  
Results: There were multiple influenza epidemics occurring each year and lasting a median duration of 
2-4 months. On average, there were two epidemics occurring each year in most of the regions in Kenya, 
with the first epidemic occurring between the months of February and March and the second one 
between July and November. Specific humidity was independently and negatively associated with 
influenza activity. Combinations of low temperature (<18oC) and low specific humidity (<11g/Kg) were 
significantly associated with increased influenza activity. 
Conclusions:  Our study broadens understanding of the relationships between seasonal influenza activity 
and meteorological factors in the Kenyan context.  While rainfall is frequently thought to be associated 
with influenza circulation in the tropics, the present findings suggest low humidity is more important in 
Kenya. If annual vaccination were a component of a vaccination strategy in Kenya, the months of April to 
June are proposed as optimal for associated campaigns.  
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6.1 Introduction 
Influenza exerts a significant health burden on human populations across temperate, sub-tropical 
and tropical regions (1, 2). In temperate regions, influenza epidemics exhibit clear seasonality with peaks 
during winter months (3, 4) suggestive of an association with climatic factors. In these regions lower 
temperature, and lower specific humidity have been shown to be significantly associated with increased 
influenza activity (5, 6). In contrast, influenza seasonal characteristics are less predictable in tropical and 
sub-tropical regions which are characterized by semi-annual epidemics or year-round influenza activity 
(5, 7-10). A meteorological factor that is frequently reported to be associated with high influenza 
incidences in the tropical areas is rainfall (8, 9, 11).  
In temperate countries a well-defined seasonality allows for a precise timing of influenza vaccination 
campaigns to precede periods of peak circulation. However in tropical African countries more data are 
needed on influenza seasonality and its determinants. In Kenya, where there is currently no influenza 
vaccination strategy in place, these data may help to inform vaccine implementation strategy decisions. 
Kenya experiences long rains that occur from March to May and short rains occurring in October and 
November. Temperatures are highest during the months of January to March (12). However there is 
considerable climate variability within Kenya such that influenza surveillance has been set up in different 
locations, including the coastal tropical regions characterized by hot and humid weather year round; 
semi-arid and desert-like conditions in the Northern and North Eastern part of Kenya; and cooler 
highland locations in Central and parts of Western of Kenya.  Data collected from influenza sentinel 
surveillance sites across the country have suggested increased influenza activity during rainy seasons 
(11, 13) but the full extent of how meteorological factors influence influenza activity is yet to be 
elucidated.  
We assessed the relationship between the onset week of influenza activity as well as the weekly 
number of influenza cases with temperature, rainfall, and specific humidity during the years 2007-2013. 
We also described the patterns of periods of increased influenza circulation in different regions in Kenya 
and suggested possible implications for future vaccination programs. 
 
6.2 Methods 
 
6.2.1 Study sites and population 
We analyzed data collected between January 2007 and December 2013 from patients of all ages at 
all the twelve sites that conduct surveillance for influenza in Kenya. Included in our analysis were four 
sites from the Western Kenya region; four sites from the Central Kenya region; two sites from the 
Northern/North Eastern Kenya region; and two sites from the Coastal Kenya region (Figure 6.1 and Table 
6.1). These surveillance sites are representative of four climatic regions (Western, Central, 
Northern/North Eastern and Coastal) in Kenya.  
The Western region receives more rainfall (1250 –1700 mm annually) with average monthly 
temperatures ranging from 18°C to 26°C. The Central region has a relatively higher altitude compared to 
the other regions, and experiences some of the lowest temperatures in the country (as low as 7°C 
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during the July-August cold season).  The Northern/North Eastern regions have semi-arid and desert-like 
conditions and experience sunny and dry weather most of the year. The Coastal region experiences hot 
and humid weather conditions year-round with average monthly temperatures ranging between 25°C 
and 29°C and an average annual rainfall of over 1,000 mm (14, 15). 
                                            
                Figure 6.1: Map of Kenya showing the influenza surveillance sites   
 
6.2.2 Laboratory confirmation of influenza 
     Samples were collected from influenza-like illness (ILI) outpatient case-patients; and hospitalized 
severe acute respiratory infection (SARI) case-patients (Table 6.1) (13). At Kilifi County Hospital (KCH), 
samples were collected from children <5 years who were hospitalized with severe or very severe 
pneumonia. The case definitions used are provided in Appendix 6.1. Samples collected were tested by 
real-time reverse transcription polymerase chain reaction (rRT-PCR) for influenza A and B viruses. 
Influenza A-positive specimens were subtyped for A(H1N1), A(H3N2), and A(H1N1)pdm09.   
6.2.3 Influenza activity patterns 
     To assess influenza circulation over time, we calculated the average monthly proportion of influenza 
positive cases among those tested across the study period. Data from the pandemic period (August 
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2009 to July 2010) were excluded because (i) these were likely to influence the pattern of results, and 
(ii) we were interested in seasonal influenza. We also calculated the proportion of specimens that tested 
positive for influenza in the first half of the year within which the first epidemic typically occurs (January 
to June), and in the second half of the year within which the second epidemic occurs (July to December). 
Data from all the twelve surveillance sites were included in this analysis. 
6.2.4 Defining “influenza circulation periods” 
      “Influenza circulation periods” were defined as a period of ≥2 successive weeks where ≥10% of the 
total weekly cases tested were positive for influenza (9, 16).  The 10% threshold was close to the 
average proportion (12%) of cases that tested positive for influenza over the entire study period. In 
situations where there were <25 cases tested in a week, we considered the proportions as unstable and 
used the five-point moving average method to estimate the number of influenza cases and the 
percentage positive for influenza (17). Influenza circulation periods separated by ≥5 successive weeks 
where there was low influenza activity (<10%) were considered as two distinct periods. The first week of 
influenza circulation period is herein referred also as the start-week or onset week (Appendix 6.2).  
6.2.5 Meteorological Data 
      The environmental data used in this analysis were satellite-derived measurements and were 
collected over the same period of time as the influenza data.  These variables were, average surface 
temperature (0C), and near surface specific humidity (g/Kg) obtained from the Global Land Data 
Assimilation System (GLDAS) (18); and accumulated rainfall (mm) obtained from the Tropical Rainfall 
Measuring Mission (TRMM) (19) (Appendix 6.1).  
 
6.2.6 Data Analyses 
6.2.6.1 Descriptive analyses for influenza and meteorological factors 
      Influenza circulation was described using proportions of influenza A and/or B positive cases. The age 
distribution, and the influenza activity patterns were described using medians and ranges. The 
meteorological factors were described using means and standard deviations (SD).   
6.2.6.2 Bivariate and multivariate analyses of influenza activity 
Data from nine out of the twelve sites were used when assessing the associations between influenza 
activity and meteorological variables. Three surveillance sites (Kenyatta National Hospital, Mombasa 
County Referral Hospital, and Ting’wang’i Health Center) were excluded from these analyses because of 
multiple missing data points in the time series (Appendix 6.1).  
We applied two analytical approaches to determine the association between influenza activity and 
meteorological variables: (i) logistic regression to determine the association between the onset of 
influenza activity and meteorological variables, and (ii) negative binomial regression to determine the 
association between the weekly number of influenza cases and meteorological variables. In the first 
approach, the binary outcome variable “start-week” was coded as “1” if the week considered was the 
onset week of influenza activity or otherwise coded as “0”. In the second approach, the outcome 
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variable was the weekly count of influenza positive cases identified at each site. Negative binomial 
regression was chosen over the over Poisson regression to account for over-dispersion in the data. The 
variables that were considered as covariates in the models were, site, year and week of the year (week= 
1, 2, 3,…, 52). With the exception of the site and year variables which were analyzed as a categorical 
variables, all the other variables were entered into the respective models as continuous variables.  
We investigated associations of up to 4 lagged weeks on all meteorological variables to assess a 
possible delayed weather effect on influenza activity (Appendix 6.1) (7, 18). We additionally assessed if 
“cold-dry” and “humid-rainy” conditions - as suggested in a recent global seasonality study - were 
associated with influenza activity (5). We used combinations of temperature and specific humidity at 
thresholds of <180C and <11g/kg respectively to define “cold-dry” conditions; and combinations of 
specific humidity and rainfall at thresholds of >14g/kg and >150mm respectively to define “humid-rainy” 
conditions. In addition to investigating the effect of the “cold-dry” and “humid-rainy “conditions on 
influenza activity, we also assessed the effect of the two-way product interaction (included as 
continuous variables) between temperature and specific humidity, and between specific humidity and 
rainfall. The interactions were evaluated in the model alongside the main effects of temperature, 
specific humidity and rainfall. 
The multiple variable models for the logistic and negative binomial regression analyses were fitted 
by including the site variable as well as all the variables that were associated with influenza in the 
bivariate analysis at overall p-value<0.2. Statistical significance was considered if the p-value was <0.05. 
All data analyses were performed using Stata version 13.0 (StataCorp. 2013. Stata Statistical Software: 
Release 13. College Station, TX: StataCorp LP). 
 
6.3 Ethical considerations 
The study protocols were approved by both the institutional review board (IRB) of the U.S. CDC 
(CDC-3308, CDC-4566), and the ethical review committee of the Kenya Medical Research Institute 
(KEMRI) (SSC-1801, SSC-932, SSC- 1161, SSC-1055, 1526, 1858). At Nakuru, Kakamega and Nyeri County 
Referral Hospitals, the Kenya Ministry of Health (KMoH) issued a letter stating that sentinel surveillance 
for influenza, should be considered part of routine public health surveillance, and therefore did not 
require formal ethical review. Verbal consent at these sites was obtained from all patients before 
questionnaires were administered and specimens were collected. For children, verbal consent was 
obtained from guardians. 
 
6.4 Results 
 
6.4.1 Descriptive analyses 
A total of 55,192 patients were tested for influenza at the twelve surveillance sites over the period 
2007 to 2013 of which 6,721(12%) tested positive for influenza. The proportion of patients who tested 
positive for influenza ranged from 4% in Kilifi to 19% among patients who were seen at Dadaab refugee 
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camp. The median age of the patients who were tested for influenza was 1.7 years [interquartile range 
(IQR)=0.8-4.2 years] (Table 6.1).  
The mean average weekly temperature was lowest in Nakuru (18.20C), and highest at Dadaab 
refugee camp (30.70C) (Table 6.2). The mean average weekly specific humidity ranged from 11.1 g/Kg to 
15.1 g/Kg with Nyeri recording the lowest measurements, while Kilifi recorded the highest. The “cold-
dry” conditions defined earlier were observed in only at two sites in the Central Kenya region (Nakuru 
and Kibera). However, the “humid-rainy” conditions were only experienced at the coastal site (KCH) and 
at only four different time-points (weeks) over the course of the study period. 
6.4.2 Influenza activity patterns 
A total of 48 periods of increased influenza circulation were identified across the nine study sites. 
Nineteen of these episodes occurred within the first quarter of the year [median onset month was 
February]; 16 episodes occurred in the second quarter [median onset month was July]; and the 
remaining 13 occurred in the last quarter [median onset month was October]. On average, most of the 
study sites experienced two episodes of increased influenza circulation annually which lasted for a 
median duration of 2-4 months.  
When we analyzed the monthly seasonal cycle of influenza activity, there was a pattern showing 
periods of increased influenza circulation occurring between February and March; and between July and 
November. There were more influenza positive cases identified in the last half of the years included in 
the analysis - within which the second epidemic occurs - compared to the first of half of the years [3,886 
(58%) influenza cases during July – December vs. 2,835 (42%) during January - June]. The month of May 
had the lowest influenza activity (Figure 6.2 and Appendix 6.2).  
 
6.4.3 Bivariate and multivariable analyses 
      In the bivariate models for onset of influenza activity, specific humidity was significantly and 
negatively associated with the onset of influenza activity (p<0.05). In the negative binomial regression 
models, influenza activity was found to be negatively associated with both temperature and specific 
humidity (p<0.05). The presence of the “cold-dry” conditions, defined earlier, were also found to be 
significantly associated with influenza activity (p<0.05). No statistically significant associations were 
observed between influenza activity and rainfall (Table 6.3).  
      In the multivariable logistic regression model, specific humidity was independently and negatively 
associated with the onset of influenza activity at lag-weeks one [odds ratio (OR)=0.79 (95% CI 0.66-
0.94)] and two [OR=0.82 (95% CI 0.69-0.98)] in the models that adjusted for the site variable. Similarly, 
specific humidity was significantly associated with influenza activity in the negative binomial regression 
models for the weekly count of influenza cases at the current week [incidence rate ratio (IRR)=0.94 (95% 
CI 0.90-0.98)], and at all the four lag weeks investigated (p<0.001). The presence of “cold-dry” 
conditions was also found to be positively associated with influenza activity when we adjusted for the 
site variable at current week [IRR=1.90 (95% CI 1.20-3.01)], and at lag weeks one [IRR=2.07 (95% CI 1.21-
3.55)] and three [IRR=1.95 (95% CI 1.11-3.44)]. However, temperature was not significantly associated 
with influenza activity when we adjusted for the site variable.  All the other variables assessed including 
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rainfall and the two-way interactions between specific humidity and temperature, and between specific 
humidity and rainfall were not significantly associated with influenza activity when we adjusted for the 
site variable (Table 6.4). An exploratory analysis to assess the relationship between the onset week of 
influenza activity and meteorological variables showed similar results to the ≥10% activity threshold 
when we used the median proportion (7% threshold) to define the onset of influenza activity (results 
not shown). 
                                                    
                 
           
                                    Figure 6.2: Monthly seasonal cycle of influenza activity in Kenya by region 
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6.5 Discussion 
In this study, we found that there were multiple periods of increased influenza activity annually in 
Kenya. On average, there were two epidemics occurring each year in most of the regions in Kenya and 
these epidemics lasted a median duration of 2-4 months. The first epidemic occurred between February 
and March, and the second between July and November. The period between April and May had the 
least influenza activity. We also identified that lower specific humidity was significantly, associated with 
influenza activity in Kenya.  As has been noted in other continents (5), we found that influenza was more 
likely to circulate when both temperature and specific humidity were below 18oC and 11g/Kg 
respectively, independent of the study site. Contrary to what has been hypothesized previously (5), we 
found no significant association between influenza activity and rainfall.   
Unlike temperate climates, the presence of multiple influenza epidemics each year in most of the 
regions in Kenya presents a challenge to the selection of the appropriate influenza vaccine formulation 
to use. Recent investigations have found that the Southern Hemisphere (SH) vaccine formulation was 
well-matched [80% (95% CI 77-84) over a nine-month period] to circulating strains over the period 2007 
to 2013 [Waiboci et al; accepted for publication in Vaccine]. The Northern Hemisphere (NH) vaccine 
formulation was also well matched [82% (95% CI 78-85) over a nine-month period]. These findings 
suggest that for the primary period of increased influenza circulation in Kenya (July-November), the SH 
vaccine formulation (available in April) could offer good protection. While this vaccine could also provide 
protection during the subsequent February and March peaks as well, the NH formulation (available in 
November) could also be considered for that period.  
Our finding of a negative association between influenza activity and specific humidity is consistent 
with findings from other studies that were conducted in temperate (5, 20), and sub-tropical regions. 
This is also consistent with experimental results which have linked low humidity to prolonged influenza 
virus survival (IVS) as well as efficient aerosol transmission (21, 22). These findings also suggest a site-
specific association between temperature and influenza activity as temperature was negatively and 
significantly associated with influenza activity in the bivariate analysis but not when we adjusted for the 
site variable. Whereas rainfall has previously been suggested to be correlated with influenza activity in 
tropical and sub-tropical regions (5, 7), our study did not find a significant association. A recent global 
study found that “humid-rainy” (high specific humidity and rainy) conditions were associated with 
influenza circulation (5). However, our analysis did not support this finding. The lack of association 
between the “humid-rainy” conditions with influenza activity in our study context may in part be 
explained by the fact that we do not experience necessary thresholds of high specific humidity (>14g/Kg) 
and high rainfall (>150 mm) measurements as previously suggested (5). Indeed, these conditions were 
only experienced at four different time-points over the course of the study period at the coastal site 
(KCH). 
The relative merits of annual influenza vaccination vs. the integration of influenza vaccination into 
routine immunization schedules remain to be evaluated in Kenya, and are beyond the scope of this 
discussion. However if annual mass vaccination campaigns are being considered, the period between 
April and June would perhaps be the optimal time for several reasons. First, this would potentially offer 
better protection considering the fact that the period of influenza activity between July and December 
account for most of the annual influenza cases (58%). Considering the possibility of waning immunity 
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over time (23, 24), it would probably be preferable to vaccinate during the month of June. However, a 
wider period may need to be considered in the context of the possible logistical challenges of vaccine 
delivery and accessing the target populations. Second, according to the Kenyan education calendar, 
schools are closed for holidays during the months of April, August and December. April would therefore 
be a more convenient time for school-going children to be immunized in non-school settings. Lastly, 
caretakers of young children may take advantage of the presence of older children during these holidays 
in order to take care of household chores as they attend to other health-related matters such as taking 
the smaller children for immunization.   
Our study was subject to some other important limitations. First, we were not able to account for 
the effect of other factors such as social-economic conditions, population susceptibility, and human 
migration dynamics on the association between influenza activity and meteorological variables because 
these data were not collected. Second, we only relied on satellite derived meteorological measurements 
for our analysis. Even though we had a reasonable temporal resolution in the meteorological data, using 
actual ground data could possibly have provided more accurate results. Third, although we tried to 
adjust for the effect of the site differences in our models, we could not sufficiently explore the regional 
variation of meteorological factors in Kenya and how they correlate with influenza activity because of 
limited influenza testing data available. Lastly, we could not explore if the association between influenza 
activity and meteorological factors varied by age as older persons were underrepresented in the 
hospital-based surveillance because of low healthcare seeking behavior (25). 
     In conclusion, our study broadens our understanding of the relationships between seasonal influenza 
activity and meteorological factors in tropical regions, and more specifically in the Kenyan context. We 
additionally highlight the influenza activity patterns in Kenya with regard to the onset-months of periods 
of increased influenza circulation. These could help to inform the timing of future influenza vaccination 
campaigns in Kenya, and highlight periods when added diagnostic measures, treatment efforts or 
infection control strategies may be put in place. 
 
Acknowledgments: We thank the Kenya Ministry of Health, the surveillance officers, the laboratory, and 
data management staff for their role in influenza surveillance in Kenya. We also offer sincere thanks to 
the KEMRI/Wellcome Trust Research Programme in Kilifi, the parents and children who participated in 
the PERCH study, and the PERCH staff and the PERCH Study Group. The work was funded in part by The 
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Table 6.1: Descriptive statistics for influenza testing, January 2007 - December 2013 
Hospital/clinic 
Period of 
data 
included in 
analysis 
Number 
tested 
Tested 
positive for 
influenza                          
n(%) 
 
Hospitalized SARI 
cases tested 
 
SARI cases 
tested positive 
for influenza 
n(%)  
 
Outpatient 
ILI/ALRIc 
cases 
tested 
 
ILI/ALRI cases 
tested positive 
for influenza 
n(%)  
Male          
n(%) 
Median age 
in years 
(IQR) 
St. Elizabeth Hospital 
(Lwak)a 
2007-2013 7,493 1,107(14.8) 1,162 105(9.0) 6,331 1002(15.8) 3,655(48.8) 5.0(2.1-12.8) 
Siaya County Referral 
Hospital (CRH) 
2010-2013 4,769 325(6.8) 4,769 325(6.8) N/A N/A 2,373(49.8) 1.8(0.8-7.6) 
Kakamega CRH 2008-2013 5,801 630(10.9) 3,970 331(8.3) 1,831 299(16.3) 3,226(55.6) 1.7(0.8-3.5) 
Ting’wang’i Health Center 2010-2013 1,453 191(13.1) N/A N/A 1,453 191(13.1) 690(47.5) 2.2(1.1-4.2) 
Western Kenya region 2007-2013 19,516 2,253(11.5) 9,901 761(7.7) 9,615 1,492(15.5) 9,944(51.0) 2.7(1.0-7.0) 
Kenyatta National Hospital 2008-2013 3,576 268(7.5) 2,288 124(5.4) 1,288 144(11.2) 2,019(56.5) 0.8(0.5-1.5) 
Tabitha Clinic (Kibera)a 2008-2013 6,964 1,263(18.1) N/A N/A 6,964 1,263(18.1) 3,306(47.5) 5.2(1.9-15.3) 
Nyeri CRH 2008-2013 4,927 653(13.3) 3,159 351(11.1) 1,768 302(17.1) 2,741(55.6) 1.3(0.8-3.0) 
Nakuru CRH 2008-2013 4,138 561(13.6) 2,288 250(10.9) 1,850 311(16.8) 2,258(54.6) 1.0(0.7-2.2) 
Central Kenya region 2008-2013 19,605 2,745(14.0) 7,735 725(9.4) 11,870 2,020(17.0) 10,324(52.7) 1.6(0.8-4.4) 
Dadaab refugee camp 2008-2013 3,064 571(18.6) 2,165 384(17.7) 899 187(20.8) 1,713(55.9) 1.4(0.8-4.0) 
Kakuma refugee camp 2007-2013 4,942 649(13.1) 3,584 441(12.3) 1,358 208(15.3) 2,701(54.7) 1.0(0.7-3.0) 
Northern/North Eastern 
region 
2007-2013 8,006 1,220(15.2) 5,749 825(14.4) 2,257 395(17.5) 4,414(55.1) 1.0(0.7-3.0) 
Mombasa CRH 2008-2013 2,907 278(9.6) 2,097 171(8.2) 810 107(13.2) 1,669(57.4) 1.0(0.5-2.0) 
Kilifi CHb 2007-2013 5,158 225(4.4) 5,158 225(4.4) N/A N/A 2,995(58.1) 0.7(0.2-1.5) 
Coastal Kenya region 2007-2013 8,065 503(6.2) 7,255 396(5.5) 810 107(13.2) 4,664(57.8) 0.8(0.3-1.7) 
All sites 2007-2013 55,192 6,721(12.2) 30,640 2,707(8.8) 24,552 4,014(16.3) 29,346(53.2) 1.7(0.8-4.2) 
aPopulation-based disease surveillance sites; bAt Kilifi CH, samples were collected from children <5 years who were hospitalized with severe or very severe pneumonia; cAcute Lower Respiratory Illness; 
N/A; Not applicable. 
113 
 
Table 6.2: Descriptive statistics for the meteorological variables used in the analysis, January 2007 - December 2013 
Hospital/clinic 
Period of data 
included in 
analysis 
Yearly number 
of influenza 
circulation 
periods 
Temperature (0C) Specific humidity (g/Kg) Accumulated rainfall (mm) 
Mean 
(SD) 
Median 
(IQR) 
Mean 
(SD) 
Median 
(IQR) 
Mean 
(SD) 
Median 
(IQR) 
St. Elizabeth Hospital (Lwak) 2007-2013 2 21.4(1.5) 21.2(20.3-22.3) 13.0(1.3) 13.3(12.4-13.9) 32.8(27.7) 26.2(10.5-46.2) 
Siaya CRH 2010-2013 2 21.2(1.4) 20.9(20.3-21.9) 13.0(1.2) 13.1(12.5-13.7) 34.1(28.4) 26.4(10.6-49.0) 
Kakamega CRH 2008-2011 1 21.4(1.6) 21.2(20.3-22.5) 13.2(1.3) 13.4(12.5-14.0) 32.9(28.6) 25.1(11.4-43.4) 
Ting’wang’i Health Centera N/A - N/A  N/A  N/A  
Western Kenya region 2007-2013 2 21.4(1.5) 21.2(20.3-22.3) 13.0(1.2) 13.3(12.4-13.9) 32.8(27.7) 26.2(10.5-46.2) 
Kenyatta National Hospitala N/A - N/A  N/A  N/A  
Tabitha Clinic (Kibera) 2009-2013 2 19.8(1.3) 19.7(18.8-20.7) 11.5(1.3) 11.6(10.7-12.6) 15.0(24.1) 4.5(1.1-19.3) 
Nyeri CRH 2009-2012 2 19.8(1.1) 19.6(19.0-20.6) 11.1(1.4) 11.3(10.3-12.1) 21.2(28.0) 9.5(3.0-31.1) 
Nakuru CRH 2009-2013 2 18.2(1.2) 17.9(17.3-18.8) 11.1(1.5) 11.6(10.4-12.3) 23.9(21.5) 17.5(7.6-33.8) 
Central Kenya region 2009-2013 2 19.2(1.2) 19.0(18.4-20.0) 11.3(1.3) 11.5(10.6-12.1) 20.0(22.1) 11.9(5.2-28.5) 
Dadaab refugee camp 2008-2009 2 30.7(1.8) 30.9(29.4-32.1) 13.4(1.6) 13.1(12.2-14.5) 5.8(14.5) 0.0(0.0-2.0) 
Kakuma refugee camp 2007-2012 2 30.1(1.7) 30.1(29.1-31.1) 11.7(2.1) 11.8(10.2-13.3) 6.4(11.7) 0.0(0.0-7.2) 
Northern/North Eastern 
region 
2007-2012 2 30.0(1.8) 30.1(29.1-31.2) 12.1(2.0) 12.2(10.9-13.5) 6.6(11.8) 0.4(0.0-8.4) 
Mombasa CRHa N/A - N/A  N/A  N/A  
Kilifi CH 2007-2013 1 27.6(1.5) 27.5(26.4-28.7) 15.1(1.5) 15.3(13.7-16.3) 12.5(29.0) 4.3(1.2-12.4) 
Coastal Kenya region 2007-2013 1 27.6(1.5) 27.5(26.4-28.7) 15.1(1.5) 15.3(13.7-16.3) 12.5(29.0) 4.3(1.2-12.4) 
All sites 2007-2013 2 24.77(4.5) 25.5(20.5-28.9) 13.0(2.1) 13.1(11.6-14.3) 18.3(26.1) 8.1(1.8-25.5) 
aData from these sites were excluded from the analysis of association of influenza activity and meteorological variables because of multiple missing data points in the time series; N/A; Not applicable.
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Table 6.3: Bivariate analysis of the meteorological factors associated with influenza activity in Kenya, January 2007 - 
December 2013 
  
Association with the onset of influenza 
activity 
Absolute association with influenza activity 
  
  
Odds Ratio                         
(95% CI) 
p-value 
Incidence Rate Ratio                    
(95% CI) 
p-value 
Year  0.233*  <0.001* 
    2007 0.70(0.23-2.15) 0.538 0.45(0.37-0.55) <0.001 
    2008 0.74(0.30-1.84) 0.516 0.78(0.64-0.94) 0.010 
    2009 0.34(0.10-1.18) 0.089 0.79(0.62-1.00) 0.048 
    2010 0.31(0.07-1.36) 0.120 0.96(0.79-1.16) 0.649 
    2011 Ref  Ref  
    2012 0.99(0.46-2.11) 0.979 0.60(0.49-0.74) <0.001 
    2013 0.42(0.14-1.27) 0.125 0.69(0.56-0.85) <0.001 
Week 0.98(0.97-1.00) 0.123 1.00(0.99-1.00) 0.285 
Site  0.813*  <0.001* 
    St. Elizabeth Hospital Ref  Ref  
    Tabitha Clinic (Kibera) 1.52(0.56-4.12) 0.410 1.70(1.36-2.11) <0.001 
    Nyeri CRH 0.75(0.19-2.85) 0.667 0.83(0.64-1.08) 0.169 
    Kakamega CRH 1.00(0.30-3.37) 1.000 1.07(0.83-1.36) 0.609 
    Nakuru CRH 1.13(0.39-3.30) 0.825 0.77(0.61-0.97) 0.025 
    Siaya CRH 1.10(0.35-3.41) 0.871 0.67(0.53-0.85) 0.001 
    Dadaab refugee camp 1.44(0.37-5.57) 0.594 0.94(0.73-1.22) 0.649 
    Kakuma refugee camp 1.05(0.38-2.94) 0.924 0.88(0.71-1.09) 0.238 
    Kilifi County Referral Hospital 0.49(0.15-1.66) 0.253 0.25(0.19-0.33) <0.001 
Temperature (0C)     
    No lag 0.99(0.93-1.05) 0.682 0.97(0.95-0.98) <0.001 
    Lag 1 week 0.98(0.92-1.04) 0.484 0.96(0.95-0.98) <0.001 
    Lag 2 weeks 0.97(0.91-1.04) 0.350 0.96(0.95-0.98) <0.001 
    Lag 3 weeks 0.97(0.91-1.04) 0.346 0.96(0.95-0.98) <0.001 
    Lag 4 weeks 0.97(0.91-1.04) 0.394 0.96(0.95-0.98) <0.001 
Specific humidity (g/kg)     
    No lag 0.86(0.75-0.98) 0.031 0.86(0.84-0.89) <0.001 
    Lag 1 week 0.82(0.71-0.94) 0.004 0.85(0.83-0.88) <0.001 
    Lag 2 weeks 0.84(0.73-0.96) 0.013 0.85(0.82-0.87) <0.001 
    Lag 3 weeks 0.89(0.78-1.02) 0.108 0.84(0.82-0.87) <0.001 
    Lag 4 weeks 0.86(0.75-0.99) 0.035 0.84(0.82-0.86) <0.001 
Accumulated rainfall (mm)     
    No lag 1.00(0.99-1.01) 0.807 1.00(1.00-1.00) 0.360 
    Lag 1 week 0.99(0.98-1.00) 0.115 1.00(1.00-1.00) 0.268 
    Lag 2 weeks 1.00(1.00-1.01) 0.409 1.00(1.00-1.00) 0.074 
    Lag 3 weeks 1.00(0.99-1.01) 0.677 1.00(1.00-1.00) 0.138 
    Lag 4 weeks 1.00(0.99-1.01) 0.811 1.00(1.00-1.00) 0.106 
Presence of cold-dry conditions§      
    No lag 8.17e-06(0--) 0.295 1.65(1.09-2.50) 0.019 
    Lag 1 week 8.17e-06(0--) 0.295 2.05(1.10-3.83) 0.024 
    Lag 2 weeks 8.17e-06(0--) 0.295 1.58(0.98-2.53) 0.059 
    Lag 3 weeks 8.17e-06(0--) 0.295 2.12(1.13-4.01) 0.020 
    Lag 4 weeks 8.18e-06(0--) 0.319 1.25(0.74-2.11) 0.401 
  §-Cold-dry periods were defined as weeks when the average temperature was <18oC and specific humidity was <11g/Kg; *Overall p-value 
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Table 6.4: Multivariable analysis of the meteorological factors associated with influenza activity in Kenya, January 2007 - 
December 2013  
  Association with the onset of influenza activity Absolute association with influenza activity 
  
Odds Ratio                              
(95% CI) 
p-value 
Incidence Rate Ratio                    
(95% CI) 
p-value 
Temperature (0C)     
    No lag 1.06(0.87-1.28) 0.573 1.03(1.00-1.08) 0.086 
    Lag 1 week 0.97(0.80-1.18) 0.752 1.01(0.97-1.05) 0.720 
    Lag 2 weeks 0.90(0.74-1.10) 0.308 1.01(0.97-1.05) 0.750 
    Lag 3 weeks 0.90(0.74-1.10) 0.299 0.99(0.95-1.02) 0.464 
    Lag 4 weeks 0.93(0.76-1.13) 0.443 0.98(0.94-1.01) 0.219 
Specific humidity (g/kg)     
    No lag 0.85(0.71-1.02) 0.078 0.94(0.90-0.98) 0.005 
    Lag 1 week 0.79(0.66-0.94) 0.007 0.91(0.87-0.95) <0.001 
    Lag 2 weeks 0.82(0.69-0.98) 0.027 0.90(0.86-0.94) <0.001 
    Lag 3 weeks 0.91(0.76-1.09) 0.307 0.88(0.85-0.92) <0.001 
    Lag 4 weeks 0.86(0.71-1.02) 0.088 0.88(0.85-0.91) <0.001 
Accumulated rainfall (mm)     
    No lag 1.00(0.99-1.01) 0.761 1.00(1.00-1.00) 0.955 
    Lag 1 week 0.99(0.97-1.00) 0.099 1.00(1.00-1.00) 0.671 
    Lag 2 weeks 1.00(0.99-1.01) 0.348 1.00(1.00-1.00) 0.798 
    Lag 3 weeks 1.00(0.98-1.01) 0.623 1.00(1.00-1.00) 0.778 
    Lag 4 weeks 1.00(0.99-1.01) 0.763 1.00(1.00-1.00) 0.841 
Presence of cold-dry conditions§      
    No lag NE - 1.90(1.20-3.01) 0.006 
    Lag 1 week NE - 2.07(1.21-3.55) 0.008 
    Lag 2 weeks NE - 1.64(0.97-2.78) 0.062 
    Lag 3 weeks NE - 1.95(1.11-3.44) 0.021 
    Lag 4 weeks NE - 1.15(0.59-2.24) 0.675 
§-Cold-dry periods were defined as weeks when the average temperature was <18oC and specific humidity was <11g/Kg; NE-Not estimated 
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Appendix 6.1: Supplementary Methods 
Case definitions 
 Influenza-Like Illness: was defined as an axillary temperature ≥38oC and cough or sore throat in an 
outpatient of any age (1, 2). 
Severe Acute Respiratory Illness (SARI): was defined differently for children under five years and for 
persons ≥5 years. Among children aged <5 years, SARI was defined using a modified version of the 
World Health Organization’s Integrated Management of Childhood Illness (IMCI) definition for 
pneumonia. This was defined as hospitalization with cough OR difficulty breathing, AND at least one of 
(maternal report of lower-chest wall in-drawing, stridor in a calm child, unable to drink or breast feed, 
vomiting, convulsions, lethargic or unconscious, oxygen saturation <90%). Among persons aged 5 years, 
SARI was defined as hospitalization with cough OR difficulty breathing OR shortness of breath AND a 
documented fever (≥38oC) (1, 2). 
At the Kilifi site, severe pneumonia was defined as cough OR difficult breathing AND lower chest 
wall in-drawing and no signs of very severe pneumonia. Very severe pneumonia was defined as cough 
OR difficult breathing AND at least one of (hypoxia (oxygen saturation <90%), cyanosis, prostration 
(inability to drink or breast feed, inability to sit), or coma at admission) (3). 
 
Missing data 
We applied several procedures to handle missing data at each site. First, we excluded data for 
the whole year if there were five or more successive weeks with no influenza testing conducted. Second, 
if no data were collected in a specific week but data were collected in the previous and succeeding 
weeks, we substituted the missing data point by the average of two immediate weeks (one from each 
side). This applied to 2% of the weeks in the entire dataset. Lastly, for cases where data were missing for 
2-4 successive weeks, we substituted the missing observation with data from the last week when 
influenza testing was conducted. This applied to 3% of the weekly data points in the dataset. Overall, we 
obtained 1,872 weeks of influenza surveillance data for further analyses of which 5% were imputed. 
 
Meteorological Data 
All the environmental data used in this analysis were satellite-derived measurements obtained 
from The National Aeronautics and Space Administration (NASA), and were collected over the same 
period as the influenza data.  The environmental variables included in the analysis were, average surface 
temperature (0C), and near surface specific humidity (g/Kg) obtained from the Global Land Data 
Assimilation System (GLDAS) (4); and accumulated Rainfall (mm) obtained from the Tropical Rainfall 
Measuring Mission (TRMM) (5). The temperature and specific humidity measurements were all three-
hourly temporal datasets with a spatial resolution of 1.00 x 1.00 latitude/longitude. The rainfall data were 
daily temporal datasets and had a finer resolution of 0.250 x 0.250 latitude/longitude. These data were 
downloaded through NASA’s Goddard Earth Sciences and Data Information Service Center (GES-DISC) 
Interactive Online Visualization and Analysis Infrastructure (GIOVANNI). All the meteorological 
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measurements (3-hourly and daily) were then averaged over each week to obtain the weekly 
measurements which were used in the final analysis.  
To determine if influenza was associated with earlier measurements of the meteorological 
variables, we investigated associations of up to 4 lagged weeks on all meteorological variables. We 
selected this lag period because the exploratory analyses indicated no association when we considered 
lag periods beyond four weeks. Also given that the influenza incubation period ranges from 1-4 days 
after exposure and that the infected persons could continue to be infectious for another 5-7 days after 
the onset of symptoms (6) in normal circumstances, we believed that 4 weeks was an optimal period for 
an epidemic to start and spread into the community.  
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Appendix 6.2: Supplementary Figures 
Supplemental figures showing the time series of the average weekly temperature, specific humidity and 
percent influenza positive cases by site, 2007 to 2013 
The vertical lines indicates the identified onset week and the dotted horizontal line shows the 10% 
infleunza positive cut-off point. 
Definitions: 
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a) Cold-dry week was defined as the week when temperature was <180C and specific humidity 
was <11g/kg. 
 
b) Humid-rainy week was defined as the week when specific humidity was >14g/kg and rainfall 
was >150mm. 
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Abstract 
Background:  We estimated the cost-per-episode and the annual economic burden associated with 
influenza in Kenya.  
Methods: From July 2013-August 2014, we recruited patients with severe acute respiratory illness (SARI) 
or influenza-like illness (ILI) associated with laboratory-confirmed influenza from 5 health facilities. A 
structured questionnaire was used to collect direct costs (medications, laboratory investigations, 
hospital bed fees, hospital management costs, transportation) and indirect costs (productivity losses) 
associated with an episode of influenza. We used published incidence of laboratory-confirmed influenza 
associated with SARI and ILI, and the national population census data from 2014, to estimate the annual 
number of influenza-associated hospitalizations and outpatient visits and calculated the annual 
economic burden by multiplying cases by the mean cost. 
Results: We enrolled 275 patients (105 inpatients and 170 outpatients). The mean cost-per-episode of 
influenza was US$117.86 (standard deviation [SD], 88.04) among inpatients; US$114.25 (SD, 90.03) for 
children <5 years, and US$137.45 (SD, 76.24) for persons aged ≥5 years. Among outpatients, the mean 
cost-per-episode of influenza was US$19.82 (SD, 27.29); US$21.49 (SD, 31.42) for children <5 years, and 
US$16.79 (SD, 17.30) for persons aged ≥5 years. National annual influenza-associated cost ranged from 
US$2.96-5.37 million for inpatients and US$5.96-26.35 million for outpatients.  
Conclusions:  Our findings highlight influenza as causing substantial economic burden in Kenya, 
underlining the potential benefit of influenza vaccine recommendations. 
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7.1 Introduction 
In Kenya, influenza virus circulates year-round and is an important contributor to the acute 
respiratory illness associated burden, disproportionately affecting children aged <5 years (1, 2). Despite 
the documented burden of influenza disease in Kenya, a national influenza vaccination program is yet to 
be implemented. Other than the health impact caused by influenza virus infection itself, influenza illness 
has been shown to exert a considerable economic burden, although most of the data available come 
from temperate and resource rich countries (3-6). Understanding the costs of influenza-associated 
illness in Kenya is critical to allow health authorities and policy makers to develop practical plans for 
vaccine recommendations.  
We estimated the cost-per-episode, from a societal perspective, of laboratory-confirmed influenza-
associated illness in Kenya using data collected from interviews with case-patients or their care-takers, 
and abstracted from medical records. Additionally, we estimated the annual economic burden of 
influenza-associated illness in Kenya by applying the estimated costs to the annual national morbidity 
burden using previously published data on burden of influenza-associated disease. 
 
7.2 Methods 
 
7.2.1 Study sites and population 
From July 2013 through August 2014, we prospectively enrolled patients from four hospitals 
[Mombasa County Referral Hospital (CRH), Nakuru CRH, Nyeri CRH, and St. Elizabeth Mission Hospital in 
Lwak] and one outpatient facility (Tabitha clinic in Kibera) (Figure 7.1). Mombasa CRH, Nakuru CRH and 
Nyeri CRH are public health facilities. Kibera clinic is located in an urban informal settlement in Nairobi 
and is operated by Carolina for Kibera (7). St. Elizabeth Mission hospital is a rural site in western Kenya 
operated by the Franciscan Sisters of St. Anna (7).  The study sites were purposely selected for their 
diversity and their representation of populations in multiple geographical locations (Figure 7.1). 
Patients were enrolled if they met the case definitions for severe acute respiratory illness (SARI) or 
influenza-like illness (ILI) and tested positive for influenza A and/or B using the Becton Dickson (BD) 
VeritorTM rapid diagnostic test (RDT) in nasal swabs collected at interview (8, 9). SARI was defined as 
hospitalization with an acute respiratory infection within the last ten days with a history of fever or 
measured temperature ≥38 C°, and cough. ILI was defined as an acute respiratory infection within the 
last seven days with a measured temperature ≥38 C° and cough. 
7.2.2 Confirmatory testing for influenza 
Nasopharyngeal (NP) and oropharyngeal (OP) swabs were collected from all consenting and enrolled 
patients. The NP/OP swabs were combined into a single viral transport media, and tested by real-time 
reverse transcription polymerase chain reaction (rtRT-PCR) for influenza A and B virus at the Kenya 
Medical Research Institute (KEMRI) and U.S Centers for Disease Control and Prevention (CDC) laboratory 
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in Nairobi (10). Data from patients whose NP/OP specimens were confirmed to be positive for influenza 
virus by rtRT-PCR were used in the final data analysis. 
                    
                      
                                    Figure 7.1: Map of Kenya showing the location of the study sites 
 
7.2.3 Data collection 
      Patients who were aged ≥18 years were interviewed directly by trained surveillance officers using a 
structured questionnaire. For those who were aged <18 year, their care-takers were interviewed. 
Enrolled study participants were subsequently followed-up using telephone interviews to determine 
additional costs incurred over a period of 14 days from the date of testing for influenza. This period was 
chosen because most uncomplicated influenza infections resolve within a period of two weeks (11). To 
minimize the possibility of recall bias, the follow-up telephone interviews were conducted on a weekly 
basis. The first interview was conducted on the 8th day (to cover the preceding 7 days); and the last on 
the 15th day (to cover the other 7 days). Data on clinical management of the patients were abstracted 
from the medical records of the case-patients (i.e., patient files and charge sheets). As study participants 
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at the two population-based study sites receive free medical care provided by KEMRI and CDC, we used 
costs chargeable to non-study participants and costs of purchase provided by the study administrative 
staff at Lwak and Kibera, respectively.  
 
7.2.4 Direct and indirect cost components 
The direct cost components included facility-based medical-cost items (i.e. medications, laboratory 
investigations and other routine diagnostics, hospital bed fees, and hospital management costs) 
(Appendix Table 7.1), and travel costs by the case-patients and/or their household members. Facility-
based medical-cost items were obtained from the hospital bill charge sheets for inpatients, price 
catalogue charts, and receipts issued to the outpatients (Appendix 7.1 and Appendix Table 7.1). Other 
direct costs included costs incurred for seeking care prior and after discharge from the hospital or 
outpatient visit (e.g. over the counter prescriptions).  Other than children <5 years whose medical costs 
were paid for by the government in public health facilities, all costs (excluding consultation fees) were 
paid for out-of-pocket by older patients (12). The costs of testing for influenza were not included as they 
are not routinely ordered by clinicians independently from the ongoing surveillance.   
The indirect cost component was the productivity losses (days of work lost) at the household level 
by the case-patients themselves, and/or any of their household members (Appendix 7.1). Data on days 
of work lost were only considered for those who were engaged in formal or informal income generating 
employment who would otherwise not be financially compensated for the lost workdays. 
 
7.2.5 Data Analyses 
5.2.5.1 Descriptive analyses and tests of associations 
      Data on patient characteristics were described using proportions. Tests of association were 
performed using chi-square tests for categorical variables.  For continuous variables, data were 
described using means, standard deviations (SD), medians, and interquartile ranges (IQR). Comparisons 
of means were done using the independent t-test or one-way analysis of variance, and median and IQR 
were compared using Wilcoxon rank sum test or Kruskal-Wallis test as appropriate. Data analyses were 
performed using Stata version 13.0 (StataCorp. 2013. Stata Statistical Software: Release 13. College 
Station, TX: StataCorp LP). 
5.2.5.2 Cost-per-episode of influenza-associated illness 
      The cost-per-episode of influenza-associated illness was estimated as the sum of the facility-based 
medical costs, household transportation costs, the costs of seeking health care prior to the current visit, 
and the household lost productivity cost (Appendix 7.1) (6, 13). The routine service delivery cost at the 
facility – which included buildings and equipment maintenance, transport, electricity, water, fuel, 
communication, stationery, and wages for support staff – was estimated for each patient using health 
facility administration data collected over the financial year 2014 (Appendix 7.1). We also explored the 
option of using the WHO-Choice estimates for routine healthcare service costs for hospitalized patients 
(cost per bed day) and outpatients (cost per outpatient visit) (14). We found minimal differences 
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compared to when we used actual data and subsequently opted to report costs calculated using the 
actual routine healthcare service cost data collected from the study sites (Appendix 7.1). Definitions and 
data sources of the cost components are provided in Appendix Tables 7.1. 
 
5.2.5.3 National economic burden of influenza-associated illness 
To estimate the annual economic burden of influenza-associated illness, we used the published 
national annual incidence (between 2007 and 2013) of influenza-associated hospitalizations and 
outpatient visits for children <5 years and persons ≥5 years (15). We carried out a sensitivity analysis for 
the best- and worst-case scenario assuming a low and high incidence of influenza-associated illness 
respectively (15). We applied the incidence rates to the population size in 2014, projecting an annual 
growth rate of 2.7% from the 2009 national census, to estimate the annual number of hospitalizations 
and outpatient visits associated with influenza illness (16, 17). We used bootstrap samples – with 1,000 
replications of the same size as the original dataset and sampled with replacement – to estimate the 
mean costs which were then applied to the hospitalizations and outpatient visits to estimate overall 
costs. All costs reported in our analysis are in United States (U.S.) Dollars (1 US$=90 Kenya Shillings in 
2014). 
 
 
7.3 Ethical considerations 
The KEMRI Ethical Review Committee (KEMRI SSC-2492) and Institutional Review Board of U.S CDC 
(CDC IRB # 6539) approved this study. Written informed consent was obtained from all participants or 
caretakers/guardians of all minors prior to enrolment in the study and sample collection. 
 
7.4 Results 
 
7.4.1 Descriptive analyses 
From July 2013 through August 2014, a total of 418 patients were initially recruited in the study. 
After excluding patients who tested negative for influenza by rtRT-PCR and those without follow up 
data, a total of 275 case-patients were included in the final analysis (Figure 7.2 and Table 7.1). Among 
these were 105 inpatients (<5 years=88; ≥5 years=17), and 170 outpatients (<5 years=112; ≥5 years=58). 
The majority (73%) of the case-patients were children <5 years. Among persons ≥5 years, median age 
was 11 years (interquartile range [IQR], 7-30); only 7 (9%) were aged ≥40 years. Overall 135 (49%) were 
males (Table 7.1). The median length of hospitalization was 4 days (IQR, 3-6); 5 days (IQR, 3-7) among 
children <5 years compared to 4 days (IQR, 3-4) among older patients (p=0.050). The average monthly 
household income was US$ 225.83 (20,325 Kenya shillings).  
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Forty six percent of the case-patients aged <5 years were taken to care or had drugs bought for 
them over the counter prior to enrollment compared to 20% for persons aged ≥5 years (p<0.001). The 
median (IQR) number of workday opportunity losses was 2 days (0-6); 5 days (2-9) among inpatients vs. 
1 day (0-3) among outpatients (p<0.001). The median (IQR) number of school-days lost in the 
households of the case-patients was 4 days (3-6); 3 days (1-6) among inpatients vs. 4 days (3-6) among 
outpatients (Table 7.1). 
 
 
7.4.2 Cost of influenza-associated illness 
      We found differences in the distributions of the costs per-episode of influenza by site among 
outpatients (mean costs ranged from US$ 12.29 - 47.78; p=0.002), but no differences among inpatients 
(mean costs ranged from US$ 110.82 - 130.97; p=0.461). The overall mean (SD) cost per episode among 
hospitalized patients was US$117.86 (88.04): <5 years=US$114.25 (90.03); and ≥5 years=US$137.45 
(76.24). The mean (SD) cost per episode among outpatients overall was US$19.82 (27.29): <5 
years=US$21.49 (31.42); and ≥5 years=US$16.79 (17.30) (Table 7.2 and Appendix Tables 7.2 and 7.3). 
The health facility service delivery mean (SD) costs among inpatients were estimated at US$59.19 
(59.39), and were thirteen times higher compared to outpatients (US$4.34 [1.30]). Overall, the mean 
fraction of the total cost-per-episode of influenza-associated illness relative to the average monthly 
household income was 60% (95% CI 45 – 75) among hospitalized patients. However, when the costs that 
were paid by the government for children <5 years were excluded, cost-per-episode related to monthly 
income was 40% (95% CI 34 - 46). Cost-per-episode for outpatients relative to monthly income was 12% 
(95% CI 10 - 14); 11% (95% CI 9 - 13) if costs paid by the government for children <5 years were 
excluded. 
      Direct mean (SD) costs associated with influenza were ten times higher for hospitalizations (US$ 
75.43 [66.73]) compared to outpatient visits (US$ 7.68 [5.63]). The mean (SD) cost associated with 
hospitalization was US$75.42 (71.10) for children <5 years and US$75.45 (36.27) for persons ≥5 years. 
For outpatient visits the mean (SD) cost was US$8.62 (6.15) for children <5 years, and US$5.97 (4.07) for 
persons ≥5 years (Table 7.2 and Appendix Tables 7.2 and 7.3). The overall mean (SD) indirect cost-per-
episode of influenza-associated illness was US$42.01 (41.54) (<5 years=US$38.94 [38.59]; and ≥5 
years=US$58.61 [53.37]) among hospitalized patients compared to US$12.84 (27.17) (<5 
years=US$13.87 [31.36]; and ≥5 years=US$10.88 [16.65]) among outpatients.  
7.4.3 National economic burden of influenza-associated illness 
      Assuming the lowest (<5 years= 2.7 per 1,000 children; ≥5 years= 0.2 per 1,000 persons) and highest 
(<5 years=4.7 per 1,000 children; ≥5 years=0.4 per 1,000 persons) published incidence of 
hospitalizations associated with influenza activity in Kenya [15], we estimated total hospitalizations to 
range from 25,154 to 45,672 (<5 years=17,875 - 31,115; ≥5 years=7,279 - 14,557). These would result in 
costs ranging from US$ 2.96 to 5.37 million (<5 years= US$2.04 – 3.55 million; ≥5 years= US$1.00 – 1.99 
million) (Table 7.3). Similarly, assuming lowest (<5 years= 21.8 per 1,000 children; ≥5 years= 4.3 per 
1,000 persons) and highest rates (<5 years= 58.0 per 1,000 children; ≥5 years= 26.0 per 1,000 persons) 
[15], we estimated that outpatient visits associated with influenza would range from 300,813 to 
1,330,200 [<5 years=144,322 - 383,977; ≥5 years=156,491 - 946,223]. These would translate to a total 
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cost ranging from US$5.96 to 26.35 million (<5 years= US$3.09 – 8.23 million; ≥5 years=US$2.64 – 15.96 
million).  The overall cost associated with influenza (combining in- and outpatients) could range from 
US$ 8.92 to 31.72 million. 
 
                                                            
 
 
 
     
 
 
 
 
 
 
 
 
 
                     
 
 
 
 
 
 
Figure 7.2: Data flow diagram 
 
  
Tested positive for influenza at the health facility by rapid diagnostic test 
(RDT) and were enrolled in the study (n=418) 
Hospitalized patients with 
initial interviews at the facility 
(n=178) 
Patients with both initial and follow-up 
interviews done (n=156) 
Outpatients with initial 
interviews at the facility 
(n=240) 
With no follow-up data 
collected (n=22) 
Included in analysis (n=105) 
Tested negative for 
influenza by RT-PCR 
(n=51) 
Patients with both initial and follow-up 
interviews done (n=213) 
 
Included in analysis (n=170) 
With no follow-up 
data collected (n=27) 
 
Tested negative for 
influenza by RT-PCR 
(n=43) 
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7.5 Discussion 
This is the first estimate of the economic impact associated with medically-attended influenza in 
Kenya. We found that, depending on annual influenza virus circulation, the costs associated with 
influenza in Kenya could be as high as US$ 32 million.   We estimated that the overall mean cost per 
episode was US$118 for hospitalization and US$20 for outpatient visits, a substantial burden for Kenyan 
families when we consider their average monthly income, the loss of self-employment wages by missed 
days at work, and that most of medical costs are paid out-of-pocket. Influenza vaccine is the most 
effective way to prevent influenza and should be considered for groups at risk of influenza-associated 
complications and hospitalizations in Kenya.  
The overall cost-per-episode of influenza-associated hospitalizations was six times higher when 
compared to outpatient visits. This was driven by the facility-based medical cost component, where the 
hospitalization cost was thirteen-fold higher, and was similar to the results published in Bangladesh (13). 
Because of the higher frequency of outpatient visits, the annual economic burden for outpatient 
influenza-associated illness in Kenya was substantially high relative to hospitalizations, which is 
consistent with results reported from other studies (3, 13). However, the overall cost-per-episode of 
influenza in our study was lower than reported elsewhere in developed countries (5, 18). This could be 
explained by the relative lower cost of healthcare and the comparatively low income level in Kenya 
where the gross national income per capita is estimated at US$939 (19).  
The duration of hospitalization was higher for children <5 years compared to older persons. This is 
contrary to findings reported elsewhere (6) and may be explained by the fact that in our study 
population only 7 persons were >40 years old. Older adults tend to stay longer in hospital due to 
complications associated with underlying diseases (20). We also found that the cost-per-episode when 
the illness involved a child <5 years old was similar to the cost among older patients aged ≥5 years.  
Other than the effect of underrepresentation of older patients in our study, this finding could also be 
explained by the fact that a higher percentage (46%) of children <5 years compared to older patients 
(20%) had sought healthcare or had drugs bought over the counter prior to the hospitalization or 
outpatient visit. The fact that an influenza-associated illness involving young children – who are at a high 
risk of influenza-associated complications (21, 22) – also results in high economic cost highlights the 
need for the development of targeted vaccination and other preventive strategies among this age 
group.  
Besides the loss of income opportunities, influenza-associated illness also resulted in school 
absenteeism with a median of 4 days of missed school, which was comparable to findings from a study 
conducted in Hong Kong (23), and another study conducted in the US (4). Notably, we found that school 
absenteeism was higher among households of outpatients compared to those of hospitalized patients. 
This could be explained by the fact that older siblings may be asked to stay at home and take care of the 
younger ones as the caretakers take the sick child to a health facility. However, in a case of 
hospitalization - where it may not be certain when the mother/parent will return - young children may 
be left at the care of relatives or neighbors.  
Overall, a single episode of influenza-associated hospitalization resulted in a substantial cost of 
approximately 60% of the household average monthly income while outpatient-associated influenza 
costs represented 12%. Regardless of the fact that medical costs at the hospital were covered by the 
government for children < 5 years (12), the overall resultant costs from an influenza-associated 
hospitalization – which were paid out-of-pocket (40% of the household average monthly income) – 
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could put a financial strain on families (24) and may also negatively impact on other competing 
household priorities such as food and education. Considering the possibilities of influenza-associated 
complications, the financial impact to the household arising from such cases could even be greater.  
The mean cost-per-episode of influenza among children <5 years in our study (US$114) was similar 
to the coast reported in a study of malaria patients that was conducted in Kenya in 2009 which reported 
a mean cost of US$100 (25). However, there were some differences in the methodologies of these 
studies that would limit our ability to make direct comparisons. Unlike in our study, death was included 
in the household indirect cost where it was calculated as the net present value of future potential 
earnings. The resultant total indirect cost accounted for 60% of the overall mean cost per episode of 
malaria.  
Our study had some important limitations. First, older patients were underrepresented in our 
patient-population as healthcare seeking is low in this group (26), and our cost estimates associated 
with influenza could be underestimated in this group, principally considering the high prevalence of 
underlying medical conditions that could lead to prolonged hospitalization. Indeed, as routinely seen in 
our hospital-based surveillance, only 3% of the study participants were aged ≥40 years. Second, we did 
not include the physician’s fees in our analysis. We also did not incorporate the indirect cost of days 
with reduced activity among case-patients, productivity loss for non-income generating activities, and 
deaths in our data collection and subsequently in the analysis. This could have further served to 
underestimate the actual costs associated with influenza. Third, the self-reported costs on prior 
expenditures and post-discharge expenditures could have suffered some degree of under- or over 
reporting as they were not substantiated by receipts. Fourth, we were not able to stratify our cost 
analysis by underlying comorbidities, e.g., only 5% of the study participants had been tested for HIV. 
Lastly, we did not include costs incurred by persons who did not seek care because of influenza illness; 
costs of self-medication within the community and related loss of productivity by these persons went 
unmeasured.  
Our findings show that medically attended, influenza-associated illness in Kenya generate substantial 
direct and indirect costs. The burden is driven mostly by outpatient visits. Recommendations to 
vaccinate young children <5 years may be warranted as this age group bears a disproportionately high 
influenza disease burden which results in substantial financial costs to their families and the government 
(27). Whereas this study highlights an important societal economic impact of influenza-associated 
illness, further studies should explore the cost-effectiveness of targeted influenza vaccination in Kenya 
and account for years lost due to death or disability.  
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Table 7.1: General characteristics of study patients with influenza-associated illnesses in Kenya, July 2013 - August 2014 
Variable All data 
(n=275) 
  Inpatients   Outpatients 
  
 <5 years 
(n=88) 
≥5 years 
(n=17) 
Total 
(n=105) 
 <5 years 
(n=112) 
≥5 years 
(n=58) 
Total 
(n=170) 
Hospital, n(%)           
      Coast PGH 38 (13.8)  25 (28.4) 0 (0.0) 25 (23.8)  13 (11.6) 0 (0.0) 13 (7.7) 
      Nyeri PGH 35 (12.7)  28 (31.8) 5 (29.4) 33 (31.4)  2 (1.8) 0 (0.0) 2 (1.2) 
      Nakuru PGH 98 (35.6)  35 (39.8) 12 (70.6) 47 (44.8)  45 (40.2) 6 (10.3) 51 (30.0) 
      Tabitha Clinic (Kibera) 89 (32.4)  0 (0.0) 0 (0.0) 0 (0.0)  48 (42.9) 41 (70.7) 89 (52.4) 
      St. Elizabeth Hosp. (Lwak) 15 (5.5)  0 (0.0) 0 (0.0) 0 (0.0)  4 (3.6) 11 (19.0) 15 (8.8) 
Sex of patient (Male), n(%) 135 (49.1)  50 (56.8) 7 (41.2) 57 (54.3)  58 (51.8) 20 (34.5) 78 (45.9) 
Age of patient (<5 years), n(%) 200 (72.7)  88 (100.0) N/A 88 (83.81)  112 (100.0) N/A 112 (65.9) 
Relationship of respondent to patient, n(%)           
      Self 31 (11.3)  0 (0.0) 8 (47.1) 9 (8.6)  0 (0.0) 22 (37.9) 22 (12.9) 
      Mother 222 (80.7)  81 (92.0) 8 (47.1) 88 (83.8)  105 (93.8) 29 (50.0) 134 (78.8) 
      Father 13 (4.7)  4 (4.6) 0 (0.0) 4 (3.8)  6 (5.4) 3 (5.2) 9 (5.3) 
      Other 9 (3.3)  3 (3.4) 1 (5.9) 4 (3.8)  1 (0.9) 4 (6.9) 5 (2.9) 
Sought care prior to this hospitalization/outpatient visit, n(%) 107 (38.9)  58 (65.9) 10 (58.8) 68 (64.8)  34 (30.4) 5 (8.6) 39 (22.9) 
       Purchased any medications prior to hospital/clinic visit, n(%) 
77/107 
(72.0) 
 42/58 
(72.4) 
7/10 (70.0) 
49/68 
(72.1) 
 24/34 (70.6) 4/5 (80.0) 
28/39 
(71.8) 
Sought care after discharge from the hospital/clinic, n(%) 26 (9.5)  8 (9.1) 3 (17.7) 11 (10.5)  11 (9.8) 4 (6.9) 15 (8.8) 
Household member(s) missed work due to illness, n(%) 177 (64.4)  72 (81.8) 17 (100.0) 89 (84.8)  54 (48.2) 34 (58.6) 88 (51.8) 
Total number of workdays lost in a household,  median(IQR) 4 (3-8)  7 (4-10) 6 (3-13) 6 (4-10)  3 (2-6) 3 (2-5) 3 (2-5) 
Average number of household workdays lost due to illness, median 
(IQR)* 
4 (2-7)  5 (3-9) 6 (3-12) 5 (3-9)  3 (2-5) 3 (2-4) 3 (2-5) 
Household member(s) missed school due to illness, n(%) 90 (32.7)  17 (19.3) 6 (35.3) 23 (21.9)  35 (31.3) 32 (55.2) 67 (39.4) 
Total number of school days missed, median(IQR) 4 (3-6)  2 (1-6) 5 (4-9) 3 (1-6)  3 (2-6) 4 (3-7) 4 (3-6) 
Paid for child care in the course of sickness, n(%) 6 (2.2)  3 (3.4) 0 (0.0) 3 (2.9)  1 (0.9) 2 (3.5) 3 (1.8) 
Paid for child care in the course of sickness, n(%) 6 (2.2)  3 (3.4) 0 (0.0) 3 (2.9)  1 (0.9) 2 (3.5) 3 (1.8) 
NA – Not applicable; *Calculated as the total number of workdays lost by all household members who reported to be engaged in an income activity divided by the number of persons who reported to be 
engaged in an income activity. 
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Table 7.2: Overall costs, including direct and indirect costs, related to influenza-associated illness in Kenya, July 2013 - August 2014 
  Costs among inpatients    (US$ⱡ )   Costs among outpatients    (US$ⱡ ) 
Expenditure item <5 years ≥5 years Total  <5 years ≥5 years Total 
  n Mean(SD) n Mean(SD) n Mean(SD)  n Mean(SD) n Mean(SD) n Mean(SD) 
Direct cost 76 75.42 (71.10) 14 75.45 (36.27) 90 75.43 (66.73)  100 8.62 (6.15) 55 5.97 (4.07) 155 7.68 (5.63) 
Healthcare prior to hospital/clinic visit 88 7.59 (16.95) 17 6.56 (8.48) 105 7.42 (15.86)  110 2.04 (4.67) 58 0.17 (0.82) 168 1.39 (3.90) 
Total facility-based medical costs 83 59.81 (63.60) 15 55.77 (27.05) 98 59.19 (59.39)  108 4.30 (1.27) 57 4.43 (1.36) 165 4.34 (1.30) 
       Medications 83 13.90 (52.47) 15 18.31 (17.45) 98 14.58 (48.72)  108 0.96 (1.11) 57 1.10 (1.20) 165 1.01 (1.14) 
       Hospital bed fees 83 22.11 (13.95) 15 15.70 (6.13) 98 21.13 (13.24)  0 N/A 0 N/A 0 N/A 
       Procedure fees (non-   
       /surgical) 83 2.48 (5.03) 15 2.44 (2.19) 98 2.48 (4.70)  108 0.00 (0.00) 57 0.00 (0.00) 165 0.00 (0.00) 
       Diagnostic tests 83 4.59 (9.72) 15 7.84 (10.33) 98 5.09 (9.83)  108 0.11 (0.51) 57 0.11 (0.24) 165 0.11 (0.43) 
       Routine health facility service    
       management costa 83 16.59 (10.24) 15 11.40 (4.02) 98 15.80 (9.72)  108 3.23 (0.00)* 57 3.23 (0.00)* 165 3.23 (0.00)* 
Total transportation costs 88 4.68 (8.02) 17 6.86 (9.78) 105 5.03 (8.32)  112 0.48 (0.83) 58 0.25 (0.94) 170 0.40 (0.87) 
       Personal car/taxi  10 10.88 (9.51) 5 23.91 (28.40) 15 15.22 (18.14)  1 0.56 (-) 0 - 1 0.56 (-) 
       Matatu/bus 70 9.39 (9.79) 17 6.74 (5.35) 87 8.87 (9.13)  42 3.91 (8.42) 6 8.24 (9.52) 48 4.45 (8.58) 
       Motorbike/bike/tuktuk 15 5.36 (5.08) 2 16.39 (12.18) 17 6.66 (6.73)  17 2.59 (1.95) 5 3.33 (1.96) 22 2.76 (1.93) 
Healthcare after discharge 88 3.25 (5.95) 17 3.43 (7.53) 105 3.28 (6.19)  112 2.46 (4.77) 58 1.19 (3.48) 170 2.03 (4.40) 
Child care cost 88 0.14 (0.81) 17 0.00 (0.00) 105 0.11 (0.75)  112 0.04 (0.42) 58 0.13 (0.78) 170 0.07 (0.57) 
Indirect cost (Average household 
productivity lossb)  81 38.94 (38.59) 15 58.61 (53.37) 96 42.01 (41.54)  106 13.87 (31.36) 56 10.88 (16.65) 162 12.84 (27.17) 
Total cost per episodec 76 114.25 (90.03) 14 137.45 (76.24) 90 117.86 (88.04)  100 21.49 (31.42) 55 16.79 (17.30) 155 19.82 (27.29) 
Total cost per episode paid out of pocket 76 76.45 (55.13) 14 137.45 (76.24) 90 85.94 (62.49)   100 19.21 (30.70) 55 16.79 (17.30) 155 18.35 (26.69) 
SD–Standard Deviation; NA-Not applicable; aRoutine healthcare facility management costs for healthcare service costs per day (equipment maintenance, electricity, water, 
stationary, e.t.c); bEstimated by multiplying the average days when the household lost income opportunities by the household average daily  income; cSum of direct and indirect 
costs. 
ⱡ1 US$=90 Kenya Shillings; *No variability as the same amount was used for all patients 
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Table 7.3: Estimated annual costs (in millions of 2014 US$) of influenza-associated illnesses in Kenya 
  Hospitalized patients   Outpatients 
Cost Item (per episode) Best-case scenario Worst-case scenario  Best-case scenario Worst-case scenario 
  
Estimated 
cases 
Cost 
(US$ⱡ Millions) 
(95% CIc) 
Estimated 
cases 
Cost 
(US$ⱡ Millions) 
(95% CIc) 
 
Estimated 
cases 
Cost 
(US$ⱡ Millions) 
(95% CIc) 
Estimated 
cases 
Cost  
(US$ⱡ Millions) 
(95% CIc) 
Children <5 yearsa 17,875  31,115   144,322  383,977  
 Total direct costs  1.34 (1.10-1.63)  2.34 (1.92-2.84)   1.25 (1.09-1.41)  3.33 (2.89-3.76) 
  Facility-based medical costs  1.08 (0.89-1.34)  1.87 (1.54-2.33)   0.62 (0.59-0.66)  1.65 (1.56-1.75) 
  Transportation costs  0.08 (0.06-0.12)  0.15 (0.10-0.21)   0.07 (0.05-0.09)  0.18 (0.13-0.24) 
  Other costsb  
0.20 (0.13-0.27) 
 
0.34 (0.23-0.47) 
  
0.66 (0.48-0.85) 
 
1.76 (1.27-2.25) 
 Total indirect   0.70 (0.56-0.85)  1.21 (0.97-1.48)   2.01 (1.23-2.97)  5.35 (3.28-7.91) 
 Total costs   2.04 (1.73-2.41)  3.55 (3.01-4.19)   3.09 (2.32-4.07)  8.23 (6.18-10.84) 
Persons ≥5 yearsa 7,279 
 
14,557 
 
 156,491 
 
946,223 
  
 Total direct costs  0.55 (0.41-0.69)  1.10 (0.81-1.37)   0.93 (0.78-1.11)  5.64 (4.72-6.69) 
  Facility-based medical costs  0.41 (0.32-0.53)  0.81 (0.63-1.07)   0.69 (0.64-0.75)  4.20 (3.89-4.55) 
  Transportation costs  0.05 (0.02-0.09)  0.10 (0.04-0.18)   0.04 (0.01-0.08)  0.24 (0.05-0.50) 
  Other costsb  
0.07 (0.04-0.11) 
 
0.15 (0.07-0.22) 
  
0.23 (0.10-0.40) 
 
1.42 (0.63-2.43) 
 Total indirect   0.43 (0.26-0.65)  0.86 (0.51-1.30)   1.69 (1.09-2.40)  10.24 (6.61-14.49) 
 Total costs    1.00 (0.71-1.30)   1.99 (1.42-2.59)     2.64 (1.99-3.38)   15.96 (12.02-20.43) 
All ages 25,154  45,672   300,813   1,330,200  
 Total direct costs  1.89 (1.60-2.25)  3.44 (2.90-4.09)   2.32 (2.08-2.58)  10.24 (9.18-11.40) 
 Total indirect   1.06 (0.86-1.28)  1.92 (1.55-2.33)   3.87 (2.71-5.24)  17.11 (11.98-23.17) 
 Total costs   2.96 (2.57-3.41)  5.37 (4.66-6.19)   5.96 (4.80-7.49)  26.35 (21.22-33.14) 
aEstimated using published rates of influenza-associated disease in Kenya [hospitalization rate (<5 years=2.7-4.7 per 1,000; ≥5 years=0.2-0.4 per 1,000) and outpatient rate (<5 years=13.0-58.0 per 
1,000; ≥5 years=4.3-26.0 per 1,000)]; bCombines costs for childcare, and healthcare seeking prior and after hospitalization or outpatient visit; cMean cost and 95% confidence intervals estimated using 
1,000 bootstrap samples 
Best-case scenario: Assuming the lowest published incidence rate of influenza-associated illness 
Worst-case scenario: Assuming the highest published incidence rate of influenza-associated illness 
ⱡ1 US$=90 Kenya Shillings (2014). 
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Appendix 7.1: Supplementary methods 
Estimation of the routine service delivery cost 
The routine service delivery cost – which included buildings and equipment maintenance, transport, 
electricity, water, fuel, communication, stationery, and wages for support staff – was estimated per 
day for each patient using the following steps: 
1. Using a structured questionnaire, we obtained data on the actual service delivery costs 
covering the items mentioned above from the administrative personnel at the five study 
sites for the financial year 2014 (FY2014).  
2. From the health records office, we obtained data on the total bed occupancy (daily sum of 
the patients who were hospitalized) and the outpatient visits over the same period 
(FY2014). 
3.  We then calculated the average cost per patient by dividing the total annual cost 
(combining data from all the five sites) by the sum total of hospitalized patients and 
outpatients seen each day at the five facilities over the period FY2014. 
4. For hospitalized patients in our study, we then multiplied the estimate calculated in step 3 
above by the number of days the patients was hospitalized. For outpatients, the estimate 
calculated in step 3 was used as the cost of routine health facility service delivery. 
To minimize the potential for double counting costs, registration fees were not included in the 
analysis of the facility-based medical fees as such. 
Estimation of the lost opportunity cost 
To estimate the household lost opportunity cost, we used data on average monthly household 
income and number of people who missed work or income opportunities due to the illness of the 
case-patient. Studies conducted elsewhere have limited their calculation of opportunity loses to the 
case-patient and/or their care taker (1-3). In our context, we thought that this would potentially 
underestimate the cost involved as household members tend to play an important role in an illness 
episode which may include absenteeism from work and school (4). We used the following steps to 
calculate the household opportunity cost: 
1. For each household of the case-patient enrolled in our study, we collected data on the 
average monthly household income. We also collected data for each person in the 
household (including the case-patient) who missed work or income opportunities as a result 
of the illness of the case-patient, and the total number of days when they missed such 
opportunities.  
2. As the next step, we calculated the household average number of days of missed work 
opportunities by dividing the sum total of the number of days of work missed by all the 
household members by the number of people in the household who reported to be 
engaged in an income generating activity. 
3. We then calculated the average daily household income by dividing the average monthly 
household income by 30 days.  
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4. The average daily household income was then multiplied by the average number of days of 
missed work opportunities in the household as calculated in step 2 above to estimate overall 
opportunity cost over the duration of the illness episode. 
We also considered using data on the individual-based opportunity cost reported for each of the 
household members who missed work opportunities but refrained from using the data as we found 
that some of the numbers reported were unusually high and in contradiction to the reported 
monthly household income. 
Comparison of cost data estimated with and without WHO-CHOICE estimates 
We explored the option of using the WHO-CHOICE estimates for health facility service delivery costs 
[5]. However, we found minimal differences when we used actual data collected from the study 
sites to estimate the health facility service delivery costs compared to when we used the WHO-
Choice estimates.  Among inpatients the overall mean (SD) cost per episode was US$117.86 (88.04) 
using the actual data compared to US$112.06 (87.41) when we used the WHO-Choice estimates 
(p=0.658). Among outpatients the overall mean (SD) cost per episode was US$19.82 (27.29) using 
the actual data compared to US$19.14 (27.31) when we used the WHO-Choice estimates 
(p=0.8254). Similarly, no statistically significant differences were found when we compared the 
overall medical costs among inpatients using these two different methods [mean (SD) = US$59.35 
(61.12) using actual data compared to mean (SD) = US$53.55 (60.87) using the WHO-Choice 
estimates]. However, the medical costs were significantly higher among outpatients when we used 
the actual data [mean (SD) = US$ 4.29 (1.24)] compared to [mean (SD), US$3.60 (1.23)] when we 
used the WHO-Choice estimates (p<0.001).   
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Appendix Table 7.1: Definition and data source of key study variables 
Variable Definition Rationale Data source 
Facility-based 
medical costs 
All medical costs incurred at the facility. Includes registration fees, cost of 
medications, hospital bed fees, medical procedure costs, diagnostics, and Healthcare 
service delivery cost. Costs were calculated up to a maximum of 14 days from the 
date when the patient was tested for influenza. Costs among children<5 years are 
paid for by the government while costs among persons >5 years are borne by the 
patient. There were no extra charges on hospital bed fees for  caretakers inpatients  
Component of direct costs  These data were collected at the time of discharge by referring to the 
patient files, hospital discharge billing sheets and outpatient receipts, 
catalogue of prices for medications and laboratory tests. Additional costs 
of medication collected during follow-up interviews for patients who 
sought healthcare after discharge. 
Routine service 
delivery costs 
Cost of routine management of the health facility including (buildings and equipment 
management, transport, electricity, water, fuel, communication, Stationery, wages 
for support staff). These costs are borne by the government 
Component of direct costs  Health facility administrative records  
Healthcare cost 
prior to 
hospital/clinic 
visit 
Total costs (medications and transportation) associated with current illness episode 
for which healthcare was sought prior to hospitalization or outpatient visit.  These 
costs are borne by the patient 
Component of direct costs  Self-reported in the initial interview upon enrolment 
Post-discharge 
healthcare cost  
Total costs (medications and transportation) to the household associated with 
current illness episode for which healthcare was sought after the case-patient was 
discharged and to a maximum of 14 days from the date of testing for influenza. 
These costs are borne by the patient 
Component of direct costs Self-reported costs during follow-up interviews. Excludes medication 
costs for the days the patient was still hospitalized 
Transport cost Costs to facilitate movement to and from the medical facility or place of seeking care 
by the patient and household members. Includes both private and public means. 
These costs are borne by the patient 
Component of direct costs self-reported during the initial interview and follow-up interviews 
Child care cost Cost paid for childcare of other children in the household while the respondent was 
ill or taking care of the patient. These costs are borne by the patient 
Component of direct cost Self-reported during the initial interview and follow-up interviews 
Lost work days Workdays lost by any of the household members due to influenza-associated illness Component of in-direct costs 
and used to estimate the 
household productivity loss cost 
Self-reported during the initial interview and follow-up interviews 
Household lost 
work days 
Average number of days when the household missed work opportunities  Used to estimate the household 
productivity loss cost  
Collected during the initial and follow-up interviews. Calculated as the 
total numbers of work days opportunities missed by all the household 
members divided by the number of people in the household who lost 
such opportunities 
Household daily 
income 
Self-reported daily income for the household Used to estimate the household 
productivity loss cost. The 
midpoint value of the income 
category was used to represent 
household income 
Estimated from the self-reported household monthly income. For each 
case-patient, the daily income was calculated by dividing the average 
monthly income amount (for each income category reported) by 30 days. 
The income categories were ≤5,000; 5,001-10,000; 10,001-25,000; 
25,001-50,000; 50,001-100,000 and ≥100,000. 
Household 
productivity loss 
The monetary loss of productivity per household due the illness Component of indirect costs Self-reported during the initial interview and follow-up interviews 
Lost school days School days not attended by any member of the household due to influenza 
infection 
Component of indirect costs but 
was not quantified in monetary 
terms 
Self-reported during the initial interview and follow-up interviews 
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Appendix Table 7.2: Overall costs, direct and indirect costs, related to influenza-associated illness among inpatients, Jul 2013 - Aug 2014 
  Costs among inpatients    (US$ⱡ ) 
Expenditure item <5 years ≥5 years Total 
  n Median(IQR) n Median(IQR) n Median(IQR) 
Direct cost 76 64.96(38.18-94.80) 14 78.85(45.23-88.57) 90 65.31(39.57-90.47) 
Healthcare prior to hospital/clinic visit 88 2.11(0.00-7.78) 17 5.56(0.00-7.22) 105 2.11(0.00-7.78) 
Total facility-based medical costs 83 52.12(28.90-73.24) 15 54.68(38.57-60.12) 98 52.46(32.79-69.79) 
       Medications 83 3.89(1.11-15.11) 15 17.56(2.44-22.00) 98 5.95(1.11-16.78) 
       Hospital bed fees 83 20.00(11.11-30.00) 15 15.00(11.11-20.00) 98 20.00(11.11-27.78) 
       Procedure fees (non-/surgical) 83 0.56(0.00-4.44) 15 3.33(0.00-4.44) 98 0.56(0.00-4.44) 
       Diagnostic tests 83 2.22(0.00-4.44) 15 5.56(0.00-15.56) 98 2.22(0.00-5.00) 
       Routine health facility service   management  
       costa 83 16.13(9.68-22.58) 15 9.68(9.68-12.90) 98 12.90(9.68-19.35) 
Total transportation costs 88 2.22(0.00-6.39) 17 2.22(0.78-7.78) 105 2.22(0.00-7.00) 
       Personal car/taxi  10 8.00(5.56-11.11) 5 11.11(2.22-38.89) 15 10.00(4.44-22.22) 
       Matatu/bus 70 6.67(3.33-13.33) 17 4.67(2.33-12.00) 87 6.67(3.00-12.67) 
       Motorbike/bike/tuktuk 15 3.33(2.22-6.11) 2 16.39(7.78-25.00) 17 3.33(2.67-7.78) 
Healthcare after discharge 88 0.50(0.00-3.89) 17 0.00(0.00-3.89) 105 0.33(0.00-3.89) 
Child care cost 88 0.00(0.00-0.00) 17 0.00(0.00-0.00) 105 0.00(0.00-0.00) 
Indirect cost (Average household productivity 
lossb)  81 25.93(11.11-58.33) 15 38.89(19.44-77.78) 96 30.09(12.04-59.72) 
Total cost per episodec 76 91.35(69.07-136.54) 14 122.39(75.01-163.35) 90 92.98(69.45-141.30) 
Total cost per episode paid out of pocket 76 60.85(39.33-88.41) 14 122.39(75.01-163.35) 90 68.00(45.93-107.22) 
IQR – Interquartile Range; NA-Not applicable; aRoutine healthcare facility management costs for healthcare service costs per day (equipment maintenance, electricity, water, 
stationary, e.t.c); bEstimated by multiplying the average days when the household lost income opportunities by the household average daily  income; cSum of direct and indirect costs. 
ⱡ 1 US$=90 Kenya Shilings 
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Appendix Table 7.3: Overall costs, direct and indirect costs, related to influenza-associated illness among outpatients, Jul 2013 - Aug 2014 
  Costs (US$ⱡ ) 
Expenditure item <5 years ≥5 years Total 
  n Median(IQR) n Median(IQR) n Median(IQR) 
Direct cost 100 6.39(4.14-11.11) 55 3.95(3.67-6.95) 155 5.47(3.73-10.17) 
Healthcare prior to hospital/clinic visit 110 0.00(0.00-1.89) 58 0.00(0.00-0.00) 168 0.00(0.00-0.00) 
Total facility-based medical costs 108 3.73(3.50-4.64) 57 3.83(3.50-5.56) 165 3.80(3.50-4.75) 
       Medications 108 0.50(0.28-1.38) 57 0.60(0.28-1.78) 165 0.58(0.28-1.44) 
       Hospital bed fees - N/A - N/A - N/A 
       Procedure fees (non-/surgical) 108 0.00(0.00-0.00) 57 0.00(0.00-0.00) 165 0.00(0.00-0.00) 
       Diagnostic tests 108 0.00(0.00-0.00) 57 0.00(0.00-0.00) 165 0.00(0.00-0.00) 
       Routine health facility service   management  
       costa 108 3.23(3.23-3.23)* 57 3.23(3.23-3.23)* 165 3.23(3.23-3.23)* 
Total transportation costs 112 0.00(0.00-0.78) 58 0.00(0.00-0.00) 170 0.00(0.00-0.56) 
       Personal car/taxi  1 0.56(0.56-0.56) 0 - 1 0.56(0.56-0.56) 
       Matatu/bus 42 1.72(1.11-2.78) 6 5.00(0.56-15.33) 48 1.72(1.11-3.22) 
       Motorbike/bike/tuktuk 17 1.56(1.11-4.44) 5 2.78(2.22-3.33) 22 1.94(1.11-4.44) 
Healthcare after discharge 112 0.00(0.00-4.17) 58 0.00(0.00-0.00) 170 0.00(0.00-1.89) 
Child care cost 112 0.00(0.00-0.00) 58 0.00(0.00-0.00) 170 0.00(0.00-0.00) 
Indirect cost (Average household productivity lossb)  106 0.00(0.00-16.67) 56 2.78(0.00-13.89) 162 0.00(0.00-16.67) 
Total cost per episodec 100 11.36(4.94-24.61) 55 9.23(4.60-23.51) 155 10.89(4.75-23.78) 
Total cost per episode paid out of pocket 100  8.056(4.19-22.78) 55 9.23(4.60-23.51) 155 8.67(4.18-23.33) 
IQR – Interquartile Range; NA-Not applicable; aRoutine healthcare facility management costs for healthcare service costs per day (equipment 
maintenance, electricity, water, stationary, e.t.c); bEstimated by multiplying the average days when the household lost income opportunities by the 
household average daily  income; cSum of direct and indirect costs. 
ⱡ 1 US$=90 Kenya Shilings; *No variability as the same amount was used for all patients 
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Chapter 8: General Discussion 
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8.1 Introduction 
The main objective of this thesis was to generate information needed to inform influenza 
prevention and control policies, particularly those related to influenza vaccination in Kenya. In order 
to achieve this objective, we conducted several epidemiologic studies in Kenya seeking to address 
the specific research questions listed below: 
i) What is the morbidity and mortality burden of influenza-associated disease in Kenya, and 
which segments of the population are most affected? 
ii) What are the risk factors for influenza infection and/or severe influenza in Kenya?  
iii) What is the economic burden of influenza-associated disease in Kenya? 
These research questions were addressed in chapter 2 to chapter 7 of this thesis. In this final 
chapter, we present a synthesis and overview of the key findings of the studies included in this 
thesis, as well as compare our findings to published research conducted elsewhere. In this chapter, 
we also highlight the strengths and weaknesses of the studies; discuss the implications of the 
findings from these studies, make recommendations for further research that is needed, and 
finalize with the general conclusion. 
 
8.2 Summary of key findings and comparison to related research 
 
8.2.1 Morbidity and mortality burden of influenza in Kenya 
5.2.1.1 Morbidity burden 
Research question (i) was addressed through studies presented in chapters 2, 3 and 4. In 
chapter 2, we provided a comprehensive summary of published studies describing the morbidity 
burden of influenza in Kenya. Ten studies met the inclusion criteria set in the systematic review. Of 
the ten studies reviewed, four presented data on influenza-associated hospitalizations and 
outpatient visits; five presented data on hospitalizations alone; and one study presented data on 
outpatient visits only. From this literature review, we established that published data on the burden 
of influenza in Kenya was expanding. In general, the review showed a high burden of influenza 
among young children, especially those aged less than two years. Indeed, studies included in our 
literature review showed that there were an estimated 3 to 5 cases of influenza per 1,000 among 
children less than five years who were hospitalized with severe acute respiratory illness (SARI); and 
these rates were 7-10 times higher than those observed in persons aged five years or older. 
Additionally, we found that rates of influenza-associated hospitalization were higher among 
residents of the refugee camps of Kakuma and Dadaab compared to the rates in general 
communities in other parts of Kenya. Rates of hospitalizations associated with influenza infection 
were similar to rates reported in South Africa (1), Asia (2-7), and Latin America (8). However, some 
of the rates were up to seven times higher than those reported in the United States (9-14) and 
Europe (15, 16).   
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In chapter 3, we found that influenza was associated with a high burden of hospitalization for 
SARI among children aged less than six months in Western Kenya with an estimated incidence of 6 
cases per 1,000 persons. These findings were similar to findings from another study in the same 
region which reported an incidence rate of 8 cases per 1,000 persons (17). These findings are also 
consistent with data from several other countries (10, 11, 18), which have shown a considerable 
burden of disease in young infants. Another important finding from this study was that influenza 
was associated with a high burden of non-medically attended SARI and ILI in the community which 
may be similar or even higher than the medically-attended burden. 
5.2.1.2 Mortality burden 
      Using statistical models in chapter 4, we found that influenza was associated with a higher 
mortality rate for all-respiratory conditions  among persons aged ≥50 years (35 per 100,000 person-
years), and among children aged less than five years (17 per 100,000 person-years) compared to 
persons who were aged 5-49 years (5 per 100,000 person-years). We also found that influenza was 
associated with a higher mortality rate among persons with pulmonary tuberculosis (PTB) who were 
aged ≥50 years (42 per 100,000 person-years) compared to their younger counterparts; children 
aged less than five years (2 per 100,000 person-years), and persons aged 5-49 years (7 per 100,000 
person-years). Our findings on all-respiratory mortality associated with influenza among children 
aged less than five 5 years were similar to findings from South Africa (19). However, estimates of 
the mortality rates in our study were more than ten-fold higher than rates reported in the US (20, 
21) and Europe (22). Consistent with our findings, high respiratory mortality rates associated with 
influenza among elderly persons were also reported in studies conducted in South Africa (23) and 
elsewhere (21, 22, 24). 
8.2.2 Risk factors for influenza infection and/or severe influenza in Kenya 
      Research question (ii) was addressed through studies that were presented in chapters 4, 5, and 
6. Through these studies, a) we describe the role chronic medical conditions such as HIV/AIDS and 
TB may have on influenza disease burden in Kenya, and b) we characterize the seasonality and 
meteorological factors that are associated with influenza activity in Kenya. 
5.2.2.1 Association of HIV/AIDS and TB with transmission and burden of influenza in Kenya 
In chapter 4, we presented findings on the mortality burden of HIV/AIDS and PTB related deaths. 
Here we found substantially high PTB related mortality rates that were associated with influenza 
activity; 15 per 100,000 person-years in the general population, and 42 per 100,000 person-years 
among older persons aged ≥50 years. We also observed that influenza was associated with higher 
mortality rates among older patients with PTB compared to those with all-respiratory conditions (7 
vs. 5 per 100,000 person-years among persons aged 5-49 years; and 42 vs. 34 per 100,000 person-
years among those aged ≥50 years). This was consistent with findings from a study conducted in 
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South Africa that reported very high mortality rates associated with influenza among patients with 
TB compared to those without TB (25). Although we did not have sufficiently large numbers to 
model HIV/AIDS related deaths, we observed a relatively higher mortality burden of deaths using a 
direct estimation method.  
In chapter 5, we presented findings of a study that sought to understand the potential effects of 
HIV infection on household influenza transmission dynamics in an urban informal settlement in 
Kenya. In this study, we analyzed data from household contacts of HIV-infected influenza index 
cases and compared them to contacts of their HIV-negative counterparts. It was previously 
reported that HIV-infected individuals shed influenza viruses in higher titers and for longer periods 
of time than HIV-negative individuals thereby increasing the likelihood of transmission to their 
household contacts (26, 27). Similarly, we found that household contacts of HIV-infected influenza 
index cases were about twice as likely to develop ILI compared to the household contacts of their 
HIV-negative counterparts. 
5.2.2.2 Seasonality and meteorological factors associated with influenza activity in Kenya 
      In chapter 6, we investigated the seasonality and climatic factors that were associated with 
influenza activity in Kenya. The overall aim of this study was to characterize influenza activity which 
could possibly be used to inform the future timing for influenza vaccination activities in Kenya. In 
this study, which also analyzed and presented data by four different regions (western Kenya, 
Nairobi and central Kenya, northern/northeastern Kenya, and coastal Kenya), we found that there 
were multiple periods of increased influenza activity annually in Kenya. The findings from our study 
confirm reports that have suggested year-round influenza activity with multiple peaks of influenza 
activity in tropical countries (28, 29). On average, there were two epidemics that occurred each 
year in most of the regions, and these lasted for a median duration of 2-4 months. The first 
epidemic occurred between February and March, and the second between July and November. This 
finding was consistent across the four different climatic regions studied. The second epidemic was 
responsible for a relatively higher burden, accounting for nearly 60% of influenza cases annually. 
The period between April and May had the least influenza activity in Kenya.  
      In studies conducted elsewhere, influenza activity had previously been shown to be negatively 
associated with specific humidity (28, 30) and temperature (28, 31), and positively associated with 
rainfall (28).  In our study, we found that specific humidity was significantly but negatively 
associated with influenza activity. As noted elsewhere (28), we were also able to confirm a 
hypothesis that influenza was more likely to circulate when both temperature and specific humidity 
were below the thresholds of 18oC and 11g/Kg respectively, independent of the study site. 
However, contrary to a previous hypothesis that influenza activity was associated with rainfall in the 
tropics (28), we found no significant independent association between influenza activity and 
rainfall.   
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8.2.3 The need for data on economic burden of influenza in Kenya 
To address research question (iii), we conducted a costing study for influenza-associated 
hospitalizations and outpatient visits which is presented in chapter 7. The aim of this study was to 
gain understanding of the cost of influenza-associated illness in Kenya, which may ultimately be 
useful in conducting economic evaluations of prevention strategies such as vaccination. We 
estimated the cost-per-episode of laboratory-confirmed influenza-associated illness in Kenya using 
data collected from five study sites in Kenya. Here we found that the mean cost-per-episode of 
influenza-associated hospitalization was US$118; mean cost was US$114 among children aged less 
than five years, and US$137 among patients aged five years or older. Among outpatients, the mean 
cost-per-episode of influenza-associated outpatient visit was US$20; with a mean cost of US$21 
among children less than five years old, and US$17 among older patients. These costs were 
comparable to costs reported in Bangladesh (32) But because of the relatively lower cost of 
healthcare in Kenya, our estimates were substantially lower than estimates reported in developed 
countries such as the US (33) and Germany (34).  
A sub-analysis of the data collected showed that an episode of influenza-associated illness 
resulted in a substantial economic burden to the households. For a hospitalized influenza case, the 
overall resultant cost to the families that was paid out-of-pocket was 40% of the average monthly 
household income. For an outpatient case, the resultant cost to the families – which was paid out-
of-pocket – was 11% of the average monthly household income. When we extrapolated the 
estimated costs to the general Kenyan population, depending on the annual incidence which varies 
with the type and sub-type of influenza virus in circulation, the mean annual combined cost of 
hospitalization and outpatient visits associated with influenza illness ranged from US$ 9 to 32 
million. Although the estimated cost-per-episode of influenza-associated outpatient visit was lower 
than the cost of hospitalization, the annual national economic burden of influenza was higher for 
outpatient visits compared to hospitalization due to the relatively high incidence of outpatient 
illness associated with influenza. 
 
8.3 Strengths and weaknesses of the studies 
 
8.3.1 Strengths of the studies 
Our studies were based on epidemiologic data that were collected from population-based 
platforms with well-defined catchment populations that facilitated estimation of disease burden. 
Most of the studies included in our systematic review presented in chapter 2 and the studies 
presented in chapters 3, 4, and 5 originated from areas where the Kenya Medical Research Institute 
(KEMRI) and the US Centers for Disease Control and Prevention (CDC) research collaboration has 
conducted research activities since 2001 (35). The Western Kenya health demographic surveillance 
system (HDSS) which generated most of these data serves as a platform that has been used for a 
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wide range of disease-specific observational studies (e.g. malaria, rotavirus, diarrhea, HIV/AIDS, TB, 
respiratory disease and other important infectious and non-infectious diseases among the 
community), and clinical trials (36). Over the years, a substantial amount of investment has also 
gone into training the personnel that carry out the research activities in this region.  A similar 
amount of training and investment was conducted KEMRI and CDC among the surveillance officers 
who were deployed to collect data from the influenza sentinel surveillance sites located across the 
country. 
Estimates of the morbidity burden associated with influenza and RSV that we presented in 
chapter 2 to chapter 4 were based on laboratory-confirmation of these pathogens rather than on 
clinical case definitions. Notwithstanding the huge amount of resources required to set-up and 
implement case-based surveillance with laboratory-confirmation, these data enabled us to estimate 
rates over relatively shorter periods of time using direct estimation methods. This would be a 
potential limiting factor if we were to rely on statistical models alone to estimate disease burden as 
these require data collated over sufficiently longer periods of time; preferably five or more years 
(37, 38).  
The influenza surveillance system in Kenya has a broad representation of sites from across the 
country as it was initially designed to cover each of the previous eight provinces in Kenya. This had 
the benefit of allowing us to capture data on seasonality that was presented in chapter 5, and the 
cost of influenza related illness that was presented in chapter 7 - that reflected the diverse 
geographical and climatic regions in Kenya. Another positive aspect of the studies presented in this 
thesis is that the data on influenza surveillance were collected year-round and for multiple years. 
This provided us with a basis for assessing the seasonality patterns and generating the time series 
datasets for the statistical modeling methods used in chapter 4 and 6. 
8.3.2 Limitations of the studies 
Our studies had some important limitations. A weakness in the estimation of the morbidity 
burden of influenza-associated illness studies described in chapter 2 and 3 was that we had few 
data for older age groups; largely because of the low healthcare seeking behaviors as has previously 
been documented in our setting (39, 40). Because of this limitation, we were not able to sufficiently 
estimate influenza-associated disease burden in older populations. Indeed, modelling studies 
conducted elsewhere have suggested a high mortality burden of influenza-associated 
hospitalizations among the elderly (9, 24).  This was also a limitation with the study described in 
chapter 7 where we estimated costs of influenza-associated illness in Kenya. More specifically, the 
implication of this limitation is that we potentially underestimated the economic burden of 
influenza as we did not incorporate any adjustments for cases of influenza in the community who 
did not seek healthcare. 
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As in most sub-Saharan African countries, there is an absence of systematically collected, and 
robust vital statistics data in Kenya. For this reason, we used the verbal autopsy (VA) data to 
estimate excess mortality associated with influenza and RSV as presented in chapter 4. Whereas this 
is among the few studies to use VA data in estimating excess mortality attributable to a respiratory 
illness in a resource limited setting (41, 42), the extent to which such estimates vary from estimates 
generated using clinician certified cause-of-death data remains to be determined. The government 
of Kenya has collected vital statistics data in Kenya since 1963. However, at the time when we 
conducted our analysis, these data were only available in paper format and digitization of these 
data was still ongoing.  
Lastly, because of the limited data available through our hospital-based surveillance platforms, 
we could not sufficiently explore the burden influenza among persons with underlying medical 
conditions such as HIV/AIDS, TB , cardiovascular diseases, cancer, asthma, and diabetes. Although 
we showed a substantial mortality burden associated with PTB using VA data from Western Kenya, 
the study findings that we presented in chapter 4 lacked sufficient data to model the mortality 
burden associated HIV/AIDS. 
 
8.4 Implications of the study findings 
 
8.4.1 Risk groups for influenza infections in Kenya 
      The World Health Organization through the Strategic Advisory Group of Experts (SAGE) on 
immunization have identified pregnant women, young children, the elderly, healthcare workers, 
and persons with chronic medical conditions as being at increased risk of severe outcomes due to 
influenza infection. SAGE suggests that they should be targeted for influenza vaccination (43). The 
findings that we present in this thesis that show a disproportionately high burden of influenza 
among young children, especially those aged under two years, support this recommendation and 
highlight the potential benefits of influenza vaccination in Kenya. Despite the fact that we did not 
estimate the burden of influenza among pregnant women, our findings showed a high burden of 
influenza-associated hospitalizations among children aged less than six months. These findings 
highlight the potential value of vaccinating pregnant women against influenza in Kenya (44), which 
would not only protect them from severe outcomes associated with influenza infections (45) but 
also provide the needed protection to the infants (46). A review of published data showed a 
relatively high burden of influenza-associated hospitalizations in the refugee camps, compared to 
the general communities in Kenya, which may warrant consideration for targeted influenza control 
programs. Although it remains to be determined whether these high rates were observed as a 
result of the relatively centralized access to care, the unique challenges experienced in refugee 
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camp settings (such as crowding due to high population densities, poor sanitation, and 
malnutrition) may result in elevated risk of respiratory infections including influenza (47, 48). 
      Consistent with the SAGE recommendations, our findings also suggested a substantial mortality 
rate associated with influenza in elderly persons, young children, and persons with PTB. Targeting 
persons with chronic medical conditions such HIV/AIDS with influenza vaccination could be 
beneficial to them, and also help to break the chain of influenza transmission as it has been 
suggested that they shed the virus for longer periods (49). The relatively high burden of non-
medically attended influenza-associated infections underscores the limitation of using hospital-
based surveillance estimation methods which need to be considered for overall economic burden 
evaluations. This highlights the need to implement influenza surveillance beyond the health care 
facility-based surveillance, possibly using technology-based platforms such as Google Flu Trends 
(50) and other internet-based options, to best inform public health policy in this setting. 
 
8.4.2 Timing of influenza activity and control options in Kenya 
Unlike in temperate regions where influenza epidemics exhibit clear seasonality with peaks 
during winter months (51, 52) and Figure 8.1, the presence of multiple influenza epidemics each 
year in tropical countries presents a challenge for the determination of the optimal timing for 
influenza vaccination.  
The evidence from our studies confirms that influenza circulates in Kenya year-round and that 
there are multiple epidemics of influenza that occur annually. Here we found that influenza 
circulates at relatively higher rates during the months of February and March, with a relatively 
dominant influenza epidemic from July to November. This pattern was consistent across the 
different climatic zones that we considered in Kenya. Considering that influenza circulated in Kenya 
year-round, influenza vaccination could potentially be implemented throughout the year using the 
most current vaccines as recommended by WHO (53). WHO continuously analyzes the antigenic 
and genetic characteristics of the circulating influenza viruses and makes recommendations on the 
influenza strains to be included in the two vaccine formulations each year; the Southern 
Hemisphere (SH) recommendations are made in September to inform production and availability 
for use the following April, while the Northern Hemisphere (NH) recommendations are made in 
February for vaccine production and availability for use in September (54). Evidence from our study 
suggests that the months of April to June would be the optimal periods for annual vaccination 
campaigns in Kenya (Figure 8.1), using the SH recommended vaccine, in order to offer protection 
during the dominant influenza activity period of July to November considering the potential effect 
of waning immunity over time (55, 56). This evidence is currently being considered in the planned 
influenza vaccination pilot project in Kenya where it will be evaluated alongside other vaccine 
delivery strategies for efficiency, coverage and cost-effectiveness. The evidence that we present in 
this thesis on the timing of influenza activity could also be an important reference for other 
countries in the tropics that want to follow the WHO's recommendations to initiate influenza 
vaccination programs. 
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As we found in one of the studies presented in this thesis (chapter 6), climatic factors did not 
appear to play a major role in determining influenza activity. Indeed, specific humidity was the only 
variable that was independently and negatively associated with influenza activity. However, from 
the analysis of influenza activity patterns, not all periods of increased activity or onset of influenza 
activity were associated with the lowering of specific humidity. This suggests that specific humidity 
alone may not necessarily be a good predictor of influenza activity. This could support the 
hypothesis that influenza transmission in the tropics is mainly through direct or indirect contact 
with secretions (58), and perhaps influenced by influenza activity in the temperate countries and 
the level of movement and interaction with people in these countries.  Other than through 
vaccination, which has been shown to be the most effective way of preventing influenza infections 
(59), the Government of Kenya could also consider other influenza control programs targeting 
adoption and observation of good behavioral practices such as respiratory hygiene and 
handwashing (60).   
 
 
Figure 8.1: Monthly influenza activity in Kenya, USA, and South Africa. Data for Kenya is from influenza surveillance data 
collected over the period 2007 to 2013 and presented in chapter 6. Data for USA and South Africa were obtained from Flunet 
(57). All data presented exclude data collected during the pandemic H1N1 period of 2009 and 2010.  
 
 
8.4.3 Considerations for influenza vaccination program in Kenya 
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The Kenya Ministry of Health (KMoH) through the Kenya National Immunization Technical 
Advisory Group (KENITAG) recently (in 2016) conducted a detailed review of published data on 
influenza in Kenya to inform policy recommendations and priority setting. The review process 
considered most of the data and findings presented in this thesis and concluded that there was 
sufficient evidence to prioritize influenza vaccination of children under two years of age. In this 
regard, it recommended for a pilot vaccination program in Kenya that targets children aged 6-23 
months given the limited experience with influenza vaccination in Kenya. The main objective of this 
pilot program is to understand the technical and operational requirements that would potentially 
inform a larger scale-up of influenza vaccination in the future [KENITAG’s unpublished report to the 
KMoH].  
In this pilot vaccination program, the KMoH is targeting to vaccinate approximately 600,000 
children aged 6-23 months within five Counties in Kenya (Nairobi, Mombasa, Nakuru, Nyeri, and 
Kakamega). Among the possible vaccine delivery strategy options currently considered are a) 
conducting a year-round vaccination program where influenza vaccines are available throughout 
the year at the health facilities (using the most currently available SH or NH vaccine formulation); b) 
conducting year-round vaccination with targeted vaccination campaigns during 1-2 months 
preceding the two periods of increased influenza activity; and c) only using targeted vaccination 
drives in the months preceding the two periods of increased influenza activity. Different counties 
would be selected for one of the vaccine delivery strategies listed above. As part of the pilot 
vaccination program, the KMoH in collaboration with CDC and other partners are also planning to 
collect data on knowledge attitudes and practices among caretakers of the children targeted for 
vaccination, as well as healthcare workers. Additional data will also be collected on uptake of 
influenza vaccination, and the cost of vaccine delivery which will in turn be used to determine the 
cost-effectiveness of the possible vaccine delivery strategies. 
 
8.4.4 Economic burden of influenza in Kenya 
The evidence that we present in this thesis on the cost of influenza-associated illness in Kenya, 
and for the first time in tropical Africa, shows an important economic burden associated with 
influenza infections.  Indeed we showed that influenza infections burdened households where 
nearly half of the average monthly household income was used to resolve influenza-associated 
hospitalizations. For a vaccine-preventable illness like influenza, these limited household resources 
would potentially be re-directed to other competing priorities such as food and education.  We also 
found a substantial health facility-based cost-per-episode of influenza-associated illness which 
represents potential savings for the Government of Kenya. Notwithstanding the relatively lower 
cost associated with an episode of influenza-associated outpatient visit, the resultant annual 
economic burden was higher than the burden associated with hospitalization due to the relatively 
higher incidence of outpatient illness associated with influenza.  
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Whereas our findings highlight an important societal economic impact of influenza-associated 
illness, further studies should explore the cost-effectiveness of targeted influenza vaccination 
strategies in Kenya. Indeed the KMoH, through the recommendation for a pilot vaccination program 
in Kenya by KENITAG, recommended for further efforts to conduct a full economic evaluation of the 
potential impact of influenza vaccination programs and strategies in Kenya. The data that we 
present in this thesis could be a useful basis for implementing such economic evaluations in the 
future. 
Our study findings, which show that households commit nearly half of their monthly income to 
resolving an episode of influenza-associated illness, also suggest the potential benefits of a more 
vibrant national health insurance scheme to provide accessible, affordable, sustainable, equitable 
and quality social health insurance for the Kenyan population and cushion them against sudden 
financial expenses associated with an illness. The existing National Health Insurance Fund has a 
limited overall insurance coverage of approximately 11% of the population as the membership is 
compulsory only for salaried employees and voluntary membership for self‐employed and other 
informal sector workers (61).  
 
8.4.5 Lessons for other African countries 
The general process of documenting data on influenza that is presented in this thesis was 
instrumental in informing the recommendations by the KENITAG for influenza vaccination in Kenya. 
This makes Kenya one of the very few Sub-Saharan African (SSA) countries to make such 
recommendations. Other than South Africa which has a national vaccination policy for influenza 
that targets the risk groups for influenza infections as recommended by SAGE (young children, 
pregnant women, the elderly, healthcare workers and persons with chronic medical conditions) 
(62), most of the SSA countries are yet to develop such policies. Given the similarity in 
demographics, cultural practices, and comorbidities with some other Africa countries, the findings 
from this thesis (as relates to disease burden, risk groups, and seasonality) could be applicable to 
other tropical African countries. Similar approaches to disease burden documentation could be 
replicated and used to inform and catalyze the development of influenza control policies in these 
countries. 
 
8.5 Recommendations for further research 
 
8.5.1 Additional burden data needed 
The morbidity burden of influenza among pregnant women in Kenya remains to be determined 
and, as recently recommended by KENITAG, further research is needed to document disease 
burden in this group which is also identified by SAGE as a priority group for influenza vaccination. 
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KEMRI and US CDC are currently conducting a prospective cohort study among pregnant women in 
Western Kenya. These data, once available, will be used to determine the burden of influenza-
associated respiratory illness among pregnant women. Data from this study will also be used to 
compare the birth weights of infants born to mothers with and without influenza-associated illness 
during pregnancy, as well as estimate the burden of influenza-associated illness among infants aged 
0-2 months in mothers with and without influenza infection during pregnancy.  
Similarly, additional data on influenza-associated disease burden is needed for older persons, 
and persons with chronic medical conditions such as HIV/AIDS, TB, cardiovascular diseases, cancer, 
asthma, and diabetes. As highlighted elsewhere in this thesis, we were not able to adequately 
characterize the morbidity burden due to influenza in older populations in Kenya primarily because 
of the low healthcare seeking behaviors (39, 40). Additionally, future research is needed to 
determine the impact of comorbidities such as malaria and malnutrition on the influenza disease 
burden in the Kenyan population. A recent study in western Kenya, where malaria is endemic (63), 
showed that although uncommon, coinfection of influenza with malaria was associated with a 
longer duration of hospitalization than single infections among children 24–59 months of age (64).  
Statistical modelling methods, rather than the direct estimation methods used on hospital-
based surveillance data, could be useful tools in estimating disease burden among older 
populations using household morbidity data or incorporating age-specific adjustments for 
healthcare seeking in cases of ARI that are reported in the hospital based surveillance. The latter 
would require that more accurate data are available on healthcare utilization for respiratory illness. 
These data, once available, will be helpful in conducting an evaluation of the economic impact of 
influenza in Kenya. 
Most of the studies that have estimated excess mortality associated with influenza have used 
data with the cause of death certified by a clinician (19-21). As clinician-certified cause of death 
data become available in Kenya, after the ongoing efforts by the Government of Kenya to digitize 
these data are completed, further analysis may be warranted to compare and validate those 
estimates with the data that we present in this thesis. These data, once available, will also be useful 
in generating national estimates of excess mortality due to influenza Kenya which are needed to 
inform policy decisions. 
8.5.2 Determinants of influenza activity in Kenya 
     As figure 8.1 suggests, the months of increased influenza activity in Kenya (February and March, 
and July to Nov) coincide with the peak months (or just after the peak months) of influenza activity 
in the NH and SH respectively. However, the two periods when Kenya experiences increased 
influenza activity have different weather conditions which suggests association with other 
important factors other than the meteorological variables that we investigated in chapter 6. Indeed, 
the period of February to March is typically characterized by dry and hot weather conditions, while 
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the period between October and November experiences rainy and humid weather conditions (65). 
Future studies could investigate whether the observed increase in influenza activity in Kenya is 
directly linked to the influenza activity in the NH and SH, and determine the associated factors that 
determine human influenza transmission (e.g. tourist activities, and migration patterns).  
Understanding the factors that influence influenza activity patterns would further help to inform 
decisions around influenza prevention and control programs in Kenya. 
8.5.3 Cost effectiveness data 
     The data on the cost of influenza-associated illness that we present in this thesis are an 
important step towards making an economic evaluation of the impact of influenza in Kenya. More 
work needs to be done to conduct a full economic evaluation to include cost effectiveness and cost 
benefit analyses of the potential impact of influenza vaccination programs and strategies in Kenya. 
This will be useful in helping the Government of Kenya to make evidence based decisions around 
influenza control through vaccination by putting the costs of implementing the vaccination 
strategies in context to the prevented costs and gains in health in the Kenyan population. 
Additionally, carrying out sensitivity analysis to determine the break-even price for the vaccines to 
become cost-effective would help the Kenyan Government to negotiate with the companies that 
produce vaccines. 
8.5.4 Priority setting for influenza control programs 
     There is need for further studies to be conducted on the overall knowledge attitudes and 
practices relating to vaccine acceptance, barriers to influenza vaccination uptake, and factors 
related to vaccination decisions in the general Kenyan population, and provider knowledge of 
influenza vaccine recommendations among healthcare practitioners. A previous study seeking to 
address these questions in Kenya was limited in geographical scope and may not have reflected the 
potential effect of the social and cultural diversity of the Kenyan population on attitudes and 
practices relating to influenza vaccination (66). These data, considered together with the influenza 
disease burden data and economic evaluations, would be helpful in priority setting for influenza 
control programs in Kenya. 
8.5.5 The need for data to inform future RSV vaccination 
Sub-analyses on data presented in chapters 3 and 4 of this thesis showed an important burden 
of respiratory syncytial virus (RSV) among children aged less than five years. Among these children 
the estimated incidence of hospitalization associated with RSV was nearly twice as high as the rate 
of influenza-associated hospitalizations. Similarly, the mortality rate associated with RSV among 
children less than five years was higher than the estimated mortality rate for influenza. This 
highlights the need for continued surveillance for RSV to generate data to inform possible future 
RSV vaccination interventions in Kenya. 
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8.6 Conclusion 
Our studies showed a high morbidity burden of influenza among young children in Kenya. Our 
studies also showed substantial mortality rates among young children, elderly persons, and persons 
with HIV/AIDS and/or TB. We also found that influenza-associated illness resulted in substantial 
economic burden nationally, and especially to households that pay out-of-pocket. These findings 
suggest the potential benefit of influenza vaccination in Kenya to reduce morbidity and mortality 
associated with influenza among young children, elderly persons, and persons with chronic medical 
conditions. While more work is needed, there is a possible health and economic benefit to influenza 
vaccination in Kenya that warrants further investigation.  
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Summary 
Globally, a large fraction of human respiratory tract infections are associated with viruses, quite 
notably influenza A and B, and RSV. Whereas seasonal influenza has long been recognized as a 
cause of morbidity and mortality in countries with temperate climates, recent studies have shown 
that influenza causes a significant burden of disease in countries in the tropics, such as Kenya, as 
well. To develop successful influenza prevention and control strategies in Kenya,  it is important to 
be able to adequately describe its epidemiology and economic impact.  
The aim of this thesis is to contribute to the understanding of the epidemiological and economic 
burden of influenza in Kenya. The work described in this thesis provided estimates of the morbidity 
and mortality burden of influenza-associated infections, described the risk factors for influenza 
infection as well as the timing of influenza activity, and estimated costs associated with influenza 
infections as a basis for quantifying economic impact. The main research questions addressed in 
this thesis were: 
1. What is the morbidity and mortality burden of influenza-associated disease in Kenya, and 
which segments of the population are most affected? 
2. What are the risk factors for influenza infection and/or severe influenza in Kenya? 
3. What is the cost and overall economic burden of influenza-associated disease in Kenya? 
 
Chapter 1 provided a general introduction to this thesis. Here, we provided the background 
information, the rationale, and the research objectives of this thesis.  
 
In chapter 2, we present the results of a systematic literature review of published data from 10 
articles that described the disease burden associated with influenza in Kenya. Results from this 
review, showed that influenza virus was detected in 5-27% of all medically attended patients who 
presented with acute respiratory illness, and in 5-10% of those who were hospitalized with severe 
acute respiratory illness (SARI). We also showed that the incidence of hospitalizations with influenza 
among children aged less than five years ranged from 3-5 per 1,000, and were 7-10 times higher 
compared to rates among persons aged five years or older. This review also showed that the rates 
of hospitalization for influenza were highest among persons who lived in refugee camps, even 
without incorporating adjustments for eligible cases who were not tested as was done in most of 
the other studies. Overall, our review showed an expanding set of literature on disease burden 
associated with influenza in Kenya, with a substantial burden among children under five years of 
age. The rates of hospitalization with influenza that were reported among children aged less than 
five years were 2-3 times higher than those reported in temperate countries such as the United 
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States. In general, there were notable differences in the methodologies used in the studies that we 
reviewed, particularly relating the case definitions for the syndromes that were used for 
surveillance and testing for influenza cases, as well as the adjustment factors that were applied to 
generate the estimates of the incidence rates.  
 
In chapter 3, we estimated the age-specific burden of medically-attended, and non-medically 
attended influenza and RSV in Western Kenya. Here, we estimated the mean annual incidence of 
influenza-associated hospitalization for SARI among children aged under five years to range 
between 2-4 cases per 1,000 children. This was lower than the rate of hospitalizations among 
children aged less than five years for RSV which was estimated to range between 4-7 cases per 
1,000 children. In this study, we also showed a substantial burden of influenza-associated 
hospitalizations among children aged less than six months (2-14 cases per 1,000 children) for whom 
there are no licensed influenza vaccines. For this group of children, vaccinating pregnant women is 
recommended as a means of protecting them from influenza infections during the period when 
they are not eligible for influenza vaccination. Our study also showed substantially high rates of 
influenza-associated outpatient medically-attended influenza-like illness (ILI) which ranged between 
17-35 cases per 1,000 children. Overall, estimates of the rates of hospitalization and outpatient 
visits among children aged less than five years were several fold higher than estimates among older 
persons. Using adjustments for health seeking behaviors, we also estimated the incidence rates of 
influenza- and RSV-associated non-medically-attended SARI and ILI which were higher than 
comparable rates of medically-attended illness in the community.   
 
Using verbal autopsy data collected through a health demographic surveillance system (HDSS) in 
Western Kenya, we estimated the overall and age-specific excess mortality rates associated with 
influenza virus and RSV (chapter 4). These rates were calculated for four mortality outcomes: all-
cause mortality, all-respiratory deaths (including pneumonia), HIV-related deaths, and pulmonary 
tuberculosis (PTB) related deaths. The all-cause excess mortality rate associated with influenza was 
estimated at 14 cases per 100,000 person-years (PY) compared to 11 cases per 100,000 PY for all-
respiratory deaths. The highest all-respiratory mortality rates associated with influenza were among 
persons aged fifty years or older (35 cases per 100,000 PY), and among children aged less than five 
years (17 cases per 100,000 PY). Mortality rates associated with influenza were particularly highest 
among persons with TB infections who were aged fifty years or older (42 cases per 100,000 PY). 
Similar to studies conducted in temperate countries, our estimates of all-respiratory mortality rates 
associated with RSV among children aged less than five years (39 cases per 100,000 PY) were higher 
compared to the influenza-associated mortality rates. Overall, we showed an important role of 
influenza and RSV on excess mortality in Western Kenya, particularly among children aged less than 
five years, older persons, and persons living with HIV/AIDS or those infected with TB. 
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In chapter 5 we presented findings from a household-based study that examined the association 
between the HIV status of household members and their risk of introducing influenza to the home, 
and whether the HIV status of index cases of influenza impacted the risk of developing secondary 
(ILI) among their household contacts. Here we showed that while the HIV status did not affect the 
likelihood of being an influenza index case, household contacts of HIV-infected influenza index cases 
had twice the risk of developing secondary ILI than contacts of HIV-negative index cases.  
Using data collected from twelve influenza surveillance sites distributed across the country, we 
described the patterns and periods of increased influenza circulation, and assessed the relationship 
between three meteorological variables (temperature, rainfall, and specific humidity) and influenza 
activity (Chapter 6).  In this study, we showed that there was year-round circulation of influenza in 
Kenya, with multiple epidemics that occurred annually and lasted a median duration of 2-4 months. 
On average, there were two epidemics that occurred each year in most of the regions in Kenya: the 
first epidemic occurred between the months of February and March, and the second between July 
and November. This pattern was consistent across the different climatic zones that we considered 
in Kenya. The epidemic that occurred in the second half of the calendar year, between July and 
November, was responsible for the highest number of influenza cases annually (accounting for 
nearly 60% of the cases). The months of April and May had the lowest influenza activity in Kenya. 
An assessment of the relationship between the meteorological variables showed that specific 
humidity was independently and negatively associated with influenza activity. Our analysis also 
confirmed the hypothesis that suggested that combinations of low temperature (<18oC) and low 
specific humidity (<11g/Kg) were significantly associated with increased influenza activity. However, 
we did not find evidence in Kenya to show that temperature and rainfall were associated with 
influenza activity, as previously reported in other studies that were conducted elsewhere.  
 
Chapter 7, reported results of a costing study that estimated the cost-per-episode of laboratory-
confirmed influenza-associated illness in Kenya. This study was conducted in five health facilities, 
including four hospitals and one outpatient facility. In this study, we estimated that the mean cost-
per-episode of influenza was US$118 among inpatients (US$114 for children aged less than five 
years, and US$137 for persons aged five years or older). Among outpatients, the mean cost-per-
episode of influenza was US$20 overall (US$21 for children aged less than five year, and US$17 for 
persons aged five years or older). From our analysis, we showed that an episode of influenza-
associated illness resulted in a substantial economic burden to the households. For a hospitalized 
influenza case, the overall resultant cost to the families that was paid out-of-pocket was 40% of the 
average monthly household income. For an outpatient case, the resultant cost to the families was 
11% of the average monthly household income. The median number of work-day opportunities 
missed in households of influenza case-patients was two days (four days for households of 
hospitalized case-patients, and one day for households with an outpatient). Among households of 
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influenza case-patients that had school-age children, the median number of school-days missed was 
four days (three days for households of hospitalized case-patients, and four days for households 
with an outpatient).  Overall, the national annual influenza-associated cost ranged from US$3-5 
million for inpatients, and between US$6-26 million for outpatients. 
 
In chapter 8, we provided a synthesis of the main findings of the studies that were included in this 
thesis, discussed the implications of the findings, and made some recommendations for further 
research. The studies that we presented in this thesis showed a disproportionately high morbidity 
burden of influenza among young children, especially those aged under two years, which 
highlighted the potential benefits influenza vaccination and supported the World Health 
Organization’s (WHO) recommendation for targeting young children for vaccination. Our findings 
also suggested a substantial mortality burden in Kenya that was associated with influenza among 
elderly persons, young children, and persons with TB. This was also consistent with the WHO’s 
recommendations which identified these groups as being at increased risk of severe outcomes due 
to influenza infection and are thus priority groups for influenza vaccination, together with pregnant 
women, persons infected with HIV, and healthcare workers. Furthermore, considering the relatively 
high prevalence of HIV-infection estimated at 5.6% in the general Kenyan population and the fact 
that our data suggested a higher risk of developing secondary ILI among household contacts of HIV-
infected influenza cases, targeting persons who are infected with HIV with influenza vaccination 
could also help to break the chain of influenza transmission in the community as studies have 
suggested that immunocompromised individuals shed the virus for longer periods of time. The year-
round circulation of influenza in Kenya that we showed, suggested that influenza vaccination could 
potentially be implemented throughout the year using the most currently available vaccines as 
recommended by the WHO. However, it is important to note that if annual vaccination campaigns 
were to be considered, our data suggested that the months of April to June would be the optimal 
periods for vaccination using the southern hemisphere recommended vaccine in order to offer 
protection during the dominant influenza activity period of July to November. The evidence that we 
present in this thesis on the cost of influenza-associated illness, suggested an important economic 
burden associated with influenza infections, which further highlighted the potential benefits of 
influenza vaccination in Kenya. The financial strain to families occasioned by out-of-pocket 
payments, that are nearly half their monthly household income, also suggest the potential benefit 
of a more vibrant national health insurance scheme for the Kenyan population. However, further 
studies are need on cost-effectiveness which would be used to conduct a full economic evaluation 
of the potential impact of influenza vaccination programs and strategies in Kenya. To understand 
the full impact of influenza in the Kenyan population, further studies are also needed on the burden 
of influenza among pregnant women, as well as an assessment of the impact of comorbidities such 
as malaria and malnutrition on influenza infections. 
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Samenvatting 
Een aanzienlijk deel van wereldwijd voorkomende luchtweginfecties wordt veroorzaakt door 
virussen, in het bijzonder influenza A en B en RSV. Terwijl seizoensgebonden influenza in landen 
met een gematigd klimaat als een belangrijke oorzaak van ziekte en sterfte wordt gezien, tonen 
recente studies, dat influenza ook de oorzaak is van een forse ziektelast in de tropen, bijvoorbeeld 
in een land zoals Kenia. Om succesvolle preventieve en bestrijdingsprogramma’s rond influenza in 
Kenia mogelijk te maken, is het allereerst belangrijk de epidemiologie en de economische impact 
van influenza te kennen. 
Dit proefschrift wil een bijdrage leveren aan een beter inzicht in de epidemiologie en economische 
impact van influenza in Kenia. In dit proefschrift worden schattingen van influenza geassocieerde 
ziekte en sterfte gepresenteerd, evenals van risicofactoren voor influenza, een vaststelling van het 
seizoen voor verhoogde influenza activiteit en tot slot een schatting van kosten van influenza als 
basis voor een berekening van de economische impact van de ziekte. De kernvragen die in dit 
proefschrift aan de orde komen zijn: 
1.  Wat is de ziekte- en sterftelast van influenza geassocieerde ziekte in Kenia en welk deel van de 
bevolking heeft daar het meeste last van? 
2. Wat zijn de belangrijkste risicofactoren voor (ernstige) influenza in Kenia?  
3. Wat zijn de kosten en economische impact van influenza geassocieerde ziekte in Kenia?  
 
Hoofdstuk 1 omvat de inleiding van het proefschrift. Hierin worden aanleiding, achtergrond en 
onderzoeksvragen weergegeven. 
In hoofdstuk 2 presenteren we de resultaten van een systematisch literatuuronderzoek op basis van   
10 artikelen, welke de ziektelast met betrekking tot influenza in Kenia beschrijven. Uit de resultaten 
van deze studie blijkt dat het influenzavirus wordt vastgesteld bij 5-27% van alle medische 
consulten van patiënten met acute luchtwegproblemen, en bij 5-10% van de patiënten met ernstige 
luchtwegproblemen (SARI) die in een ziekenhuis worden opgenomen. De incidentie van 
ziekenhuisopnamen vanwege influenza bij kinderen onder de vijf jaar varieert van 3-5 per 1000 en 
deze cijfers blijken 7-10 keer hoger, wanneer vergeleken met cijfers van personen van vijf jaar en 
ouder. Het aantal ziekenhuisopnamen is het hoogst bij mensen uit de vluchtelingenkampen. Dit is 
zelfs zonder correcties voor gevallen, die mogelijk wel influenza hebben, maar niet zijn getest, zoals 
in veel andere studies is gedaan. Er is een uitdijende hoeveelheid literatuur rond influenza 
gerelateerde ziektelast in Kenia, met op de voorgrond de grote ziektelast ten gevolge van influenza 
bij kinderen onder de vijf jaar. Hat aantal ziekenhuisopnamen vanwege influenza bij kinderen onder 
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de vijf jaar is 2-3 keer hoger dan cijfers gerapporteerd uit landen, zoals de Verenigde Staten.  Er zijn 
wel forse verschillen in methoden, zoals gebruikt in de bekeken studies, vooral rond ‘case 
definitions’ voor syndromen welke zijn gehanteerd  bij surveillance  en bij het testen van influenza 
gevallen, en rond correctiefactoren, welke zijn gebruikt om de incidentie te schatten   
 In hoofdstuk 3 berekenen we de leeftijdgebonden ziektelast ten gevolge van influenza en RSV bij 
mensen die wel of niet medische hulp opzoeken in West Kenia. We schatten de gemiddelde 
jaarincidentie van influenza geassocieerde ziekenhuisopnamen voor SARI bij kinderen onder de vijf 
jaar op 2-4 per 1000 kinderen.  Dit is lager dan het aantal ziekenhuisopnames van kinderen onder 
de vijf jaar met RSV, welke varieert van 4-7 gevallen per 1000 kinderen. In deze studie zien we 
vooral een behoorlijk aantal influenza geassocieerde ziekenhuisopnamen bij kinderen onder de zes 
maanden (2-14 gevallen per 1000 kinderen), waarvoor geen influenzavaccins met licentie 
beschikbaar zijn. Voor deze specifieke groep kinderen wordt vaccinatie van zwangere vrouwen 
aanbevolen om op deze manier de kinderen te beschermen tegen influenza in de periode dat ze 
nog niet in aanmerking komen voor influenzavaccinatie. De studie laat ook een behoorlijk hoge 
influenza geassocieerde ziektelast onder polikliniekbezoekers zien, welke varieert van 17-35 
gevallen per 1000 kinderen.  Het aantal ziekenhuisopnamen en polikliniekbezoeken van kinderen 
onder vijf jaar is overigens vele malen hoger dan die van oudere personen. Als een correctie op 
hulpzoekgedrag wordt doorgevoerd, kunnen we ook de incidentie van influenza en RSV 
geassocieerde SARI en ILI van mensen, die géén medische hulp zochten, berekenen. Deze cijfers 
vallen hoger uit dan vergelijkbare cijfers van mensen die wél medische hulp zochten. 
Met behulp van ‘verbal autopsie’ gegevens, welke worden verzameld in het Health Demographic 
Surveillance System (HDSS) in West Kenia, zijn ruwe en leeftijdspecifieke influenza en RSV 
geassocieerde sterftecijfers berekend. (hoofdstuk 4) . Deze cijfers zijn berekend voor vier 
sterfterisico uitkomstmaten: totale sterfterisico, totale respiratoire sterfterisico (inclusief 
pneumonie), HIV gerelateerde sterfterisico en longtuberculose gerelateerde sterfterisico. Het 
geschatte, algemene, influenza geassocieerde oversterfterisico bedroeg  14 gevallen per 100.000 
persoonjaren (PJ) in vergelijking met 11 gevallen per 100.000 PJ voor het totale respiratoire 
sterfterisico. Het hoogste influenza geassocieerde totale respiratoire sterfterisico komt voor bij 
mensen boven de vijftig jaar i.e. 35 gevallen per 100.000 PJ en bij kinderen onder de vijf jaar i.e. 17 
gevallen per 100.000 PJ. Het influenza geassocieerde sterfterisico is vooral hoog onder tuberculose 
patiënten van vijftig jaar en ouder i.e. 42 gevallen per 100.000 PJ. Evenals studies uitgevoerd in 
landen met een gematigd klimaat laten onze berekeningen van het RSV geassocieerde totale 
respiratoire sterfterisico bij kinderen onder de vijf jaar, i.e. 39 gevallen per 100.000 PJ, ook zien, dat 
dit hoger is dan het influenza geassocieerde totale respiratoire sterfterisico.  Influenza en RSV 
spelen een belangrijke rol in het oversterfterisico in West Kenia, vooral bij kinderen onder de vijf 
jaar, oudere personen en bij HIV respectievelijk TB geïnfecteerde personen.  
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In hoofdstuk 5 presenteren we de resultaten van een studie op huishoudniveau waarbij de relatie 
tussen HIV status van familieleden en het risico om influenza in het huishouden te introduceren  is  
bestudeerd, en of de HIV status van influenza index gevallen invloed heeft op het risico voor  
secundaire ILI onder hun familieleden. Waar de HIV status geen invloed had op de kans om een 
influenza index geval te zijn, hadden de familieleden van HIV geïnfecteerde influenza index gevallen 
wel een tweemaal zo hoog risico om een secundaire ILI te ontwikkelen ten opzichte van HIV- 
negatieve index gevallen. 
Met gegevens uit twaalf, over het land verdeelde, influenzasurveillance meetpunten, beschrijven 
we de patronen van en de seizoenen met verhoogde influenza activiteit en bestuderen we de relatie 
tussen drie meteorologische variabelen (temperatuur, regenval en bepaalde vochtigheid) en 
influenza activiteit. (hoofdstuk 6). In deze studie stellen we vast dat er het hele door jaar influenza 
activiteit in Kenia aanwezig is, met jaarlijks meerdere epidemieën, welke gemiddeld 2-4 maanden 
duren. Gemiddeld vinden er in de meeste regio’s in Kenia twee epidemieën per jaar plaats: de 
eerste epidemie zo rond februari - maart en de tweede tussen juli en november. Dit patroon is 
consistent voor de verschillende klimaatzones, welke Kenia kent. De epidemie, die optreedt tussen 
juli en november, zorgt voor het hoogste aantal influenza gevallen (ongeveer 60% van alle gevallen 
in een jaar). De maanden april en mei geven de laagste influenza activiteit in Kenia te zien. Onze 
studie naar de relatie tussen meteorologische variabelen en influenza activiteit laat zien dat een 
bepaalde vochtigheid, onafhankelijk en negatief is geassocieerd met influenza activiteit. Onze 
analyses bevestigen de hypothese, welke claimt, dat een combinatie van lage temperatuur (<18C) 
en lage bepaalde vochtigheid (<11g/kg) significant zijn geassocieerd met een verhoogde influenza 
activiteit. We konden echter in Kenia geen bewijs vinden voor een verband  tussen enerzijds 
temperatuur en regenval en anderzijds influenza activiteit , zoals andere studies in andere landen 
wel hebben gerapporteerd. 
Hoofdstuk 7 rapporteert over de resultaten van een kosten van ziekte studie waarbij de kosten per 
laboratorium bewezen influenza geassocieerde ziekte is berekend. Deze studie is uitgevoerd in vijf 
gezondheidinstellingen, vier ziekenhuizen en één polikliniek. We schatten de gemiddelde kosten 
per influenza episode op USD 118 voor ziekenhuispatiënten:  USD 114 voor kinderen onder de vijf 
jaar en USD 137 voor personen ouder dan vijf jaar. Bij polikliniekpatiënten zijn de gemiddelde 
kosten per influenza episode USD 20:  USD 21 voor kinderen onder de vijf jaar en USD 17 voor 
personen ouder dan vijf jaar. Uit onze studie blijkt dat een influenza episode een fors financieel 
beslag op een huishouden kan leggen.  Voor een in een ziekenhuis opgenomen patiënt met 
influenza bedragen de totale out of pocket betaalde kosten 40% van het gemiddeld maandinkomen 
van een familie. Voor een polikliniekpatiënt bedragen de totale out of pocket kosten zo’n 11% van 
het gemiddeld maandinkomen van een familie. Het mediane, aantal gemiste werkdagen in families 
met een influenzapatiënt is twee dagen (vier dagen in families met een in een ziekenhuis 
opgenomen influenzapatiënt en één dag in families met een polikliniekpatiënt). In families met 
influenzapatiënten en schoolgaande kinderen, is het mediane, aantal gemiste schooldagen vier 
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dagen (drie dagen in families met een in een ziekenhuis opgenomen influenzapatiënt en vier dagen  
in families met een polikliniekpatiënt) Concluderend: de nationale influenza geassocieerde kosten 
op jaarbasis variëren van USD 3-5 miljoen voor ziekenhuispatiënten tot US 6-26 miljoen voor 
polikliniekpatiënten.  
In hoofdstuk 8 geven we een synthese van de belangrijkste bevindingen uit de diverse studies van 
dit proefschrift, gevolgd door een discussie over de implicaties van die bevindingen en komen we 
tot slot met aanbevelingen. De studies, welke in dit proefschrift zijn gepresenteerd, laten een naar 
verhouding hoge ziektelast door influenza bij kinderen in Kenia te zien, vooral bij kinderen onder de 
twee jaar. Dit werpt nog eens een extra licht op de gezondheidswinst, die valt te boeken met 
influenzavaccinatie van jonge kinderen, hetgeen ook wordt ondersteund door de aanbevelingen 
vanuit de Wereldgezondheidsorganisatie (WHO). De studies suggereren ook een aanzienlijke sterfte 
onder jonge kinderen, ouderen en tuberculose patiënten in Kenia. Dit correleert ook met de 
aanbevelingen van de WHO, die juist deze groepen heeft geïdentificeerd vanwege hun verhoogd 
risico op een slechte afloop na een infectie door influenza en dus een hoge prioriteit verdienen om 
in aanmerking te komen voor een influenzavaccinatie, samen met zwangere vrouwen, HIV- 
geïnfecteerden en gezondheidswerkers. Daarenboven, als we de relatief hoge HIV prevalentie - 
geschat op 5.6% van de algemene Keniaanse populatie- in acht nemen, en het feit dat onze 
resultaten suggereren dat er een hoger risico is voor secundaire ILI bij familieleden van HIV-
geïnfecteerde influenza gevallen, kan door influenzavaccinatie van HIV-geïnfecteerden de keten van 
transmissie van influenza in de bevolking beter worden doorbroken, vooral ook omdat diverse 
studies aantonen, dat immunogecompromitteerde individuen het influenzavirus langere tijd blijven 
uitscheiden.  
De, in onze studies aangetoonde, het hele jaar door optredende influenza activiteit in Kenia, zou 
kunnen betekenen dat influenzavaccinatie ook het hele jaar door zou moeten plaatsvinden, daarbij 
gebruik makend van de beschikbare, door de WHO aanbevolen, vaccins. Het is echter belangrijk om 
zich te realiseren, dat mocht een jaarlijkse influenzavaccinatiecampagne worden overwogen de 
maanden april tot juni de meest aangewezen periode voor vaccinatie zijn en dat het vaccin van het 
zuidelijk halfrond dan het meeste aangewezen vaccin zou moeten zijn, vooral vanwege de, tijdens 
de dominante influenzaperiode (van juli tot november), geboden bescherming.  
De uitkomsten van onze studie naar de kosten van influenza geassocieerde ziekte, impliceren in 
feite een behoorlijke financiële last voor families, waardoor we nog serieuzer moeten kijken naar de 
potentiële opbrengsten van influenzavaccinatie in Kenia. De financiële stress van families door out 
of pocket betalingen vanwege medische hulp voor een familielid met influenza , waaraan bijna de 
helft van het maandelijkse huishoudinkomen kan opgaan, vraagt ons ook na te denken over de 
meerwaarde van een nationaal, meer dynamisch, gezondheidsverzekeringsysteem voor de gehele 
Keniaanse bevolking. Daarvoor zijn echter eerst meer kosteneffectiviteitstudies nodig, waarvan de 
resultaten kunnen worden ingebracht in een allesomvattende economische evaluatie over de 
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potentiële opbrengsten van influenzavaccinatieprogramma’s en strategieën in Kenia. Om de 
volledige impact van influenza op de Keniaanse bevolking beter te begrijpen is in ieder geval meer 
onderzoek nodig, o.a. naar influenza bij zwangere vrouwen, naast een evaluatie van de impact van 
comorbiditeit, zoals malaria en ondervoeding, op influenza.  
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